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ABSTRACT 
Human Tissue Engineered Model of Myocardial Ischemia-Reperfusion Injury 
Timothy Chen 
 
Timely reperfusion after a myocardial infarction is necessary to salvage the ischemic region; however, 
reperfusion itself is a major contributor to the final tissue damage. Currently, there is no clinically relevant 
therapy available to reduce ischemia-reperfusion injury. While many drugs have shown promise in 
reducing ischemia-reperfusion injury in preclinical studies, none of these drugs have demonstrated 
benefit in large clinical trials. Part of the failure to translate therapies can be attributed to the reliance on 
small animal models for preclinical studies. While animal models encapsulate the complexity of the 
systemic in vivo environment, they do not fully recapitulate human cardiac physiology.  
In this thesis, we utilized cardiac tissue engineering methods in conjunction with cardiomyocytes derived 
from human induced pluripotent stem cells, to establish a biomimetic human tissue-engineered model of 
ischemia-reperfusion injury. The resulting cardiac constructs were subjected to simulated ischemia or 
ischemia-reperfusion injury in vitro. We demonstrated that the presence of reperfusion injury can be 
detected and distinguished from ischemic injury. Furthermore, we demonstrated that we were able to 
detect changes in reperfusion injury in our model following ischemic preconditioning, modification of 
reperfusion conditions, and addition of cardioprotective therapeutics. This work establishes the utility of 
the human tissue model in studying ischemia-reperfusion injury and the potential of the human tissue 
platform to help translate therapeutic strategies into the clinical setting.  
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Timely reperfusion of ischemic heart is required to limit the damage caused by myocardial infarction (MI). 
However, it is recognized that reperfusion of the ischemic region paradoxically leads to additional 
ischemia-reperfusion injury (IRI). IRI is a major and potentially preventable contributor to the final damage 
after an MI; however, there is no effective clinically relevant therapy available at this time. Thus, there is 
a great interest in the discovery of a pharmacological therapy for IRI that can be introduced at the time of 
reperfusion. Despite a multitude of preclinical success in animal models, all the drugs that have made it 
to large clinical trials have failed to demonstrate a clinical benefit[1–3]. 
Criticisms have been levied on the specifics of the clinical trials [4] and the broader drug development 
process [5]. It is clear that more work needs to be done between preclinical studies and clinical trials. 
Currently, much of the preclinical testing is done in small animal models, which provide a cost-effective, 
whole-organism in vivo background to work in, but also introduce multiple confounding factors that may 
obfuscate the effects of drugs [6]. While animal studies are critical to the drug development process, it is 
evident that more attention needs to be paid to in vitro and reductionist models of IRI. In vitro models are 
important in that the direct effect of reperfusion and the drug on the cardiomyocytes can be observed. 
The various factors can be controlled for to better assess the effectiveness of a particular drug. Currently, 
most in vitro testing is performed on animal-derived cardiomyocytes, but these models do not 
demonstrate the best clinical predictivity because of the physiological differences between animals and 
humans [7]. In general, there is a great interest in developing human tissue platforms for pharmacological 




In this thesis, we developed a simple human cardiac tissue model of ischemia-reperfusion injury. 
Cardiomyocytes derived from human induced pluripotent stem cells (hIPS-CMs) were incorporated into 
tissue engineered cardiac constructs and were subjected to conditions leading to their maturation to 
provide a more physiological tissue response in the context of ischemia-reperfusion. The ischemia-
reperfusion injury (IRI) in the system was validated by differentiating the ischemic and reperfusion injury. 
Finally, treatments against IRI were tested in the cardiac constructs, and the results were compared to 
current knowledge and understanding of these treatments in the preclinical and clinical setting. 
Developing a human model of IRI allowed for better understanding of IRI to develop treatments against 




Aim 1: Design a Human Tissue-Engineered Bioreactor Model of Ischemia-
Reperfusion Injury   
We developed a bioreactor that supported the formation of a tissue engineered cardiac construct. The 
bioreactor promoted maturation of the incorporated hIPS-CMs by mechanical conditioning providing 
passive tension and allowance for auxotonic contractions. The bioreactor was designed for easy 
manufacturing and manipulation, and towards higher throughput testing of the resulting cardiac 
constructs.  
 
Aim 2: Validate Ischemia-Reperfusion Injury in the Tissue Engineered 
Cardiac Construct 
The effectiveness of the bioengineered cardiac construct used as a human model for IRI was validated by 
demonstrating the presence of reperfusion injury. To determine this, we demonstrated increased cell 
death in constructs subjugated to hypoxia-reoxygenation over normoxic constructs and increased cell 
death in constructs subjugated to hypoxia-reoxygenation over hypoxia alone. We also tested the 
effectiveness of ischemic preconditioning in decreasing IRI, and the response of immature constructs to 
simulated ischemia-reperfusion.    
 
Aim 3: Establish and Evaluate Therapeutic Strategies for Reducing IRI 
During Reperfusion  
We tested strategies to reduce IRI by modifying reperfusion conditions and introducing pharmacological 
agents. These strategies targeted effectors of IRI based on the current understanding of the 
pathophysiology of IRI. In addition, we compared these results to published testing done in other 
preclinical studies and clinical trials.  
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Background and Significance 
 
Ischemia-Reperfusion Injury is a Critical Therapeutic Target 
Cardiovascular disease is a major cause of mortality in the world [10]. Myocardial infarction (MI) occurs 
when coronary blood flow is restricted by occlusion, thus preventing oxygen and nutrient delivery to the 
downstream ischemic region. The only available therapy to limit damage to the ischemic region following 
an MI is reperfusion of the occluded artery and reestablishment of nutrient delivery. The time lapse 
between occlusion and reperfusion is critical for preventing irreversible damage of the myocardium [11]. 
Paradoxically, reperfusion of the ischemic region can lead to an increase in myocardial damage and in the 
final infarct size. Ischemia-reperfusion injury (IRI) involves the death of cells upon reperfusion that were 
still viable at the end of ischemic insult. IRI is recognized as a major contributor to the final damage after 
an MI, but it is also a potentially preventable source of damage. Reducing IRI will be a major step in 




Figure 1: Timeline of ischemia-reperfusion injury. Cell death due to ischemic injury increases with 
ischemic time (red line). Reperfusion by primary percutaneous coronary intervention (PPCI) halts 
the progression of ischemic injury (green line) but causes additional damage that leads to a larger 
final infarct size than predicted by ischemic injury alone (black line). This additional reperfusion 
injury is potentially preventable and limiting it through therapeutics would lead to better clinical 
outcomes. Adapted from Hausenloy D, et al. [12] 
 
It was first demonstrated by Murray and colleagues in 1986 that ischemic preconditioning of the heart 
can protect against IRI [13]. Ischemic preconditioning exposes the heart to short bouts of ischemia and 
reperfusion prior to the actual ischemic insult. However, this is not a clinically relevant therapy in the 
setting of an acute MI. To date, there is no clinically relevant therapy available to treat IRI. Researchers 
have experimented with ischemic postconditioning, exposing the heart to short periods of ischemia after 
the ischemic insult but before reperfusion, and remote ischemic conditioning, exposing a distant limb to 
short periods of ischemia before reperfusion. These conditioning methods have demonstrated success in 
animal studies [14]; however, ischemic postconditioning has so far shown no benefit in clinical trials [15]. 
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Remote ischemic conditioning has shown promise in early clinical trials, but more studies are still needed 
[16]. Thus, the development of a pharmacologic agent that can be introduce at the time of reperfusion is 
of great interest. 
 
Establishing New Models of Preclinical Testing 
 
Many drugs have shown promising results in animal models; however, all of the drugs that have made it 
to large clinical trials have failed to demonstrate clinical benefits [1–3]. Some criticisms have been levied 
on the specifics of these clinical trials [4], and the drug development process in general [5]. It is clear that 
more predictive testing needs to be done during translation of preclinical data into clinical trials. Currently, 
most of the preclinical testing is done in small animal models, which provide a cost-effective in vivo 
background to work in, but introduce multiple confounding factors that may obfuscate the effects of drugs 
[6]. While animal models remain critical for drug development, it may be worth considering human cell-
based in vitro and reductionist models of IRI. The in vitro models are important in that the direct effect of 
reperfusion and the drug on the cardiomyocytes can be observed, and any external factors can be isolated 
for and individually controlled. 
There is a growing notion that current preclinical models of IRI fail to translate to the clinical setting [17]. 
An entirely new approach to preclinical studies of IRI may be needed that would utilize controllable 
models with sufficient power to predict the human pathophysiology of ischemia and reperfusion. In 
particular, human tissue models have the potential to be powerful tools to facilitate translation into the 
clinical setting.  
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Pathophysiology of Ischemia-Reperfusion Injury 
Any improvements in the identification of therapeutic targets and development of effective drugs for 
myocardial infarction patients can only be based on understanding the progression and basic mechanisms 
that drive ischemia-reperfusion injury. In general, myocardial reperfusion injury encompasses more than 
just cardiomyocyte death. Reperfusion-induced arrhythmias and myocardial stunning after reperfusion 
are reversible factors of reperfusion injury. On the other hand, microvascular obstruction, the failure of 
reperfusion to reestablish blood flow in the underlying tissue, is irreversible and is an independent 
indicator of mortality.[18] However, we are primarily concerned with the pathways that lead to lethal 
reperfusion injury of cardiomyocytes. It is thought that the confluence of intracellular calcium 
accumulation, reactive oxygen species generation, and mitochondria membrane permeabilization seen in 






Figure 2 Pathophysiology of ischemia-reperfusion injury (a) During ischemia, the lack of oxygen 
drives cells from aerobic respiration to anaerobic glycolysis for ATP production. The subsequent 
decrease in ATP turnover leads to intracellular acidosis. Lactate from glycolysis helps to buffer the 
accumulated protons, but the stagnation of blood flow prevents the removal of lactate. 
Cardiomyocytes attempt to reestablish normal intracellular pH through the sodium-hydrogen 
exchanger. The subsequent accumulation of intracellular sodium drives the sodium-calcium 
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exchanger in reverse and causes intracellular accumulation of calcium. (b) During reperfusion, the 
rapid normalization of extracellular pH exacerbates the conditions seen in ischemia. The large 
proton gradient increases proton efflux and results in intracellular calcium overload. 
Reoxygenation also leads to increased reactive oxygen species (ROS) generation. Intracellular 
calcium overload and rapid ROS generation contribute to opening of the mitochondrial 




MI occurs when a dislodged plaque clogs an artery and occludes blood flow to the downstream ischemic 
region. This occlusion prevents nutrient and oxygen delivery, and the removal of metabolic by-products. 
During ischemia, the lack of oxygen causes cardiomyocytes to switch from aerobic respiration to anaerobic 
glycolysis for their primary ATP production. Because glycolysis is far less efficient at producing ATP than 
mitochondrial oxidative phosphorylation, this transition disrupts ATP turnover. The subsequent decrease 
in ATP production with an increase in ATP hydrolysis results in increased proton production and 
intracellular acidification [19]. Glycolysis also results in the production of lactate, which helps restore 
cytosolic NAD+ stores to support continued ATP generation from glycolysis. Lactate production also helps 
to buffer intracellular pH by extruding protons through the lactate-proton cotransporter [20]. Importantly, 
the lack of blood flow during ischemia results in extracellular accumulation of lactate that prevents further 
efflux of lactate. The failure to remove lactate inhibits glycolytic ATP production and contributes to 
continued intracellular acidosis [21].  
The ischemic cardiomyocytes attempt to reestablish a normal intracellular pH by utilizing the sodium-
hydrogen exchanger to excrete protons and accumulate sodium [22]. The lack of ATP prevents the 
sodium-potassium ATPase from excreting sodium. Instead, the high intracellular sodium concentration 
10 
  
drives the sodium-calcium exchanger in reverse in an attempt to normalize intracellular sodium 
concentrations, which results in intracellular accumulation of calcium (Figure 2A) [23].  
 
Reperfusion 
Reperfusion is achieved by unblocking the artery through percutaneous coronary intervention (PCI) or 
thrombolytic therapy. The restoration of blood flow salvages the ischemic region by reestablishing oxygen 
and nutrient delivery, and by removing metabolic by-products; however, reperfusion also directly leads 
to cell death. Lethal reperfusion injury is the death of cardiomyocytes upon reperfusion that were 
otherwise viable at the end of the ischemic period.  
Reperfusion restores extracellular ionic balance and normalizes the extracellular pH. The rapid 
normalization of the extracellular pH creates a large proton gradient that exacerbates the conditions seen 
in ischemia. The sodium-hydrogen exchanger accelerates excretion of hydrogen to restore physiological 
levels of intracellular pH. In turn, the rapid normalization of intracellular pH leads to an even greater 
increase in the intracellular accumulation of calcium through the sodium-calcium exchanger [24]. The high 
intracellular calcium concentration helps to activate calpains, proteases that target intracellular proteins 
[25]. Reoxygenation also leads to an increase in the generation of reactive oxygen species (ROS) that 
contribute to cell injury [26].  
Intracellular calcium overload and the generation of reactive oxygen species (ROS) lead to opening of the 
mitochondria permeability transition pore (MPTP).  The opening of the MPTP is thought to be the critical 
step in IRI, because it causes a loss of mitochondrial membrane potential, decoupling of the electron 
transport chain, and eventually the failure of ATP production. It also allows water to enter, causing 
swelling of the mitochondrial membrane. If the mitochondrial membrane is ruptured, cell death signaling 
proteins are released into the cytosol, resulting in loss of viability (Figure 2B) [27, 28]. 
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Despite the identification of this major mechanism of reperfusion injury, the exact progression and 
mechanisms of IRI are still not completely defined. Inhibition of MPTP opening by targeting its regulator, 
cyclophilin D, has proven promising in animal studies [29]. However, the use of cyclosporine A, an inhibitor 
of cyclophilin D, has not been successful in clinical trials [1, 30]. It is unclear if the failure of cyclosporine 
A in clinical trials is due to overemphasizing the importance of the MPTP and some other factors related 
to the clinical setting [4]. Researchers have also found success in limiting IRI by targeting other pathways, 
such as the unfolded protein response or histone deacetylation [31, 32]. It is possible that there are more 
unknown therapeutic targets. It is clear that the field needs to further develop our understanding of the 
mechanisms driving IRI to develop effective therapeutic modalities. A human in vitro model would provide 





Current Standard of Preclinical Testing 
To understand the failure of translating drugs from the preclinical to clinical setting, we have examined 
the current state of preclinical testing in IRI.  
 
Animal Models of Ischemia-Reperfusion Injury 
Currently, researchers primarily rely on animal models when testing new therapeutics for IRI. Ischemia-
reperfusion in animals is typically simulated by using a suture to occlude the left descending coronary 
artery for the designated ischemic time, and then releasing the suture to allow for reperfusion [33]. This 
approach best captures the process of hypoxia-reoxygenation but does not fully simulate the clinical 
setting, where an atherosclerotic artery is clogged by a dislodged plaque and then reperfused by PCI. 
Animal models are useful in that they allow for examination of the interactions between various cell types 
during reperfusion. For example, it has been found that the adhesion of neutrophils to the endothelium 
can be modified, and it decreased IRI [34]. These interactions involve paracrine signaling through a 
multitude of molecules, such as TNF-α and nitric oxide [35], and are difficult to accurately simulate in vitro. 
These other cell types play important roles and must be considered when studying IRI.   
While animal models are very helpful, they fail to fully emulate human physiology. Pigs are the closest 
analogues to humans because they have a comparable heart size and heart rate to humans, lack the 
protective coronary collateral blood flow found in dogs [36], and do not have the innate resistance to MI 
found in primates [37]. However, large animals are difficult and expensive to work with. Thus, most 
researchers rely on rodents for their in vivo work. Compared to humans, rodent hearts have a much higher 
intrinsic beating rate [38], different myosin isoform predominance, higher cardiac basal metabolism [39], 
and different electrophysiology of the heart [40]. While the relative importance of these differences is 
undefined, they influence the response to IRI. The fact that the therapeutic demonstrating success in 
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animal studies have not made the transition to clinical utility indicates that these animal models are not 
adequate  
 
Ex vivo Model of Ischemia-Reperfusion Injury 
Researchers have also explored the use of isolated perfused hearts, which maintain the physiological 
simulation of ischemia-reperfusion but allow for more control over the conditions. Their effectiveness has 
been demonstrated by reducing infarct size using various cardioprotective agents [41]. However, ex vivo 
models – similar to animal models – do not recapitulate human physiology, and motivate the need for 
development of new preclinical testing platforms.  
 
In vitro Models of Ischemia-Reperfusion Injury 
An alternative to animal models is to use in vitro models based on isolated cardiomyocytes. While these 
models do not fully recapitulate the complexity of the heart, they allow for examination of the direct 
effect of drugs on cardiomyocytes, with better manipulation and control of the various confounding 
factors found in animal models. In vitro models could provide a platform to rigorously study the important 
pathways of IRI and test the candidate therapeutic options in settings that are more predictive of the 
pathophysiology of ischemia-reperfusion than animal models.  
 
Modeling of Ischemic Conditions In Vitro 
In vitro models examine IRI in a non-physiological setting, and ischemia and reperfusion injury can be 
simulated by manipulating the cellular environment. In addition to providing a hypoxic environment, 
simulation of the ischemic state must also encompass other factors, including high extracellular 
potassium, acidosis, nutrient deprivation, and waste accumulation [42].  
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In vitro studies have attempted to simulate ischemic conditions by culturing cells in physiological salt 
solutions that are free of metabolic substrates, supplemented with additional potassium to achieve high 
extracellular potassium, and titrated to an acidic pH [43]. Additionally, lactate is added to simulate its 
accumulation due to anaerobic glycolysis. Some studies have also added 2-deoxy-d-glucose, a 
nonmetabolizable glucose analogue, into the ischemic solution to inhibit glycolysis and further shutdown 
cellular metabolism [44]. It is unknown if the non-metabolizable 2-deoxy-d-glucose phosphate interferes 
with the reperfusion process, and its effect needs to be further studied before being included in a 
simulated IRI model. The precise concentrations and compositions of the salt solutions varied across the 
different studies reviewed; however, a potassium concentration of 12 mM, lactate concentration of 20 
mM, and pH of 6.5 are most commonly used [43, 45]. The cells were placed in a gas-tight chamber, which 
is then flushed with anoxic gas (95% N2, 5% CO2) to achieve a hypoxic environment. 
Another method to achieve a hypoxic state has depended on the pelleting of cells with a minimal amount 
of media under a layer of mineral oil that hindered oxygen diffusion to create a hypoxic environment [46]. 
The key idea behind this model is to achieve ischemia through a more physiological means, with gradual 
reduction of nutrients and accumulation of wastes. However, this method is more variable and the 
pelleting through centrifugation can lead to mechanical damage to the cells. In our system, we utilize 
aspects of this method through volume restriction of the cardiac constructs during simulated ischemia.  
Metabolic inhibition through compounds, such as cyanide, to decrease oxygen consumption has also been 
explored [47]. These chemicals may be hard to wash out or may have irreversible effects that can disrupt 
a physiologically accurate reperfusion process. Overall, we chose to utilize a salt solution simulating 
ischemic conditions and a hypoxic chamber to maximize control over the in vitro model.   
The necessary ischemic time in vitro has also not been precisely determined. In animal experiments, 
ischemic times are relatively short and well defined. Thirty minutes is all that is needed to achieve an 
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ischemic state within the heart tissue [33, 48]. However, isolated cardiomyocytes cultured in vitro are at 
different levels of maturity and oxygen dependency than those in intact mature tissue. The embryonic 
heart is more resistant to hypoxia than the adult heart, and has improved recovery after an ischemic insult 
[49]. As a result, much longer ischemic times, ranging from 90 minutes [50] to 9 hours [33], are needed to 
demonstrate a decrease in cell viability. The necessary duration of ischemia is dependent on the cell 
source used, but it can also vary within the cell types used. One study had to adjust the ischemic time to 
two to five hours [32].  
Further complicating the matter, it has been found in vivo that after a certain length of ischemia, 
preconditioning no longer has cardioprotective effects with respect to the final infarct size [13]. This time 
dependence of the effectiveness of ischemic conditioning must be accounted for when assessing the 
potential of a therapeutic. The European Society of Cardiology Working Group Cellular Biology of the 
Heart has recommended that the combined ischemic and reperfusion times should be selected to result 
in 50% cell death [6]. Each in vitro model must therefore independently establish an ischemic time that 
causes enough cell death, but is not too long to affect possible preconditioning or drug benefits.  
 
Simulating Reperfusion in vitro 
Reperfusion was also simulated through non-physiological means in vitro. In clinical settings, the aim of 
reperfusion therapy is to restore nutrient and oxygen delivery and to remove the accumulated metabolic 
by-products. Reperfusion is typically simulated in vitro by replacing the ischemic solution to remove 
metabolic waste, adding normal culture media for nutrient delivery, and removing the system from the 
hypoxic chamber to return the environmental levels of oxygen to normoxia [51, 52]. 
The composition of culture media added to simulate reperfusion must be carefully selected. Most in vitro 
studies utilize commercially available basal media supplemented with serum. However, it is unclear if 
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normal cell culture media best simulates physiological conditions. The reperfusion solution needs to 
provide nutrients to the cells and normalize extracellular pH and ion balance in order to cause intracellular 
calcium overload and allow for the generation of ROS. Cell culture media provide nutrients in the forms 
of glucose in the basal media, and lipids in the serum. Cardiomyocytes are more dependent on lipids for 
metabolism [53]; however, serum supplementation may be problematic. The exact composition of serum 
is unknown and there are lot-to-lot variations, which introduces variability that may obfuscate the effect 
of the therapeutic of interest. Serum also contains antioxidants that may ameliorate the oxidative stress 
seen in IRI. Serum-free media are utilized for cardiomyocytes derived from human iPS cells [54] and a 
chemically defined reperfusion solution can help establish a consistent response to IRI.   
It is also important to re-establish the physiological extracellular calcium concentration (1-2 mM) [55] 
because intracellular calcium overload is one of the important effectors of reperfusion damage [42]. 
Certain types of basal media contain less calcium, and it has been recognized that physiological calcium 
levels are required for normal function of cardiomyocytes [56]. 
 
Isolated Cardiomyocytes as Models of Ischemia-Reperfusion Injury 
In vitro models of IRI primarily rely on isolated cardiomyocytes derived from animals, immortalized cell 
lines, or human pluripotent stem cells. The source of cardiomyocytes affects their response to IRI, and 
thus, their predictive power for pharmacologic testing.  
Most of the in vitro work has utilized cardiomyocytes derived from animal sources. Primary 
cardiomyocytes have been isolated for study from a variety of animal types, including rats, pigs, and 
rabbits, and from animals of different levels of maturity. Cardiomyocytes derived from adult animals are 
more relevant for the studies of IRI because the immature cardiomyocytes derived from neonatal animals 
are more resistant to hypoxia than adult human cardiomyocytes [49]. This resilience causes neonatal 
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hearts to respond very differently to IRI. For example, ischemic preconditioning does not protect neonatal 
hearts [57], and neonatal cardiomyocyte mitochondria are not as sensitive to IRI-induced membrane 
permeabilization [58]. These physiological differences are significant, and they need to be accounted for 
when comparing preclinical data. Therefore, therapeutics should be tested in adult-derived 
cardiomyocytes whenever possible.  
Researchers have also explored the use of cell lines, such as immortalized mouse atrial HL-1 cells or rat 
H9c2 cardiomyoblasts. These cell lines are more cost effective than primary cardiomyocytes, and have 
demonstrated similar drug responses to IRI as primary cardiomyocytes [33, 59]. However, these cell lines 
do not recapitulate the cardiac physiology because they are dividing, unlike mature cardiomyocytes, and 
they display differences in their cell death pathways and bioenergetics [60, 61]. Because mitochondria are 
important effectors of IRI, caution must be exercised when extrapolating results obtained with cell lines 
to the in vivo situation.  
Human cardiomyocytes would be ideal for in vitro models of IRI because they can provide a more 
biomimetic platform to conduct studies by avoiding the problem of interspecies comparisons. Animal and 
adult human cardiomyocytes differ in many aspects, such as the beating rate, myosin isoform 
predominance, ATP utilization, and electrophysiological properties [7, 62]. These differences can affect 
the cell response to IRI and would make it difficult to extrapolate results from animals to humans. The 
challenge is that human primary cardiomyocytes are impossible to work with because they are terminally 
differentiated, have limited proliferative potential, and are very difficult to obtain.  
In an attempt to provide models based on adult human cardiomyocytes, researchers have developed a 
proliferating human cardiomyocyte cell line (AC16) by fusing primary cells from human ventricular tissue 
with transformed fibroblasts [63]. These cells are differentiated following transfer into mitogen-depleted 
media that stops their proliferation, and they express cardiac-specific proteins and maintain cardiac 
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nuclear and mitochondrial DNA. AC16 cardiomyocytes have been used and validated in an in vitro study 
that examined the effect of asiatic acid on IRI [64]. The results were consistent with other studies in a rat 
model and an in vitro H9c2 cardiomyoblast model that also demonstrated asiatic acid attenuation of IRI 
[65, 66]. Still, there are concerns about the physiologic relevance of transformed and fused cell lines.  
The most attractive cell source for biomimetic studies of IRI are cardiomyocytes derived from human 
induced pluripotent stem cells (hiPS-CMs) or embryonic stem cells (hESC-CMs) (Table 1). It has been 
demonstrated that human stem cell derived cardiomyocytes can be cultured and differentiated in a 
defined and reproducible manner [54], and they have been used in IRI studies with some success.  
Hsieh et al found that the simulation of IRI in hESC-CMs caused an increase in the qPCR ratio of anti-
apoptotic BCL-2 to the apoptotic BAX gene following a pretreatment with sodium nitrite [67]. Paloczi et 
al demonstrated the cardioprotective effect of exogenous nitric oxide supplementation in simulated IRI 
experiments on hESC-CMs derived from embryoid bodies (EB) [52]. However, these studies failed to 
specifically separate the cardiomyocytes from the other cells in the EBs, and instead relied on a GFP 
expression to identify cardiac regions and quantify cell death. The limited range of methods that these 
studies employed makes it unclear if hESC-CMs are a suitable cell source to study IRI.  
The establishment of hIPSCs as a source of human cardiomyocytes has allowed researchers to avoid the 
ethical concerns of using hESCs and to also derive patient-specific cell lines. Specifically, hiPS-CMs allow 
for studies of patient-specific disease backgrounds [68]. There is a great interest and some success in 
utilizing hIPS-CMs in pharmacological screening [69, 70], but very little work has been done in the setting 
of reperfusion injury. In one of the few IRI studies done using hIPS-CMs, Wei et al. demonstrated their 
utility by confirming the cardioprotective effects of the herbal medicine, Danshen, in vitro [71]. These 
results were consistent with previous studies in animal models demonstrating the therapeutic benefit of 
Danshen [48]. However, hIPS-CMs are relatively immature and more closely resemble fetal than adult 
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cardiomyocytes [72]. As known, the fetal phenotype and bioenergetics are associated with non-
physiologic responses to reperfusion injury, and can pose challenges to predictive testing of drug efficacy 
and safety.  
Table 1 Cardiomyocyte sources for in vitro models of Ischemia-Reperfusion Injury 
 
 
Organ on Chip Models 
Because the fetal nature of hIPS-CMs limits their use in IRI studies, tissue engineering provides an 
intriguing avenue for maturing these cells into a more adult phenotype. Previous studies have 
demonstrated that incorporating hIPS-CMs into tissue engineered heart constructs has helped mature 
their gene expression profile, ultrastructure, metabolic and electrophysiological properties [56, 73–77]. 
However, these cells still fall short of adult cardiomyocyte function. 
One study utilized an engineered heart tissue model of IRI [78], but unfortunately, the tissue constructs 
were based on neonatal rat cardiomyocytes. Nevertheless, it is instructive to look into how tissue 
engineering can help advance the IRI research. The study examined how hypoxia affected electrical 
conduction in the tissue and used protein expression to characterize reperfusion injury. Cyclosporine A, 
akin to animal studies [79], showed cardioprotective effects in this system. This study helped establish 
tissue engineering as a useful tool for studying IRI and testing of therapeutic options.  
Cardiomyocyte Source Ease of use Predictive Utility Cell Source Issue
Animal cell source
Isolated primary cardiomyocytes
Adult cardiomyocytes Low Medium Interspecies physiolocal differences
Neonatal cardiomyocytes Low Low-Medium Immature phenotype, Interspecies physiological differences
Immortalized cell lines (e.g. HL-1, H9c2) High Low Proliferating cell line, Interspecies physiolocal differences
Human cell source
Transformed cell line (e.g. AC16) High Low Proliferating cell line
Cardiomyocytes derived from Pluripotent Stem Cells
hESC-CMs Medium Low-Medium Immature phenotype
hIPS-CMs Medium Low-Medium Immature phenotype
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Current State of the Art in Cardiac Tissue Engineering 
In order to develop a human tissue engineered model of IRI, it was first necessary to assess current 
developments in cardiac tissue engineering to determine the appropriate model (Table 2). The initial focus 
of cardiac tissue engineering was to develop a cardiac patch that could support the postinfarct region and 
improve heart function. Cell therapy by injecting cardiomyocytes has a notoriously low retention rate [80], 
and the patch would theoretically improve cell retention and provide direct mechanical support. To 
achieve this goal, it would be necessary to construct a thick tissue that can sufficiently bridge the 
postinfarct area. Making a thick tissue is challenging because cell survival is limited by the oxygen diffusion 
limit (~100-200 µm) [81]. Many cardiac tissue engineering approaches have sought to overcome this by 
incorporating a vascular network to perfuse the tissue bulk and establish a thicker cardiac tissue [82–84]. 
Other efforts have focused on generating large tissues that can cover the entire infarct area. In particular, 
the Bursac group has established methods to mature hiPS-CMs in thin (approximately 100 µm) patches 
up to 4 x 4 cm in size [74]. They cultured cardiomyocytes around polydimethylsiloxane (PDMS) posts to 
promote functional alignment of the cells, and to achieve higher force generation and faster conduction 
velocity [85]. 
A more recent development in cardiac tissue engineering has been a focus on generating in vitro models. 
Previous knowledge and methods aimed at improving cardiomyocyte maturation for implantation have 
been turned to achieve better predictive pharmacological testing and models of disease.  Unlike the 
criteria for a cardiac patch, these models should be small, easy to manufacture, and simple, depending on 
the application. In the case of a model of IRI, the exclusion of endothelial cells and microvasculature may 
be prudent in initial models to isolate the study of IRI to just the response of the cardiomyocytes. The 
need to simplify the construct and limit its size offers greater freedom in designing a bioreactor for 
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maturation of hiPS-CMs. Various groups have developed differing cardiac microtissue systems to promote 
cardiomyocyte maturation. 
 The Parker group has established a method to generate muscular thin films (MTF), where cardiomyocytes 
are seeded onto a 2D cantilever [77]. The force generated by cardiomyocytes can then be optically 
measured by deflection of the cantilever. They have used the platform to demonstrate physiologic 
responses to isoproterenol, and as a disease model to detect deficiencies in force generation in Barth 
syndrome [86]. However, the MTF chips are more 2D than 3D in nature, which could limit their predictive 
power. Furthermore, the cardiomyocytes are seeded in the cantilever and the surrounding non-mobile 
regions. This creates two different populations of cardiomyocytes that can make it difficult to utilize other 
assays besides force generation analysis.  
The Healy group established a cardiac microtissue system where cardiomyocytes were packed into a 
narrow channel between two perfused microchannels [87]. The narrow channel was 100-200 µm wide, 
and promoted alignment of the cardiomyocytes, while the perfused side channels provided constant 
nutrient delivery. The cardiac microtissue was stress-shielded from the perfused channels by a strip of 
narrow microchannels that still allowed for nutrient exchange. The researchers were able to maintain 
tissue viability and determine drug responses using optical contraction analysis of the cardiac tissues. 
However, the use of a perfusable system makes it complex to setup and perform experiments in a high-
throughput manner. Furthermore, the cardiac tissue is not anchored to any points that would provide 
passive tension to the system or allow for optical force generation analysis.   
The Radisic group established a cardiac microtissue system where they seeded cardiomyocytes in a 
collagen gel around a suture [73]. The resulting biowire featured cardiomyocytes that aligned along the 
suture. A ramped electrical stimulation was utilized in this model to further mature cardiomyocytes. These 
cardiac constructs demonstrated physiological calcium handling, and the ramped electrical stimulation 
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regime resulted in enhanced gene expression, ultrastructure organization, and electrophysiological 
properties compared to controls. However, the constructs were also not anchored to any points that 
would provide passive tension to the system or allow for optical force generation analysis.  
The most common format for engineered cardiac tissue has been the seeding of a cardiomyocyte-
hydrogel mixture between two flexible pillars. The hydrogel allows the cells to remodel and condense it 
down to a compact cellular structure. The pillars provide passive tension to the construct to promote 
alignment and maturation, and their flexibility allows for physiological auxotonic contractions by the 
constructs for mechanical conditioning [88, 89]. These platforms also allow for real time optical 
measurements of force generation by measuring pillar deflection [90, 91]. This method to generate 
cardiac constructs is simple, expandable, and has been successfully adapted by many groups  [75, 91–93]. 
In particular, our group has adapted the flexible pillar format to achieve much higher levels of maturation 
than previously seen in hIPS-CMs [75]. Early-stage hiPS-CMs, hiPS-CMs that had just started to display 
spontaneous contractions, were incorporated in a hydrogel around flexible pillars and matured through 
electromechanical conditioning. The resulting cardiac constructs demonstrated highly organized cardiac 
ultrastructure with the presence of transverse tubules that had previously never been seen in hiPS-CMs. 
Furthermore, the constructs had adult-like gene expression, a switch to oxidative metabolism, a positive 
force-frequency relationship, and functional calcium handling. The high levels of structural and functional 
maturation seen in this tissue engineered cardiac platform established the superiority of this format and 
the basis for the development of the model of ischemia-reperfusion injury. 
Other groups have developed their own flexible pillar designs for cardiac tissue engineering. The platform 
developed by the Eschenhagen group is the most similar to our published platform [94, 95]. Their 
constructs were cast in agarose molds around lids with PDMS posts, and these lids were then transferred 
for culture in normal 24 well plates. However, their constructs were formed using 10% Matrigel, which is 
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a not-fully characterized animal product that is undesirable for human disease models. Their electrical 
stimulation setup included carbon electrodes attached to the lids, and stainless-steel plates screwed into 
the carbon electrodes to descend into the tissue culture well. It has previously been established that 
carbon electrodes are optimal for electrical stimulation because their high surface area for charge 
injection [96]. Our published platform has demonstrated improved maturation compared to the one 
developed by the Eschenhagen group, and we therefore sought to adapt our published platform for the 
studies of IRI.  
The Zimmermann group has also developed a cardiac tissue engineering platform that features a circular 
construct around flexible PDMS pillars [56, 97]. They were able to demonstrate that their animal product-
free protocol demonstrated increased maturation compared to their original protocol.  While the platform 
featured a circular construct instead of the linear ones found in our platforms, many of the lessons learned 
can be applied to further enhance our cardiac construct culture. Our published platform still 
demonstrated enhanced morphological maturation with presence of t-tubules [75].   
The Chen group developed a flexible pillar platform that produced miniaturized cardiac constructs [91, 
98]. The platforms were made of PDMS and were formed in a mold constructed by photolithography. The 
constructs themselves were rapidly formed by centrifuging a cell-hydrogel mixture into microwells that 
each featured a pair of flexible pillars. The small size of the constructs allowed for high throughput testing 
while utilizing a minimal number of cells per construct. However, the small size of the construct would be 
a limitation for studies of IRI because of limited analysis and manipulation. 
The Flexcell platform is a commercially available system for generation of engineered cardiac constructs, 
and it has been used for study of hiPS-CM maturation [99]. To form the cardiac construct, hiPS-CMs were 
seeded in a hydrogel mixture between two nylon mesh tabs of a fixed distance. The nylon mesh tabs are 
porous to allow the cell-hydrogel mixture to infiltrate and provide anchors for passive tension to promote 
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alignment of the cardiomyocytes. Ruan et al. found that the static stress provided by the nylon mesh 
anchors promoted maturation over no stress.  
The Flexcell system could also be adapted to stretch the cardiac constructs by inflating the underlying 
rubber membrane to increase the distance between the anchors [89, 100]. This mechanical stretch 
conditioning is different from the auxotonic contractions of flexible pillar systems, where cardiomyocyte 
force generation causes shortening of the construct length. Mechanical stretch represents diastolic filling 
of the ventricles, whereas auxotonic contractions represent systolic force generated by the 
cardiomyocytes to contract and pump blood.  
Our published platform focused on mechanical conditioning through auxotonic contractions because we 
wanted to couple cardiomyocyte contractions with external electrical stimulation [75]. However, both 
types of mechanical conditioning are necessary to fully simulate physiological contractions. To our 
knowledge, no platform has successfully coupled dynamic mechanical stretch to electromechanical 
excitation-contraction. The Flexcell system has the additional benefit of not utilizing PDMS, which has 
been found to absorb drugs in a time dependent manner [101, 102].  
Our lab has also developed a platform to provide mechanical stretch to engineered cardiac constructs 
similar to that of the Flexcell system [103]. The platform was made of PDMS using a mold constructed 
using photolithography, and it consisted of many microwells that feature PDMS posts for the constructs 
to attach to. Mechanical stretch was induced by using a pump to inflate the underlying channel to deflect 
and increase the distance between the PDMS posts. These cardiac constructs were much smaller in scale 
(less than 1 mm in length) and allowed for the simultaneous formation of many constructs for study. 
However, all of the constructs were cultured in the same media, and it was difficult to study and 
manipulate a single construct due to its size. The platform has also only been tested for use using neonatal 
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rat cardiomyocytes. We wanted to create a cardiac construct that was larger and easier to manipulate, 
and a platform that could provide combined electromechanical stimulation.  
The Costa group has also demonstrated another method of coupling electrical stimulation and mechanical 
contractions outside of the flexible pillar system [76]. They constructed a fluid-ejecting ventricle-like 
chamber using hiPS-CMs formed in a hydrogel around a catheter bulb. They could have further added 
mechanical stretch by filling the ventricle-like structure with fluid during diastole. Their ventricle-like 
cardiac organoid demonstrated a more mature gene expression profile and functional maturation. 
Furthermore, they were able to generate pressure-volume loops and characterize changes in response to 
drug addition. However, we chose to go with the flexible pillar approach because it is a much simpler 
system that allows us to generate many constructs for analysis. The ventricular cardiac organoids are very 
time consuming to generate and prepare for experimentation, which would greatly reduce the 
throughput.  
Another cardiac tissue engineering platform was developed by Huebsch et al. [104]. This platform relied 
on the attachment of the constructs to the underlying tissue culture polystyrene substrate. However, the 
platform still utilized PDMS, as it consisted of a PDMS stencil bonded to underlying tissue culture 
polystyrene, where the stencil formed the cultured cardiomyocytes into miniaturized constructs. Each 
construct featured two square “knob” regions with a thin “shaft” region that connected them. The shaft 
region promoted the alignment of cardiomyocytes with uniaxial contractions, while the knob region 
attached the construct to the underlying substrate and provided static stress for the construct. This 
platform is advantageous in that it utilizes very few cells in each miniature cardiac construct and is easy 
to use. However, the platform does not provide any dynamic mechanical conditioning to simulate the 
heart and help mature the hiPS-CMs.  
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Our published platform was designed to promote hiPS-CM maturation through electrical stimulation that 
induced dynamic mechanical conditioning of the constructs pulling the pillars. This platform 
demonstrated superior maturation of hiPS-CMs compared to the other platforms surveyed. We adapted 
this platform into a new design suitable for studies of IRI that maintained the flexible pillar design and 





Table 2: Summary of Potential Cardiac Construct Formats for Maturation of hIPS-CMs. Construct size 
refers to general relative size compared to other cardiac tissue engineering platforms. All “small” 
construct size platforms, besides the muscular thin film [77, 86], were manufactured using 
photolithography techniques. All platforms, besides the pneumatic microfluidic system which utilized 
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In this thesis, we developed a human tissue engineered model of IRI to address shortcomings in current 
preclinical studies of IRI. None of the drugs studied and found to be effective in in vivo or in vitro models 
have improved outcomes in clinical trials, and this is partly because most of the preclinical studies are 
done in animals. As discussed, pigs are the ideal animal of choice, but are not widely utilized because of 
cost and experimental difficulties. Instead, most studies are done in rodents, which do not recapitulate 
the human cardiac physiology in critical ways. While animal studies are currently the best in simulating 
the ischemia-reperfusion process, their deficits in emulating humans are becoming apparent.   
Studies of isolated cardiomyocytes are suitable for examining the direct effects of drugs on cells. There 
are many studies on animal cardiomyocytes, but they have limited potential for translation to human 
cardiomyocytes. On the other hand, there is very little research done on human cardiomyocytes. The main 
and most promising source of human cardiomyocytes are human iPS cells. hiPS-CMs are abundant, easily 
derivable, and can be patient-specific. Unfortunately, the cardiomyocytes derived from hIPS are fetal in 
nature. Fetal cells are rather resistant to hypoxia, and this can be an issue when attempting to simulate 
IRI. Tissue engineering techniques have been demonstrated to help mature hiPS-CMs and can help in 
making a physiologically relevant model of IRI. A human tissue engineered model of heart muscle can 








Aim 1: Design a Human Tissue-Engineered Bioreactor Model of Ischemia-
Reperfusion Injury   
 
Tissue Engineering Platform 
To develop a human engineered model of IRI, we first had to develop a bioreactor to support the 
maturation of hiPS-CMs in the cardiac construct. We had previously demonstrated the formation of an 
engineered cardiac construct with superior maturity compared to existing developments in the cardiac 
tissue engineering field [75]. In this published study, we demonstrated that tissue engineered cardiac 
constructs should be formed from early-stage hiPS-CMs (soon after the development of spontaneous 
contractions) and subjected to an intensity-training regimen to best promote cardiomyocyte maturation. 
The construct training regimen was achieved through electromechanical conditioning, where mechanical 
conditioning was provided by culture on two flexible pillars that provided passive tension and allowed for 
auxotonic contractions, and electrical stimulation was provided through attached carbon rods. In addition, 
the electrical stimulation frequency was gradually increased to simulate the development of the fetal 
heart, and this intensity electrical stimulation regimen had previously demonstrated enhanced 
maturation of hiPS-CMs compared to constant or no stimulation [73]. We saw that the constructs derived 
from this platform demonstrated adult-like gene expression, highly organized ultrastructure with the 
presence of transverse tubules, mature functional response with a positive force-frequency relationship, 




Adapting the platform 
Because of the advanced maturity that was demonstrated, we wanted to utilize this platform for our 
studies of ischemia-reperfusion. However, we identified that we would need to modify and adapt the 
platform to better suit our needs. To simulate ischemia-reperfusion, we wanted to culture the constructs 
in a minimal amount of solution during ischemia to simulate stagnation of blood flow and accumulation 
of wastes, and then add a large amount of normal culture media during reperfusion to restore 
extracellular nutrient, ion, and pH balance. This would allow us to quickly change culture conditions 
between ischemia and reperfusion. The setup of the published platform prevented this because all 
constructs in a single platform (up to 12) were exposed to the same large media bath. This also meant 
that we could not differentially control the conditions or drug exposure for each individual construct, and 
the intracellular enzyme release assays that we wished to utilize for cell death were a summation of all 
the constructs in a single platform rather than a single construct. In the platform used for our studies, we 
aimed to design a bioreactor that featured a small well for construct formation that sat inside a larger 
space for normal media addition (Figure 3A). During ischemia, we could add 120 μL of the ischemic 
solution to restrict the media volume, and then reperfuse the ischemic construct by adding 2 mL of normal 
culture media. This design allowed us to rapidly change conditions between ischemia and reperfusion 
with minimal manipulation required. Furthermore, each construct was contained in its own individual well 
(up to 4 per platform), which allowed us to analyze each construct separately from the others on the same 
platform.  
Our adapted platform also allowed us to seed and culture the constructs in the same bioreactor. In the 
published platform, we had originally intended to seed and culture the constructs in the same bioreactor; 
however, we found that the culture wells only held approximately 0.5 mL of media. The media had to be 
frequently changed to maintain construct viability. A perfusion system for changing the media can be 
difficult to setup and can introduce multiple points where platform sterility can be compromised. Instead, 
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the bottom of the culture bioreactor was removed, and the entire bioreactor was placed in approximately 
30 mL of media for adequate nutrient supplementation. Because the bottom of the culture bioreactor 
was removed, we could no longer seed and form constructs on the platform. Instead, a separate seeding 
platform was created to allow the constructs to form and condense, and the constructs were then 
transferred into the culture bioreactor. We wanted to modify the platform to seed and culture the 
constructs in the same bioreactor to simplify our workflow and avoid having to transfer the constructs 
between bioreactors. We provided enough room for greater than 2 mL of media per construct to avoid 
issues with inadequate media supplementation.  
In adapting the platform for our studies of IRI, we wanted to maintain the flexible pillar design for 
mechanical conditioning of the constructs. In the published platform, the flexible pillars are vertically-
oriented and attached to a lid that allowed the tissues to be transferred from seeding to culture 
bioreactor. The pillars were made out of polydimethylsiloxane (PDMS) and separately casted onto the 
polycarbonate lids after they were manufactured. In adapting the published bioreactor for our purposes, 
we decided to orient the pillars horizontally for two reasons. The horizontal pillars allowed us to have all 
of the pillar motion in the same viewing plane as that of a normal microscope, which would allow us to 
better correlate pillar deflection with force generation in the future. Vertical pillars have motion that is 
orthogonal to the viewing plane of a microscope. Furthermore, the switch to a horizontal pillar design 
allowed us to reduce the number of components that we had to manufacture. We no longer had to 
separately manufacture a lid and cast pillars onto it, and instead, we could directly form the flexible pillars 
with the rest of the bioreactor by casting the entire structure out of PDMS in a two-part mold. We 
maintained the flexible pillar design to provide passive tension to the constructs and allow for auxotonic 
contractions for maturation through mechanical conditioning.  
A major difference between the two platforms was the material utilized. The published platform was 
primarily manufactured out of polycarbonate, but it did utilize PDMS for the flexible pillars. On the other 
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hand, the platform utilized in the current studies was entirely constructed out of PDMS. One issue with 
PDMS use is that it has been found to absorb drugs in a time dependent manner [101, 102]. However, it 
is to be noted that all platforms using the flexible pillar design utilize PDMS [75, 91–93, 105]. Our published 
platform attempted to minimize the impact of PDMS by only utilizing it in the flexible pillars while the 
majority of the bioreactor was made of polycarbonate. In the platform utilized for studies of IRI, we 
created the entire bioreactor out of PDMS as a single component. We do recognize that PDMS use is a 
potential confounding factor in this and future experiments on this platform. In the future, we will explore 
if the impact of PDMS could be reduced by creating the base of the platform out of plastic and then casting 
the PDMS flexible pillars onto the platform. There is currently no material that can replace PDMS, which 
provides the flexible and biocompatible material for flexible pillar designs, and PDMS use is a general 
limitation of these designs for cardiac tissue engineering.  
We tried to minimize changes between the two platforms, but one component we had to remove was 
electrical stimulation. Electrical stimulation has demonstrated that it is beneficial for maturation of hiPS-
CMs, and furthermore, it has been demonstrated that a ramped electrical stimulation regimen can be 
even more beneficial than a static stimulation protocol [73, 75]. The new platform supported electrical 
stimulation through embedded carbon rods adjacent to the construct formation well. However, pilot 
experiments saw that electrical stimulation caused cell damage, possibly due to unforeseen issues that 
arose due to the design changes that were made. The carbon electrodes were seated adjacent to the 
construct formation well, and the smaller space may have led to unfavorable reactions. We ultimately 
decided to remove electrical stimulation from the final experiments. Other groups have demonstrated 
enhanced maturation of hiPS-CMs on a flexible pillar format without utilizing electrical stimulation [56, 
94, 95, 97]. Thus, we aimed to promote maturation through mechanical conditioning.   
Similar to the published platform, the constructs were formed by seeding hiPS-CMs in a collagen-
fibrinogen hydrogel around the flexible pillars (Figure 3B). We utilized hiPS-CMs 12-17 days after the start 
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of differentiation, which was around the same time frame that we had defined as early stage hiPS-CMs in 
our published study [75]. The constructs were cultured for two weeks in the platform before we utilized 
them in simulated ischemia-reperfusion experiments.  
 
 
Figure 3: Bioreactor to support formation of human cardiac constructs. (A) Schematic of the 
bioreactor and a single well depicting the horizontal flexible pillars. The bioreactor was made of 
PDMS, and it allowed for the simultaneous culture of 4 separate cardiac constructs. (B) Image of 
a cardiac construct formed by seeding hIPS-CMs in a collagen-fibrinogen hydrogel around the 
pillars. Scale bar is 2 mm.   
 
Our published platform demonstrated advanced maturation of hiPS-CMs, but we needed to adapt the 
platform for studying IRI. We wanted to be able to restrict media volume during ischemia and then rapidly 
washout the ischemic solution during reperfusion to restore normal extracellular conditions. We also 
wanted to be able to analyze each construct individually in its own well instead of the platform as an 
aggregate. In adapting the platform, we maintained the flexible pillar design for mechanical conditioning, 
the embedded carbon rods for electrical stimulation, and the incorporation of hiPS-CMs soon after the 
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start of spontaneous contractions. However, we had to ultimately remove electrical stimulation from our 
final experiments due to cell damage, possible due to our design changes. We also aimed to simplified the 
platform design by orienting the flexible pillars horizontally so that the entire bioreactor could be cast out 
of PDMS in a two-part mold. This had the additional benefit of orienting all motion of the construct and 
pillars in the same viewing plane as that of a normal microscope, which will allow us to more easily 
correlate pillar deflection with force generation in future studies. The new platform design allowed us to 




Engineered Cardiac Construct Structure 
To characterize the cardiac constructs that we generated, we examined the distribution and structure of 
the hiPS-CMs by immunostaining for cardiac troponin T, which is specific for cardiomyocytes [106]. We 
found that the cardiomyocytes were not evenly distributed throughout the construct (Figure 4A). 
Furthermore, we saw that the hiPS-CMs demonstrated the highest cellular density, alignment, and 
striated morphology near the edge of the construct (Figure 4B-C). This was expected because the edge of 
the construct is exposed to the highest stress and is not limited by the diffusion of nutrients and oxygen 
compared to the center of the construct. This indicates that in order to achieve a homogenous and dense 
distribution of cardiomyocytes throughout the construct, we will need to alter our bioreactor design or 
culture conditions. We can modify our platform mold to generate a thinner construct that will be less 
restricted by diffusion limitations, and also culture our platform on a rocker to provide bulk nutrient 
delivery to center of the construct [107]. However, the presence of aligned and striated cardiomyocytes 
along the edge of the construct allowed us to assess the effect of simulated ischemia-reperfusion injury 
in a human tissue model. 
 
Figure 4: Immunofluorescence images detailing the cardiomyocytes in the engineered cardiac 
constructs. The cardiomyocytes are not homogenously distributed throughout the construct, but 
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they do demonstrate alignment and cross-striated morphology near the edge. (A-B) Cardiac 




Response to β-adrenergic Stimulation 
We assessed the functionality of the cardiac constructs by examining their responses to β-adrenergic 
stimulation. Cardiac constructs were exposed to serial dilutions of isoproterenol, a β-adrenergic agonist, 
and videos were taken for analysis. The constructs demonstrated a positive chronotropic response to 
isoproterenol stimulation, with an increase from 29.9 ± 10.6 beats per minute (BPM) at the baseline to 
54.0 ± 7.5 BPM at 10 µM (Figure 5A). The chronotropic response to isoproterenol had a measured EC50 of 
1.32 nM, which is lower than reported data for adult human ventricular tissue slices [108]. The constructs 
were also analyzed for their fractional area change (FAC) in response to isoproterenol stimulation as a 
proxy for force generation. The constructs demonstrated an increase in FAC from baseline to 100 nM, and 
nonlinear regression of the dose-response determined that it was significant compared to no response 
(Figure 5B-C). The increase in FAC in the constructs is indicative of a positive ionotropic response to 
isoproterenol. hiPS-CM monolayers have shown positive chronotropic responses to β-adrenergic 
stimulation, but because they are still immature, they do not show a positive ionotropic response [109]. 
Only hiPS-CMs cultured in tissue engineered cardiac constructs have demonstrated a positive ionotropic 
response, which is consistent with a more mature phenotype [75, 85, 91]. The constructs in our platform 
demonstrated comprehensive responses to β-adrenergic stimulation, which indicated that the platform 




Figure 5: β-adrenergic stimulation of engineered cardiac constructs. (A) Cardiac constructs 
demonstrated a positive chronotropic response to isoproterenol, with an increase in beat 
frequency. (B) Cardiac constructs demonstrated an increase in fractional area change (FAC) with 
increasing isoproterenol concentration. This is correlated with an increase in force generation, 
and it indicates a positive ionotropic response. (C) Representative FAC traces at baseline (top) and 




Further Characterization of Construct Maturity 
We would like to further characterize construct maturity in our future studies. Some of the assays we 
want to utilize, such as gene expression, will require comparisons, and others are measurements of 
inherent construct behavior. We can assess maturation of constructs by comparison with younger 
constructs, age-matched constructs where the flexible pillars were cut to not provide mechanical 
conditioning, fetal cardiac tissue, and if possible, healthy adult cardiac tissue. Comparison with younger 
constructs and constructs without mechanical conditioning will allow us to asses increased maturation in 
the platform. Comparison with fetal or adult cardiac tissue will allow us to assess maturity in terms of 
cardiac development. 
We would first like to examine changes in gene expression. We would like to examine genes that are 
associated with electrophysiology, calcium handling, and contractile proteins. We had previously 
demonstrated that our published platform increased expression of these genes relative to more immature 
constructs [75]. We can further validate these changes in gene expression by examining protein levels in 
western blot through immunostaining.  
We would then like to assess changes in construct function. We had demonstrated that our constructs 
had a positive chronotropic and ionotropic response to β-adrenergic stimulation, but there are other 
aspects of functional behavior that we would like to assess. We would like to directly quantify force 
generation and contractile stress by measuring the constructs on an organ bath. More mature constructs 
should demonstrate increased contractile stress compared to less mature ones. Measurements of adult 
ventricular cardiomyocytes have demonstrated contractile stress around 51 kN/m2 [110]. Furthermore, 
we can measure inherent properties of the construct on the organ bath. We want to assess changes in 
force in response to increasing calcium concentration and electrical stimulation frequency. Mature 
constructs should demonstrate a positive force-frequency relationship [111], and this is not seen in 
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immature hiPS-CMs [112]. Very few engineered cardiac constructs have demonstrated a positive force-
frequency relationship [56, 75].  
Furthermore, we would like to characterize the electrophysiology of the constructs. We accomplished this 
in our published platform by dissociating the cardiomyocytes from the hydrogel to demonstrate enhanced 
electrophysiology [75], but cardiac tissue engineering studies have also explored impaling electrodes into 
the constructs to directly measure readouts [56]. Immature cardiomyocytes have a higher resting 
membrane potential, decreased action potential amplitude, increased action potential duration, and 
decreased depolarization velocity compared to adult ventricular cardiomyocytes [56, 113, 114]. 
Furthermore, we can characterize conduction velocity in the construct to determine functional coupling 
of the cardiomyocytes. We have utilized a voltage-sensitive dye to optically map propagation across a 
construct in our published platform to measure conduction velocity [75].  
Finally, we would like to characterize construct metabolic activity. Fetal cardiomyocytes are more reliant 
on glycolysis for metabolism, while the mature adult heart primarily relies on fatty acid oxidation [115, 
116]. Thus, we wish to characterize an increase in mitochondrial oxidation that has been seen in some 
tissue engineered cardiac constructs [75, 88]. This can be measured by dissociating the cardiomyocytes 
from the constructs and measuring their energetics in the Seahorse platform [75]. Oxygen consumption 
rate and extracellular acidification rate can be measured to determine mitochondrial respiration and 
glycolysis in the constructs. We can also assess metabolism by using 14C-labeled energy substrates [88]. 
Furthermore, we can also measure mitochondrial mass as a measure of potential cell oxidative capability. 
Mitochondrial mass can be easily compared between constructs by using mitochondrial fluorescent dyes, 
such as Mitotracker [117], or by assessing ratio of mitochondrial proteins to cytosolic proteins [118]. 
Mitochondrial mass can also be assessed through TEM imaging. Furthermore, we can utilize TEM imaging 
to measure sarcomere length or the presence of t-tubules. T-tubules are characteristic of mature 
cardiomyocytes, and they have so far only been seen in the hiPS-CMs of our published platform [75].   
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Simulating Ischemia-Reperfusion Injury 
The bioreactor featured a small well for tissue seeding and culture and was surrounded by a larger 
reservoir for media. This feature allowed us to better simulate a myocardial infarction in vitro by precisely 
changing culture conditions between ischemia and reperfusion (Figure 6A). Constructs were cultured for 
2 weeks in the bioreactor prior to simulated ischemia-reperfusion experiments.  
To recapitulate the ischemic state, we placed the constructs in a salt solution to simulate the ischemic 
environment. This salt solution was devoid of metabolic substrates to mimic nutrient deprivation and had 
a high potassium concentration and low pH to mimic extracellular conditions seen in ischemia. 
Furthermore, we restricted the solution volume to just 120 μL to allow for the accumulation of wastes 
and further modification of the extracellular environment by the constructs to simulate the lack of blood 
flow. The bioreactor was placed in an anoxic environment (95% N2, 5% CO2) for 6 hours to induce hypoxia. 
We found that the constructs did not demonstrate spontaneous contractions when we removed them 
from the hypoxic chamber, which indicated a lack of ATP production.  
To simulate reperfusion, the constructs were returned back to a normoxic environment, and normal 
culture media was added to the larger reservoir to fully washout the accumulated waste, replenish 
nutrients, and reestablish pH and ionic balance. Constructs were analyzed after 3 hours of simulated 





Figure 6: Experimental protocol for ischemia-reperfusion injury. (A) Schematic detailing the 
ischemic state and reperfusion. Media volume is restricted during simulated ischemia to promote 
metabolic waste accumulation in the extracellular space. (B) Constructs were placed in hypoxia 




THE ISCHEMIC STATE 
Ischemia is the restriction of blood flow that prevents oxygen and nutrient delivery to the downstream 
region and removal of metabolic waste. Thus, to simulate ischemia, we not only needed to create a 
hypoxic environment, but also an environment that was deprived of substrates to stop ATP generation 
and that promoted the accumulation of wastes to simulate the lack of blood flow. Furthermore, the 
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ischemic state also involves other modifications to the extracellular environment, such as a high 
extracellular potassium concentration due to ischemic cell death and a decrease in extracellular pH. We 
simulated ischemic conditions by placing the constructs in a substrate-free solution under hypoxia with a 
minimal amount of volume to simulate lack of blood flow. Under ischemic conditions, the cardiomyocytes 
should have a decrease in ATP turnover that leads to cessation of normal function, such as spontaneous 
contractions, and eventually cell death. We saw that our constructs were not beating after the ischemic 
period, indicating a lack of ATP production, and demonstrated an increase in cell death compared to 
normoxic constructs (Figure 8).  
 
RECAPITULATING THE ISCHEMIC STATE 
Inhibition of ATP production 
To decrease ATP turnover in simulated ischemia, we needed to inhibit the ATP generating processes 
glycolysis and oxidative metabolism. Cardiomyocytes are primarily dependent on oxidative 
phosphorylation for their ATP production [53]; thus, we placed the cardiac constructs into a hypoxic 
environment to shut down oxidative metabolism. Without oxygen, the cardiomyocytes must instead rely 
on the much less efficient anaerobic glycolysis for their ATP production. Glycolysis converts glucose to 
pyruvate to produce ATP, with reduction of NAD+ to NADH. NAD+ stores need to be replenished to 
continue glycolysis and production of ATP. The cell can accomplish this by converting pyruvate to lactate 
using lactate dehydrogenase, which also oxidizes NADH to NAD+. Overall, glycolysis causes cardiomyocytes 
to produce lactate. To inhibit glycolysis, we placed the constructs in a glucose-free environment to deprive 
them of metabolic substrates. Many other studies have further inhibited glycolysis with either the 
addition of lactate or 2-deoxyglucose [32, 33, 44, 45, 52, 67, 119–123] to prevent the metabolism of any 
leftover glucose. Lactate addition would inhibit glycolysis through the accumulation of its end product, 
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while 2-deoxyglucose is a direct competitive inhibitor of glycolysis. We decided to further inhibit glycolysis 
with the addition of lactate because it is a physiological compound, unlike 2-deoxyglucose.  
 
Lactate Addition 
The addition of lactate to the ischemic solution can be contentious because the heart can also utilize 
lactate for ATP production [124]. This would subvert the intended goal of lactate addition, which is to 
simulate its accumulation during ischemia and inhibit glycolysis to decrease cell ATP production. Lactate 
is metabolized through two pathways. In the first pathway, lactate is converted into pyruvate by lactate 
dehydrogenase. Pyruvate can then be converted by pyruvate dehydrogenase and utilized in the 
tricarboxylic acid cycle and oxidative phosphorylation to produce ATP [125]. However, under hypoxic 
conditions, the lack of oxygen should block the metabolism of lactate through this mechanism. 
Alternatively, pyruvate can be converted by pyruvate carboxylase into oxaloacetate, which can then be 
converted into glucose through the ATP-consuming gluconeogenesis pathway [126]. Gluconeogenesis 
primarily occurs in the liver as part of the lactic acid cycle [127], but cardiomyocytes have been found to 
have low expression of some of the important enzymes required for gluconeogenesis [128]. However, this 
pathway is ATP-consuming, and it would not be utilized in the ATP-depleted hypoxic environment. It has 
been seen that a cardiac construct subjected to anoxia in a lactate-only environment ceased beating, while 
the glucose-only construct maintained beating [88]. In the anoxic environment the cardiac constructs are 
placed in, the additional lactate would not be utilized as a substrate for further metabolism.  
The necessity of lactate addition for simulation of ischemic conditions has not been conclusively 
determined. Multiple in vitro studies have utilized lactate addition in their respective ischemic solutions 
to simulate ischemic conditions [32, 33, 45, 52, 67, 120–122], but other studies have not [50, 129]. In an 
anoxic, glucose-free environment, cellular ATP production should eventually cease without the addition 
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of lactate. Lactate addition to the ischemic solution can help further decrease glycolysis, but there is a 
concern that lactate will instead become a metabolic substrate. Without oxygen, this should not be a 
concern, but there is a worry that the hypoxic chamber does not maintain a hypoxic environment that 
would prevent the oxidation of lactate. A leaky hypoxic chamber would allow further metabolism of 
lactate and defeat its purpose.  
To address these concerns, we utilized relatively short simulated ischemia times of 6 hours to minimize 
gas leakage, flushed the chamber with anoxic gas (95% N2, 5% CO2 instead of 1% O2, 94% N2, 5% CO2) to 
maintain hypoxic conditions, purged the chamber a second time one hour after the first to maintain 
hypoxic conditions, and continuously monitored oxygen levels using oxygen sensor spots (PreSens PSt3) 
to confirm hypoxia (<1% O2). These measures have been demonstrated to maintain experimental 
consistency [130]. A model of oxygen consumption in cardiomyocytes found that 0.004 mM extracellular 
oxygen is the unsustainable concentration for maintenance of ATP for non-beating cardiomyocytes [131]. 
Our oxygen sensor consistently measured around 0.31% O2 in the hypoxic chamber, which corresponds to 
a dissolved oxygen concentration of approximately 0.0029 mM. The limit of detection of the sensor is 
0.03% oxygen with a 0.05% accuracy at low oxygen levels. This indicated that our method of inducing 
hypoxic conditions should have provided an environment of depleted cellular ATP. 
Elevated blood lactate levels are seen in patients with acute MI. A venous blood lactate level > 1.5 mM 
was found to be sensitive for an acute MI [132], and patients with an arterial blood lactate levels > 4 mM 
had a large increase in mortality [133]. However, most of the patients had an arterial blood lactate level 
between 1-2 mM. On the other hand, the lactate concentration utilized in in vitro studies ranged from 5 
– 40 mM, with a mode of 20 mM [32, 33, 45, 52, 67, 120–122]. This discrepancy between in vitro 
simulations and the clinical setting can be explained by differences between the infarcted myocardium 
and the circulating blood. Local levels of lactate around ischemic cardiomyocytes should be much higher 
than the systemic circulation due to lack of blood flow during an MI. However, it is unclear what local 
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extracellular concentration of lactate is appropriate. There are no measurements of local levels of lactate 
after a myocardial infarction, but it has been found that transient levels of blood lactate can reach up to 
15-25 mM during exercise [134]. These high transient increases further indicate that the local extracellular 
concentration is much higher than that in the circulation. The lactate added to the ischemic solution 
should be a higher concentration than the systemic blood levels. We utilized a concentration of 20 mM 
for our ischemic solution. A concentration of 20 mM does not seem unreasonable given how high 
transient levels can reach, but further titration of concentrations may be informative to better understand 
the role of lactate in the ischemic state.  
The necessity of lactate addition for simulated ischemia-reperfusion may be further examined by 
comparing cell injury of cardiac constructs with or without lactate addition. None of the studies reviewed 
have made this comparison. In particular, we would seek to determine if the addition of lactate to the 
ischemic solution is cardioprotective. Lactate addition should lead to increased cell death due to 
downregulation of glycolysis under our current experimental conditions, but if lactate is being utilized in 
oxidative metabolism, we should see increased cell survival. Furthermore, the use of radio-isotope labeled 
lactate and measurement of 14CO2 production could be performed to measure lactate oxidation during 
ischemia. 
The aim of simulated ischemia conditions was to inhibit ATP production in the cardiomyocytes. Oxidative 
phosphorylation was inhibited by culture in a hypoxic environment, while glycolysis was inhibited by 
culture in a glucose-free environment and by addition of the end product of glycolysis, lactate. Lactate 
can be utilized by the heart for ATP production, but this process requires oxidative phosphorylation, which 




2-deoxyglucose for Inhibition of Glycolysis 
Further inhibition of glycolysis can also be achieved through the addition of 2-deoxyglucose. 2-
deoxyglucose is a nonmetabolizable glucose analog that can competitively inhibit glycolysis and consume 
ATP stores through its phosphorylation by hexokinase. It has been included in simulations of ischemia for 
metabolic inhibition of isolated cardiomyocytes [44, 119, 123]. 2-deoxyglucose addition is an alternative 
to lactate addition for inhibition of glycolysis on top of substrate deprivation. However, we chose to not 
include it in our studies because it is unclear how else 2-deoxyglucose can influence cellular behavior. 2-
deoxyglucose is not a physiological compound and is not washed out during reperfusion. Thus, we chose 
to utilize lactate addition in addition to glucose deprivation for inhibition of glycolysis during simulated 
ischemia.  
 
Extracellular Potassium Concentration 
A high extracellular potassium concentration is seen in an MI due to cell death [135, 136]. High 
extracellular potassium concentrations lead to alterations in cardiomyocyte electrophysiology that can 
lead to development of arrhythmias and injury [137]. The ischemic solutions that we based our solution 
off of only utilized 5.4 mM potassium [52, 67], which is only mildly elevated compared to normal 
potassium levels between 3.5-5 mM [138]. However, measurements of potassium concentration in the 
heart during an MI have demonstrated increases up to 11-12 mM [136]. Thus, we decided to increase the 
concentration of potassium to 12 mM to better simulate the expected concentration in the local 





We further titrated the ischemic solution to an acidic pH to better simulate ischemic conditions. 
Intracellular acidification during ischemia and rapid normalization of intracellular pH is an important part 
of the pathophysiology of IRI. Intracellular acidification occurs due to low ATP turnover, with increased 
hydrolysis and decreased synthesis of ATP that leads to excess production of protons [20]. The 
cardiomyocytes attempt to buffer the intracellular acidification through transport of protons through the 
monocarboxylate transporter (MCT) and sodium hydrogen exchanger (NHE), which results in acidification 
of the extracellular environment. It is the rapid restoration of the extracellular pH to neutral that causes 
rapid normalization of intracellular pH and intracellular calcium overload.  
We simulated ischemic conditions by titrating the ischemic solution to pH 6.4 based on previous studies 
[52, 67, 120]. A pH of 6.4 is around the intracellular pH in ischemic hearts, which has been measured to 
be as low as 6.2 [139]. Other studies have utilized a higher [33, 121] and lower pH [50] for their 
simulations, but we ultimately decided on pH of 6.4 to provide an order of magnitude difference between 
ischemia and reperfusion conditions. We also later attempted to utilize reperfusion with acidic media as 
a cardioprotective strategy. Previous studies on rat hearts utilized reperfusion with acidic media of pH 6.4 
[140], and we wanted to maintain the same pH for the acidic media as the ischemic media.  
There is an argument to not titrate to an acidic pH. The cardiomyocytes should acidify their environment 
through the natural process of lactic acidosis and decreased ATP turnover [20]. One of the concerns we 
had when starting this study was that we would not be able to see the cell death due to IRI. While the 
ischemic solution attempts to be physiologic, it inherently cannot capture the in vivo environment by 
itself. There may be interactions that we are not accounting for. Acidification of intracellular and 
extracellular space is an important part of the pathophysiology of IRI, and we wanted to ensure that we 
were able to capture this with an acidic pH during ischemia and a return to neutral pH during reperfusion. 
It has been demonstrated that lowering the pH in simulated ischemia leads to an increase in cell death 
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[50]. With further understanding of the cellular response, we can create ischemic conditions that will 
naturally promote intracellular acidification for a more physiologic process rather than imposing it on the 
cells through titration to an acidic pH. However, in our current studies, we wanted to have more control 
over ischemic conditions.  
 
Buffers 
The ischemic solutions used in in vitro studies relied on 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES) or bicarbonate for their buffering capabilities [32, 33, 45, 52, 67, 120–122], and the ischemic 
solution we utilized used 5 mM HEPES. HEPES and bicarbonate are the most common buffers utilized in 
cell culture; however, HEPES has a pKa of 7.31 with a useful range of pH 6.8-8.2. Sodium bicarbonate does 
have a pKa of 6.4, but its buffering capabilities are dependent on atmospheric carbon dioxide levels and 
may not work as well during excessive handling under room air. Thus, we wanted to avoid bicarbonate 
buffering. No studies have explored the use of other buffers, such as 2-(N-morpholino) ethanesulfonic 
acid (MES) which has a pKa of 5.97 at 37°C with working range of pH 5.5-6.7. These other buffers may be 
more appropriate for maintaining the low extracellular pH seen in ischemia, but we wished to avoid them 
because of their current nonexistent use in in vitro studies. 
A more important factor in simulating ischemia is that the buffering capabilities of the ischemic solution 
must not overwhelm the cells’ ability to modify their extracellular environment. Intracellular acidification 
and rapid normalization during reperfusion are critical to the pathophysiology. To address this, we utilized 
lower concentrations of HEPES compared to the standard working range of ≥10 mM [141], the ischemic 
solution was titrated to an acidic pH to begin with, and a minimal amount of solution was added. These 
factors forced ischemic conditions onto the construct and allowed the cells to exert more control over 





We utilized an ischemic time of 6 hours for experiments conducted in this thesis. The ischemic time was 
chosen based off a cardiac tissue engineering platform utilizing neonatal rat cardiomyocytes for study of 
IRI [78]. In general, in vivo studies use much shorter ischemic times to induce injury compared to in vitro 
studies [33, 48]. This is because the intact heart is much more mature and reliant on its blood supply than 
any isolated cardiomyocyte. In particular, hiPS-CMs still fall short of adult maturity and are resistant to 
hypoxia. The ischemic time we utilized in these studies demonstrated differences in cell death that we 
could explore, but there are reasons to alter the ischemic time in future studies.  
It is recognized that the cardiac construct subjected to simulated ischemia-reperfusion does not represent 
the entire myocardial infarct. In this model, the entire construct is subjected to the same ischemic 
conditions and ischemic time. On the other hand, the center and border of the infarct area are subjected 
to different degrees of injury in vivo. The border zone is partially sustained by collateral circulation, is 
more resistant to ischemic injury, and thus, demonstrates better survival compared to the center of the 
infarct region. Under the current ischemic time, most of the constructs did not regain beating and are 
more representative of the center of the infarct area. Decreasing the ischemic time would allow us to 
better assess the response of cardiomyocytes in the border zone to ischemia-reperfusion and give us a 
better understanding of the entire myocardial infarct area.  
 
REPERFUSION 
Reperfusion serves to restore nutrients and oxygen to the cells, washout accumulated waste, and 
reestablish normal extracellular pH and ionic balance. In our model, reperfusion was achieved by returning 
the constructs back to a normoxic environment and by the addition of 2 mL of RPMI 1640 supplemented 
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with 1.4 mM calcium chloride (for a final calcium concentration of 1.8 mM) and 2% B27 supplement, minus 
antioxidants. The media helped to restore metabolic substrates and washout the ischemic solution. This 
media was also utilized for culture of the normoxic constructs for the duration of simulated ischemia-
reperfusion to minimize culture differences between the reperfused groups and controls. The media 
utilized for reperfusion was very similar to that used for normal culture of cardiac constructs, but it had a 
higher concentration of calcium and removed antioxidants. Calcium concentration in base RPMI 1640 
media is 0.42 mM, which is much lower than the 1-2 mM found in normal blood levels [55]. Additional 
calcium was supplemented into the reperfusion media to bring levels into the physiological range, and 
this  would also allow for calcium overload of the cardiomyocytes during reperfusion through the sodium-
calcium exchanger (NCX) [142]. Furthermore, we removed antioxidants from the reperfusion media by 
utilizing B27 supplement without antioxidants and by not including ascorbic acid. It has been recognized 
that oxidative stress and generation of reactive oxygen species is an important component of reperfusion 
injury [26], and we wanted to ensure that we were not artificially limiting it.  
The reperfusion media we utilized was buffered using bicarbonate. The sodium-bicarbonate cotransporter 
(NBC) is important in the regulation of intracellular pH, and it helps to extrude acid by cotransport of 
sodium and bicarbonate into the cell [143, 144]. Thus, the transport of bicarbonate from the extracellular 
to intracellular space contributes to reperfusion injury through rapid intracellular pH normalization. 
Studies have attempted to isolate out the effects of bicarbonate using HEPES-buffered media [140], but 
we thought it was appropriate to include bicarbonate in the reperfusion media because it is prevalent in 
blood and physiological reperfusion. The bicarbonate concentration in the media was 23.8 mM, which is 
within the normal serum bicarbonate range of 22-29 mM [145]. We sought to reperfuse our cardiac 
constructs using modified normal culture media to minimize differences between culture and reperfusion 
conditions but also allow for changes during reperfusion.  
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We analyzed our constructs after 3 hours of reperfusion. Reperfusion times for studies of IRI vary 
drastically, with as short as 15 minutes [119] to as long as 17 hours [50]. Most studies analyzed their 
samples after 1-6 hours of reperfusion [32, 33, 45, 120, 146]. Many of the mechanisms that cause 
reperfusion injury happen in the short period surrounding reperfusion, but there are also many signaling 
pathways that are activated to cause long term changes. We decided to analyze our samples after 3 hours 
of reperfusion in an attempt to capture both the short and long-term changes caused by reperfusion. 
Further characterization of shorter and longer reperfusion times will allow us to build a better timeline of 




As illustrated in the model of cardiomyocyte oxygen consumption, ATP utilization is much higher when 
the heart is beating [131]. Electrical stimulation has been utilized to help promote maturation, but it can 
also help to improve simulation of ischemia-reperfusion. Under the global hypoxia conditions utilized in 
our experimental setup, the cardiomyocytes in the cardiac construct can go into hibernation, stop 
contracting, and reduce their energy demands [147]. However, the heart does not have this luxury during 
an acute MI and still needs to meet contractile demands. This puts a greater stress on the in vivo 
cardiomyocytes and forces higher ATP utilization than what is seen in the in vitro cardiomyocytes. To help 
simulate this process, electrical stimulation during ischemia can help drive construct contraction to help 
force contractile work by the cardiac constructs.  
The bioreactor platform was originally designed to incorporate electrical stimulation through carbon rods. 
However, technical issues lead to the removal of electrical stimulation from the final experiments because 
it seemed to damage cardiomyocytes and prevent formation of a cohesive contracting cardiac construct. 
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Our adapted platform is capable of providing electrical stimulation to the constructs, but the issues with 
electrical stimulation that arose will need to be solved to allow for improved maturation of the cardiac 
construct and improved simulation of ischemia-reperfusion.  
 
PROPOSED BIOREACTOR TO SIMULATE OXYGEN GRADIENT IN AN MI 
Currently, we subject the entire cardiac construct to an anoxic environment to simulate the infarct region. 
However, a complete anoxic environment is not necessarily representative of the full MI. The human heart 
does have some collateral coronary circulation that can provide partial oxygenation to parts of the infarct 
area [148]. Recapitulation of these dynamics is difficult to achieve in vitro. One study attempted to 
simulate a spatially controlled MI in a microfluidic device [149]. Cardiomyocytes were seeded in a central 
channel, which was surrounded by 2 perfusable channels. Only one channel was perfused with carbonyl 
cyanide p-trifluoromethoxyphenylhydrazone (FCCP), which uncouples oxidative phosphorylation and ATP 
synthesis, in an attempt to simulate ischemia. This led to a gradient of FCCP and cell death between the 
two perfused channels. However, the use of a drug for metabolic inhibition to simulate ischemia is 
undesirable because of difficulties in washing it out to simulate reperfusion. Instead, a bioreactor that 
supports partial oxygenation of the cardiac construct can examine how minute changes in oxygen 
concentration affect the cardiomyocyte response.  
We developed the concept of a bioreactor that could potentially allow for partial oxygenation of the 
cardiomyocytes with a functional microvasculature. The bioreactor was based on a previous platform 
developed by Nguyen et al. to study angiogenic sprouting of endothelial cells between two channels [150], 
but it features critical differences that optimize the platform for study of ischemia-reperfusion. Nguyen et 
al. demonstrated that the endothelial cells lining the channel could be induced to sprout into the hydrogel 
through a combination of proangiogenic factors and shear stress through culture on a rocker. In this 
platform, the hydrogel would instead by seeded with cardiomyocytes to form a cardiac parenchyma for 
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the endothelial cells to sprout into and form a functional microvasculature. Shear stress and flow would 
be introduced by culture on a rocker, and proangiogenic factors would be added to promote the formation 
of a functional microvasculature that connects the two channels (Figure 7A). The original reactor was 
made of PDMS, which is permeable to gases. On the other hand, this reactor was constructed out of 
polymethylmethacrylate (PMMA) to be impermeable to gases and allow for potential hypoxic conditions. 
PMMA, similar to PDMS, is cheap and transparent to allow for optical examination of the cardiac tissue. 
The reactor was formed by solvent bonding laser cut layers of PMMA together, but PMMA can also be 
formed by injection molding for large scale manufacturing (Figure 7B). A PMMA cap with a gasket could 
be screwed to one half of the reactor to block access to atmospheric oxygen, and the idea was that oxygen 
levels would eventually be depleted on that side to create a hypoxic environment in one channel (Figure 
7C). This would create an oxygen gradient through the cardiac construct and allow for examination of 
cardiomyocyte response to varying oxygen concentrations. We were able to demonstrate that we could 
form two separately perfusable channels in the formed hydrogel by removal of steel rods after hydrogel 
casting (Figure 7D). 
This platform of course has multiple issues that must be overcome, and it is merely a concept of potential 
directions to better understand the response of cardiomyocytes to ischemia-reperfusion. The current 
platform offers no methods to help promote maturation of the cardiomyocytes through electrical 
stimulation or mechanical conditioning. The method of inducing hypoxia and oxygen depletion also 
depends on cellular consumption of existing oxygen on one half of the reactor, which offers less control 
and more variability than the current method of purging environmental gas in the hypoxic chamber. It is 
unclear how long it would take for hypoxic conditions to take hold, but this may be helped by making the 
media wells smaller on that side so that there is less dissolved oxygen that needs to be consumed. 
However, the platform does offer certain advantages over the existing platform. The use of perfusion and 
endothelial cells to form a microvasculature would allow us to examine interactions between endothelial 
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cells and cardiomyocytes [151]. Nitric oxide is synthesized by the endothelium, increased synthesis is seen 
during ischemia, and it can be cardioprotective in ischemia-reperfusion [52, 152–154].  
Since this thesis was the first to explore ischemia-reperfusion in a human tissue model, we decided to 
focus on the cardiomyocytes themselves, exclude other cell types, and focus on a simplified engineered 
cardiac construct. We aimed to focus on utilizing cardiac tissue engineering to promote the maturation of 
hIPS-CMs for simulation of ischemia-reperfusion.   
 
 
Figure 7: Proposed bioreactor to induce oxygen gradient in cardiac construct with functional 
microvasculature. (A) Schematic of the cardiac construct hydrogel with infiltrating endothelial 
cells and two perfusable channels. An oxygen gradient can be induced by restricting oxygenation 
of one channel. (B) Schematic of the bioreactor. Different polymethylmethacrylate (PMMA) layers 
are solvent-welded together to form an oxygen impermeable platform. (C) Oxygen can be 
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restricted by addition of a PMMA cap with gasket to one side of the bioreactor. (D) Initial testing 
of the bioreactor demonstrated the formation of two separate channels in the hydrogel that can 
be perfused through culture on a rocker.   
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Aim 2: Validate Ischemia-Reperfusion Injury in the Tissue Engineered 
Cardiac Construct 
 
Criteria to Validate Ischemia-Reperfusion Injury 
Because in vitro models examine IRI in non-physiological settings, they must first be validated to 
demonstrate that IRI can be observed. Critically, we wanted to distinguish ischemic injury from 
reperfusion injury. In these studies, we sought to demonstrate the presence of IRI and that we can detect 
changes in it by demonstrating: (1) an increase in cell death in the hypoxia-reoxygenated group over 
normoxic control, (2) an increase in cell death after hypoxia-reoxygenation compared to hypoxia only, and 





Distinguishing Ischemic Injury from Reperfusion Injury 
We first assessed the presence of ischemia-reperfusion injury in the engineered cardiac constructs by 
comparing the response of ischemia-only (referred to as “Isch”) and ischemia followed by reperfusion 
(referred to as “Rep”) constructs. Isch constructs were subjected to 6 hours of simulated ischemia, while 
Rep constructs were subjected to 6 hours of simulated ischemia followed by 3 hours of simulated 
reperfusion. This comparison allowed us to differentially assess the effects of ischemia and reperfusion 
injury. The Isch and Rep groups were further compared to constructs under normal culture conditions 
(referred to as “Norm”) (Figure 8A).  
Lactate dehydrogenase (LDH) and adenylate kinase (AK) release were used to assess membrane integrity 
and cell death. Isch constructs demonstrated a significant increase in cell death over Norm constructs. 
Reperfusion led to further cell injury, which was reflected by the significant increase in cell death in Rep 
over Isch constructs (Figure 8B-C). These differences were further confirmed in measurements of cell 
activity to assess cell viability. The Isch group demonstrated a significant decrease in cell viability 
compared to Norm controls, and reperfusion lead to a further decrease in the Rep group (Figure 8D). 
These results demonstrated that simulated ischemia caused cell injury in the cardiac constructs, and 
reperfusion further increased the cell injury and decreased cell viability compared to ischemia alone.  
To further characterize IRI in the constructs, we utilized JC-1 staining to assess mitochondrial membrane 
permeability. Opening of the MPTP with subsequent mitochondrial membrane depolarization is a critical 
step leading to cell death in lethal reperfusion injury. The JC-1 dye was used to assess the mitochondrial 
membrane permeability and the state of the MPTP. The JC-1 dye normally aggregates in the mitochondria 
with a peak emission at 590 nm, but depolarization of the membrane causes it to disperse into the cytosol 
with a peak emission at 528 nm. By comparing the relative fluorescence of the dye, it is possible to 
determine the relative permeability of the mitochondria membrane. In the constructs, we saw a 
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significant increase in mitochondrial membrane permeability in the Isch group over the Norm group. 
Reperfusion led to an even larger increase in mitochondrial membrane permeability, with a significant 
increase in Rep constructs over ischemia-only (Figure 8E). This large increase is likely due to opening of 
the MPTP during reperfusion, which depolarizes the mitochondrial membrane, releases its contents into 
the cytosol, and leads to cell death.  
Reperfusion and restoration of oxygen to the infarct region also leads to the rapid generation of reactive 
oxygen species (ROS) and oxidative stress that contributes to reperfusion injury [155]. As expected, 
reperfused constructs demonstrated higher levels of ROS compared to ischemia-only and normoxic 
constructs (Figure 8F). This indicates that the generation of ROS after reperfusion could be contributing 
to IRI in the human tissue model, and antioxidant therapy should be explored.    
Ischemia leads to lactic acidosis and a decrease in ATP turnover that leads to intracellular acidosis [20]. 
Furthermore, we titrated the ischemic solution to a pH of 6.4 to simulate the acidic extracellular 
environment seen in ischemia. Reperfusion washes out the acidic extracellular environment to restore a 
neutral pH, which causes a rapid normalization of intracellular pH that leads to cell injury and death. We 
utilized Phrodo staining to measure intracellular pH and confirmed that our ischemia-only constructs 
demonstrated a lower intracellular pH compared to both normoxic and reperfused constructs (Figure 8G). 
Our constructs demonstrated a normalization of intracellular pH after reperfusion, and we need to target 




Figure 8: Comparing response of cardiac constructs to simulated ischemia only (referred to as 
“Isch”) and simulated ischemia followed by reperfusion (referred to as “Rep”). (A) Schematic of 
the experimental protocol for the comparison groups. (B-C) Lactate dehydrogenase (LDH) and 
adenylate kinase (AK) release were used to assess cell membrane permeability and death. (D) Cell 
viability was determined by measuring cell activity using RealTime Glo assay. (E) Mitochondrial 
membrane permeability was determined by comparing emission of JC-1 dye at 528 nm and 590 
nm, where increased ratio is correlated with higher permeability. (B-E) Data represents 
aggregated results from 5 independent experiments. (F) Reactive oxygen species (ROS) levels in 
cardiac constructs as measured by ROS-Glo assay. Data represents aggregated results from 4 
independent experiments. (G) Measurement of intracellular pH using pHrodo dye. Higher 
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fluorescence signal indicates a lower intracellular pH. Data represents aggregated results from 2 
independent experiments and are depicted as individual data points with mean ± SD. Statistical 
analysis was done using ANOVA with post-hoc Tukey’s HSD, # indicates statistical significance 
compared to all other groups, * indicates significant difference between groups, p < 0.05.  
 
Constructs were also fixed and stained to examine ultrastructural changes after ischemia and reperfusion. 
Normoxic constructs demonstrated aligned and striated staining for cardiac troponin T. This organization 
was mildly disrupted in Isch constructs, but the Rep constructs demonstrated highly disorganized 
structure. The Rep constructs did not demonstrate the aligned and striated staining seen in the Norm 
constructs. Reperfusion and intracellular calcium overload leads to activation of intracellular proteases 
[25, 156], and this is reflected in the disorganized ultrastructure seen in reperfused constructs.  
 
 
Figure 9: Representative images of cardiac construct ultrastructure (cardiac troponin T staining). 
Images demonstrate increased disorganization of ultrastructure after ischemia, and further 




While ischemia leads to initial activation of apoptotic pathways to cause cell death, reperfusion leads to 
a further large increase in apoptosis to cause even greater injury [157–160]. We assessed the activation 
of apoptosis in the constructs by examining the cleavage of caspase 3 into its active form through western 
blot analysis. As expected, Isch constructs demonstrated a small increase in the ratio of cleaved to total 
caspase 3, and Rep constructs demonstrated a significantly higher increase in caspase 3 cleavage (Figure 
10). Caspase inhibition during reperfusion has helped to decrease IRI [161], but there is also a significant 
amount of necrosis during reperfusion that contributes to the final injury [162]. 
 
 
Figure 10: Western blot analysis of apoptosis in the cardiac constructs. Apoptosis was 
determined by activation and cleavage of caspase 3 and demonstrates an increase after 
reperfusion. Data is from 3 independent experiments, mean ± SD. Statistical analysis was done 
using ANOVA with post-hoc Tukey’s HSD, * indicates significant difference compared to other 




The presence of reperfusion injury was established by comparing ischemia-only to ischemia-reperfusion 
constructs. Reperfusion lead to higher cell death, lower cell viability, and an increase in mitochondrial 
membrane permeability due to opening of the MPTP. We also saw disorganized cardiomyocyte 
ultrastructure in the reperfused constructs, and an increase in apoptosis upon reperfusion. By establishing 
the differential response of the constructs to ischemia and reperfusion, we can next explore 
cardioprotective strategies to treat IRI.  
 
Discussion 
MEASURING CELL DEATH 
To validate the presence of ischemic and reperfusion injury in our platform, we needed to assess and 
characterize cell death. However, cell death is a difficult endpoint to measure, and every assay has 
deficiencies in its use. It has been recommended to analyze cell death utilizing multiple assays that are 
methodologically different [163]. In our studies, we utilized intracellular protein release, measurements 
of cell activity, and mitochondrial membrane permeability as our primary assays to analyze our primary 
endpoint, cell death. We saw that ischemia-only constructs demonstrated an increase in intracellular 
enzyme release, reduced cell activity, and increase in mitochondrial membrane permeability compared 
to normoxic constructs. Reperfusion lead to a further significant difference in these assays compared to 
the ischemia-only constructs. We were able to utilize these cell death assays to demonstrate that 
reperfusion lead to a further increase in construct injury over ischemia alone.  
One of our primary assays to assess cell death was to measure release of the intracellular proteins lactate 
dehydrogenase (LDH) and adenylate kinase (AK). Release of these enzymes indicates cell membrane 
permeability and cell death, and their release can be measured by sampling cell media supernatant and 
measuring enzyme activity by addition of a substrate. Measuring enzyme release is a simple method and 
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can be rapidly scaled up to analyze many constructs. However, this method of quantification can also be 
problematic because enzyme activity can be affected by other factors. In particular for our study, we were 
concerned with how pH differences could affect enzyme activity. Our ischemia-only constructs were 
subjected to pH 6.4 ischemic solution. To measure enzyme release, we added culture media to normalize 
pH and volume, and then quickly sampled the media to minimize differences compared to the reperfused 
constructs. Critically, we saw that our ischemia-only constructs demonstrated an increase on LDH and AK 
release over normoxic controls, which demonstrated that these assays are able to detect cell death due 
to ischemic injury. Another method we attempted in order to normalize conditions was to use a lysis 
buffer to obtain 100% lysis of the construct for full LDH and AK measurements. However, we had issues 
with variable results due to variable penetration of the lysis solution into the tissue bulk. To further 
confirm the increase in LDH and AK release that we saw with reperfusion, we utilized other 
methodologically different assays to assess cell death after ischemia-reperfusion.  
Another method that we could utilize to measure intracellular protein release is enzyme-linked 
immunosorbent assay (ELISA). ELISA would allow for the direct quantification of proteins in the cell media 
without being dependent on enzyme activity. In particular, ELISA to quantify release of cardiac troponin I 
would allow us to assess cardiomyocyte cell death after ischemia-reperfusion. ELISA is an expensive assay 
that is cost-prohibitive for large-scale use, but it can be utilized in future studies to confirm the initial 
findings in the less expensive intracellular protein release assays.  
In addition to intracellular enzyme release, we sought to measure cell activity to assess cell viability after 
ischemia-reperfusion. Tetrazolium dye-based assays, such as the MTT assay, are widely utilized for 
determination of cell metabolic activity. These tetrazolium dye assays are dependent on the cell reduction 
of a water-soluble substrate to an insoluble product, which can then be analyzed and quantified. However, 
we found that these assays had many issues when used for our purposes, and the product seemed to 
negatively impact the viability of the cardiac constructs in pilot experiments. Instead, we utilized 
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RealTime-Glo, a nonlytic luminescent assay, that allowed us to detect cell reduction of the substrate with 
minimal manipulation of the cardiac constructs. It was an ideal assay to facilitate analysis of many 
constructs at a time. Using the RealTime-Glo assay, we were able to demonstrate that reperfusion led to 
a further decrease in construct viability compared to ischemia alone. The major concern for utilizing assays 
that measure cell metabolic activity to assess cell death is that there are many reasons unrelated to cell 
death for why metabolic activity can decrease. For our current comparisons of ischemia-only and 
ischemia-reperfusion this was not an issue. But these concerns do need to be accounted for once we 
modify reperfusion conditions in non-physiological manners to decrease IRI. Thus, we still relied on 
multiple assays to understand cell death in our model.  
We also examined mitochondrial membrane permeabilization as an assay for cell death. Permeabilization 
of the mitochondrial membrane is implicated in all forms of cell death [164]. Moreover, opening of the 
MPTP is critical in the pathophysiology of reperfusion injury [27, 28], and thus, it was important to assess 
mitochondrial membrane permeability in characterizing cell death in IRI. We utilized the JC-1 dye to 
measure mitochondrial membrane potential and found that reperfusion led to a significant increase in 
the mitochondrial membrane permeability. This result indicated that IRI in our platform activated 
mitochondria-dependent cell death pathways. However, IRI also involves oxidative stress, activation of 
intracellular proteases, and other mechanisms of injury that are not necessarily dependent on 
mitochondria [25, 26]. It was important in our characterization of IRI to assess total cell death, and not 
just the mitochondria.  
 
OXIDATIVE STRESS 
After demonstrating an increase in cell death after reperfusion, we sought to further characterize IRI in 
our cardiac constructs by examining other aspects of the pathophysiology that contribute to injury. We 
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aimed to characterize oxidative stress by measuring ROS levels in our constructs. There are 2 main types 
of ROS that are measured in experiments, superoxide anion and hydrogen peroxide [165], and both have 
demonstrated increases after reperfusion [166]. However, superoxide is a less stable ROS and 
disproportionates into hydrogen peroxide, a more stable ROS. Thus, we chose to analyze hydrogen 
peroxide levels to assess cell ROS levels and oxidative stress. Furthermore, hydrogen peroxide is cell 
membrane permeable, which allowed us to measure ROS levels in our constructs without a need for cell 
lysis or microscope observation. There are many fluorescent dyes available to assess hydrogen peroxide 
levels, but we chose to utilize the nonlytic luminescent assay, ROS-Glo. The luminescent assay allowed us 
to multiplex the assay with other fluorescent readouts. By measuring construct hydrogen peroxide levels, 
we are able to determine that reperfused constructs had higher levels of ROS, which could be contributing 
to the greater injury seen in these constructs through oxidative stress.  
In addition to cell ROS levels, mitochondrial ROS generation can also be characterized by utilizing 
mitochondrial specific dyes. MitoSOX and MitoB are fluorescent dyes that can detect mitochondrial 
superoxide and hydrogen peroxide levels respectively. Reactivation of the electron transport chain during 
reperfusion is thought to drive the production of ROS [166], and thus, characterization of mitochondrial 
ROS production will help us further demonstrate changes due to reperfusion. Luminescent and 
fluorescent assays for ROS levels can be analyzed on a plate reader for simple readings and comparisons.  
We could have further characterized oxidative stress by measuring glutathione. Glutathione is an 
endogenous antioxidant that is produced by cells, and reduction in reduced glutathione (GSH) levels is 
indicative of oxidative stress [167]. Furthermore, the antioxidant, N-acetylcysteine (NAC) that we utilized 
in later studies functions by replenishing glutathione levels. However, assays to directly measure GSH 
levels require cell lysis to function, which may give us variable results due to variances in ability to 
completely lyse a 3D construct. Instead, measurements of free thiol levels can be an alternative method 
to assess GSH levels because reduced glutathione comprises the majority of free thiols in a cell [168]. The 
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ThiolTracker Violet dye is a fluorescent dye that can even by fixed for analysis of cell glutathione levels in 
future studies. Measuring GSH levels can give us a better understanding of the cell response to total 
oxidative stress during reperfusion.  
 
INTRACELLULAR PH 
We also measured the intracellular pH after simulated ischemia and confirmed that the constructs had a 
reduction in intracellular pH during ischemia. Rapid normalization of intracellular pH upon reperfusion is 
an important mechanism in causing IRI [42]. Intracellular pH was assessed utilizing the pHrodo dye, a 
fluorescent dye that has higher fluorescence with a decrease in pH, and we saw higher fluorescence in 
the constructs after ischemia. We later attempted to prevent the rapid normalization of intracellular pH 
by reperfusion with acidic media. In future studies, we wish to examine intracellular pH over the time 
course of reperfusion to better assess how therapeutic strategies can change the rate of intracellular pH 
normalization for cardioprotection. 
 
APOPTOSIS 
To further demonstrate differences between ischemic and reperfusion injury, we sought to characterize 
apoptosis through the cleavage and activation of caspase 3. Ischemia is thought to be primarily a necrotic 
cell death process, while reperfusion leads to increased necrosis and activation of apoptosis [159]. 
However, it is important to note that the majority of injury seen in ischemia-reperfusion injury is due to 
necrosis [162]. Caspase 3 is one of the executioner caspases and is responsible for enacting apoptosis 
[169]. Western blot allowed us to assess the cleavage and activation of caspase 3 by utilizing different 
antibodies for the differential comparison of the cleaved and pro-form of caspase 3. Alternatively, there 
are other assays to assess caspase activation through the introduction of luminescent or fluorogenic 
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substrates for caspase cleavage. However, we found that these assays were difficult to utilize in our model 
in initial studies because they depended on complete lysis of the cardiomyocytes to isolate the caspases 
and measure their activity. Instead, western blot analysis allowed us to utilize longer and more aggressive 
lysis and homogenization protocols that did not require preservation of enzyme function. We were able 
to demonstrate that ischemia led to very little change in caspase 3 activation, but reperfusion lead to a 
large increase in cleaved caspase 3 and apoptosis. It is important to note that caspase inhibition does not 
prevent cell death, and caspases are involved in non-lethal intracellular signaling [170, 171]. While 
western blot is not a high throughput analysis method, it did allow us to characterize differential activation 
of apoptosis in IRI.  
Western blot can also be utilized to further characterize apoptosis in our cardiac constructs by differential 
assessment of the cytosolic and mitochondrial fractions. For example, the proapoptotic protein BAX 
normally resides in the cytosol, but is directed to the mitochondrial membrane upon activation of 
apoptosis to assist in membrane permeabilization [172]. Mitochondrial membrane permeabilization also 
releases proapoptotic proteins, such as cytochrome c, which are directed into the cytosol to activate 
caspases [173]. Thus, translocation of proteins between the cytosolic and mitochondrial fractions can be 
assessed by western blot in future studies to further characterize apoptosis.  
In addition to caspase activation, apoptosis can also be morphologically characterized by double strand 
DNA breaks [174]. This characterization is most often accomplished by terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL). However, TUNEL staining is also very non-specific, and we 
found in initial studies that TUNEL staining was inappropriate for our cardiac constructs. Cardiomyocytes 
that had died during the formation of the construct were retained within the hydrogel, and it was 




Further morphological characterization of apoptosis can be done through electron microscopy. Apoptosis 
is characterized by chromatin condensation, membrane blebbing with formation of apoptotic bodies, and 
nuclear fragmentation [175]. Electron microscopy is a low throughput process, and it should only be 
utilized for secondary characterization and not for primary assays.  
Early apoptosis can also be assessed by detecting the exposure of phosphatidylserine to the outer cell 
membrane using Annexin V. Furthermore, early apoptosis can be distinguished from late apoptosis or 
necrosis by also staining with a cell impermeable dye, such as propidium iodide (PI). We would expect 
that ischemia-only constructs have low single-staining for Annexin V and moderate staining for double 
staining of Annexin V and PI due to primarily necrotic cell death. Reperfusion would lead to increased 
single staining of Annexin V and double staining for Annexin V and PI, demonstrating an increase in 
apoptotic and necrotic cell death respectively. Annexin V and propidium iodide staining is typically 
assessed on flow cytometry, but this proved to be difficult on our human tissue platform. The constructs 
required long dissociation times to isolate the single cells necessary for flow cytometry. Furthermore, the 
wash steps for staining caused loss of some of the dead cells for incomplete analysis of the total 
population. We would also expect lower forward scatter and higher side scatter measurements of 
cardiomyocytes from reperfused constructs, which would reflect decreased cell size and increased 
granularity associated with apoptosis upon reperfusion. Currently, flow cytometry analysis is not an ideal 
tool to assess cell death in our constructs after IRI due to technical limitations and low throughput.  
 
INTRACELLULAR CALCIUM 
One aspect of IRI that we did not characterize was the accumulation of intracellular calcium seen during 
reperfusion [176]. This can be assessed by utilizing a calcium dye. We initially tried to assess calcium 
overload and differences in calcium cycling using the FLUO-4 dye, but this caused changes in construct 
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behavior. Normoxic constructs displayed slowed beating, while the reperfused constructs, if beating, 
completely stopped and demonstrated no signal. These issues were possibly due to calcium chelation by 
the dye. Different calcium dyes may need to be experimented with, but future studies should explore the 
use of genetically encoded calcium indicator cell lines, such as the GCaMP6f hIPS cell line [177]. This would 
allow for minimal manipulation of the cardiac constructs during reperfusion to better assess calcium 
overload and defects in calcium propagation. Furthermore, mitochondrial calcium overload has been 
implicated in the pathophysiology of IRI [178, 179]. The rho-2 AM calcium indicator localizes to 
mitochondria and can be utilized to assess mitochondrial calcium overload. Calcium overload can be 
measured through a fluorescence plate reader, and defects in calcium propagation and construct 
contraction can be assessed through optical video analysis.  
 
CALPAIN ACTIVITY 
Intracellular calcium overload during reperfusion also leads to the activation of calpains, calcium-
dependent proteases that target intracellular proteins. Inhibition of calpain activity has demonstrated a 
decrease in IRI and should be a target to be further explored in future experiments [180, 181]. Calpain 
activity can be assessed by introducing fluorescent or luminescent substrates to measure enzyme activity, 
but these assays require cell lysis in order to function. Calpain activity can alternatively be assessed by 
examining its translocation from the cytosol to the cell membrane and its targeting and cleavage of 
membrane-associated cytoskeletal proteins (such as α-fodrin) through western blot [25]. Furthermore, 
we can measure levels of the endogenous inhibitor of calpain activation, calpastatin. Calpastatin is 
normally associated with calpain to inhibit it, but reperfusion leads to degradation of calpastatin [25, 182]. 
Thus, increased calpain activity during reperfusion can also be indirectly measured through reduced 





Analysis of cardiac construct contraction was not done in this thesis because most reperfused constructs 
did not regain spontaneous beating. Lowering the ischemic time in future experiments will allow more 
reperfused constructs to regain beating in order for us to analyze their contractile properties. Contracting 
cardiac constructs can be tracked through optical video analysis. Increased cell death is correlated with 
decreased beat frequency and fractional area change. Variations in the time interval between beats and 
fractional area change per beat can be indicative of increased arrhythmic events. We expect 
cardioprotective strategies to reduce cell death and arrhythmic events. 
 
AUTOPHAGY 
One aspect of IRI that was not explored in this thesis is autophagy. Autophagy helps in cell maintenance 
by processing damaged organelles into autophagosomes for transport to lysosomes for degradation, and 
it is activated under ischemic conditions to break down cellular components to maintain energy stores 
[183, 184]. Stimulation of autophagy has been found to be cardioprotective in IRI [32, 129, 185], and 
decreased autophagic flux or clearance of autophagosomes has been seen on reperfusion [186]. However, 
overactivation of autophagy leads to cell death [187]. The role of autophagy in IRI is still not fully 
understood, and it should be characterized for better understanding of IRI and as a cardioprotective 
strategy in future studies.  
Autophagy can be characterized in a variety of manners. Electron microscopy can be utilized to directly 
assess the presence of autophagosomes, but it is a very costly and low throughput process. Alternatively, 
monodansylcadaverine (MDC) is a fluorescent dye for autophagosomes [188], and can be detected 
through flow cytometry, fluorescence microscopy, or a fluorescent plate reader. Staining of microtubule-
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associated protein light chain 3 (LC3) has also been used to characterized autophagy. LC3 precursors are 
diffusely distributed in the cytosol. Activation of autophagy causes processing of LC3 into LC3-I and then 
LC3-II, where LC3-II associates with the autophagosomes and demonstrates a more punctate distribution. 
Fluorescence microscopy can assess the rearrangement of LC3, but it may not be possible to utilize in our 
model due to tissue thickness. Western blot can also be utilized to assess autophagy by analysis of LC3-I 
conversion to LC3-II and overall LC3-II levels. Higher LC3-II levels correspond with increased formation of 
autophagosomes, but LC3-II is also degraded once the autophagosome fuses with the lysosome. Thus, 
western blot analysis of LC3-II levels alone is unable to distinguish between increased autophagy and 
formation of autophagosomes or decreased autophagic degradation in lysosomes.  
Measuring autophagic flux is important to demonstrate that the autophagy process reaches its endpoint. 
Autophagic flux can be demonstrated by introducing lysosome inhibitors and assessing LC3-II levels to 
determine that lysosome inhibition causes an increase in LC3-II levels [189]. Another method of assessing 
autophagic flux involves the addition of lentiviral vectors expressing red fluorescent protein (RFP) and 
green fluorescent protein (GFP) tagged LC3 (RFP-GFP-LC3). The presence of combined red and green 
fluorescence demonstrates the formation of autophagosomes, while the acidic pH of lysosomes quenches 
GFP fluorescence and only leaves a red signal [32]. This method is amenable for use in our platform and 
can allow for more rapid analysis of autophagy in the cardiac constructs.  
 
SUMMARY 
We differentially characterized cell death in our studies due to ischemia and reperfusion by utilizing 
intracellular enzyme release, cell activity, and mitochondrial membrane permeability. We sought to 
further characterize the changes caused by reperfusion by examining oxidative stress, intracellular pH, 
and apoptosis. There are other aspects of IRI that we did not characterize in this thesis, but that we wish 
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to assess and target for cardioprotective strategies in future studies. In particular, we want to decrease 
ischemic times to reduce injury and allow more constructs to regain beating after reperfusion. This will 
allow us to assess changes in construct contractile behavior due to cardioprotective therapies. We 
demonstrated that reperfusion leads to a significant increase in injury compared to ischemia alone, and 




Failure to Reperfuse the Infarct Region 
Cardiac constructs subjected to simulated ischemia for the full 9 hours (referred to as “Isch (9hr)”) were 
compared to constructs subjected to simulated ischemia for 6 hours (referred to as “Isch (6hr)”) and 
constructs reperfused after 6 hours (referred to as “Rep”) (Figure 11A). The cardiac constructs subjected 
to 9 hours of simulated ischemia represented a failure to reperfuse the infarcted myocardium in a timely 
manner. Constructs subjected to 9 hours of simulated ischemia demonstrated a significant increase in cell 
death compared to those under only 6 hours of ischemia, confirming that increased ischemic time leads 
to increased cell death (Figure 11B-C). The difference between the two groups corresponds to the 
infarcted myocardium that is potentially salvaged by reperfusion therapy. When the constructs that were 
reperfused were compared to constructs that were not reperfused, the significance of reperfusion injury 
becomes apparent. Reperfused constructs demonstrated increased cell injury compared to non-
reperfused constructs, which was significant on measurements of adenylate kinase release but not on 
lactate dehydrogenase release. Reperfused constructs exhibit much higher cellular injury than their 
counterparts exposed to the same ischemic time, but this is potentially preventable damage. Reducing IRI 





Figure 11: Cardiac constructs were subjected to 9 hours of simulated ischemia to model failure 
to reperfuse the infarct region. (A) Schematic of the experimental protocol for the comparison 
groups. (B-C) Lactate dehydrogenase (LDH) and adenylate kinase (AK) release were used to assess 
cell membrane permeability and death. Data represents aggregated results from 3 independent 
experiments, and are depicted as individual data points with mean ± SD. Statistical analysis was 
done using ANOVA with post-hoc Tukey’s HSD, # indicates statistical significance compared to all 




In this study, we utilized our intracellular enzyme release assays to characterize cell death due to increased 
ischemic time. One aspect of these assays that we were concerned with was that unlike other groups 
tested in this thesis, the 6-hour ischemia-only group had a wash step 3 hours into the experiment to switch 
the constructs from normoxic conditions to simulated ischemia. The difference in intracellular enzyme 
release assays between the ischemia-only group and reperfused constructs could be due to this wash step 
that washed away any LDH or AK that was released during the first 3 hours of the experiment. To assuage 
these concerns, we demonstrated that ischemia-only constructs had a significant increase in intracellular 
enzyme release over normoxic constructs. This demonstrated that the assays were sensitive enough to 
detect an increase in ischemic cell death over normoxic controls despite the difference in culture time, 
and baseline readings would not significantly impact results. Furthermore, we compared our ischemia-
only and reperfused constructs on other cell death assays and other methods to characterize reperfusion 
injury to confirm that we visualized a true difference in cell death on intracellular enzyme release assays.    
The constructs subjected to 9 hours of simulated ischemia demonstrated an increase in LDH and AK 
release over 6 hours of ischemia, which further confirms the validity of utilizing intracellular enzyme 
release to measure cell death. An increase in ischemic time lead to a significant increase in measured cell 
death. Moreover, the 9-hour ischemia-only group demonstrated a difference in the intracellular enzyme 
release assays compared to the reperfused group despite the same culture time. This result further 
establishes that reperfusion leads to changes in behavior that cause injury over ischemia only.  
In our future studies, we would like to characterize cell death due to ischemia and reperfusion injury as a 
percentage of overall cell death. This would allow us to move away from construct comparisons into a 
quantifiable standard of therapeutic efficacy. Our initial attempts to accomplish this relied on complete 
lysis of the cardiomyocytes for 100% LDH and AK release; however, we encountered many issues due to 
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variable penetration of the lysis reagent into the construct. It may be necessary to enzymatically dissociate 
the constructs to separate out the cardiomyocytes from the matrix components before lysing. We will 
also focus on making design modifications to the bioreactor to create a thinner construct to allow for 




Ischemic Preconditioning to Decrease IRI 
We next sought to demonstrate the utility of the system by examining current strategies to prevent IRI 
and applying them to the engineered cardiac constructs. Currently, ischemic preconditioning is the only 
treatment known to robustly decrease IRI, and it has been demonstrated to be beneficial across various 
animal species [190]. Ischemic preconditioning involves subjecting the heart to brief periods of hypoxia 
and reperfusion that cause no cell injury prior to the actual ischemic insult.  
Ischemic preconditioning has not unequivocally been demonstrated to decrease IRI in humans because it 
is very difficult to study in the clinical setting. Also, preconditioning must occur before the ischemic insult, 
and thus, cannot be studied in patients with acute MI. Small-scale studies on patients undergoing coronary 
artery bypass surgeries (CABG) have indicated that preconditioning decreases cardiac injury [191, 192]. 
Preconditioning has also been thought to be the mechanism behind reduced infarct size and better 
outcomes in patients with angina prior to their MI [193, 194]. In the laboratory setting, preconditioning 
has shown benefit in the limited models of quiescent primary human ventricular cardiomyocytes and 
isolated atrial trabeculae [195, 196]. An engineered human tissue model offers a better and more robust 
platform to test and examine ischemic preconditioning and the potential benefits of this treatment.  
We simulated ischemic preconditioning by subjecting the constructs to 30 minutes of ischemia and 15 
minutes of reperfusion, before the actual ischemia-reperfusion regimen of 6 hours of ischemia and 3 
hours of simulated reperfusion (constructs referred to as “PreC”) (Figure 12A). Preconditioned constructs 
demonstrated a decrease in cell death as measured by lactate dehydrogenase and adenylate kinase 
release (Figure 12B-C) and an increase in cell viability compared to the Rep group (Figure 12D). 
Furthermore, JC-1 staining demonstrated that preconditioning helped to partially prevent the increase in 
mitochondrial membrane permeability seen in the reperfused constructs (Figure 12E). Western blot 
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analysis also indicated that preconditioning helped to decrease caspase 3 cleavage and apoptosis, 
although the difference was not statistically significant (Figure 13A).  
 
 
Figure 12: Ischemic preconditioning of cardiac constructs to decrease IRI (A) Schematic of the 
experimental protocol for comparison groups. Ischemic preconditioned constructs referred to as 
“PreC”. (B-C) Lactate dehydrogenase (LDH) and adenylate kinase (AK) release were used to assess 
cell membrane permeability and death. (D) Cell viability was determined by measuring cell activity 
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using RealTime Glo assay. (E) Mitochondrial membrane permeability was determined by 
comparing emission of JC-1 dye at 528 nm and 590 nm, where increased ratio is correlated with 
higher permeability. Data represents aggregated results from 4 independent experiments and are 
depicted as individual data points with mean ± SD. Statistical analysis was done using ANOVA with 
post-hoc Tukey’s HSD, # indicates statistical significance compared to all other groups, * indicates 
significant difference between groups, p < 0.05. 
 
Ischemic preconditioning is cardioprotective through the activation of pro-survival kinases [197, 198]. 
Western blot analysis of the cardiac constructs determined that there was increased phosphorylation and 
activation of the cell survival factor Akt in the preconditioned constructs (Figure 13B). This difference was 
not statistically significant, but it does suggest that the activation of kinases in animals can also be seen in 
human tissue models. Reperfused constructs have lower levels of intact protein despite the addition of 
equal amounts of total protein into each well. This is consistent with the increased activation of caspase 
3 and degradation of cardiac ultrastructure seen previously (Figure 9, Figure 10). Studies have identified 
several survival pathways that are activated by ischemic preconditioning [199], in studies done in animals. 
It would be important to identify the exact kinases and pathways in humans for clinical translation. For 
example, STAT3 activation and STAT5 attenuation was cardioprotective in mouse models [200], but the 
opposite was found in humans [201]. Deeper understanding of the exact composition of kinases that are 






Figure 13: Western blot analysis of ischemic preconditioning in cardiac constructs. (A) Analysis 
of apoptosis by cleaved to total caspase 3 ratio. Results were not statistically significant by paired 
t-test. (B) Analysis of Akt and pro-survival kinase activation by phosphorylated to total Akt ratio. 
Data was not statistically significant by ANOVA. Data are from 3 independent experiments, mean 
± SD.  
 
Ischemic preconditioning reduced IRI in the engineered cardiac constructs, with a decrease in cell death 
and improvement in cell viability. We also saw that the preconditioned constructs displayed decreases in 
mitochondrial membrane permeability upon reperfusion, and these results are consistent with previous 
studies that demonstrated cardioprotection in ischemic preconditioning by prevention of MPTP opening 
[202]. Ischemic preconditioning is extremely difficult to study in humans. Overall, these results support 
the use of the engineered cardiac construct as a human model of ischemic preconditioning. We therefore 
utilized the platform to gain insights into the cardioprotective mechanisms of ischemic preconditioning. 
 
While preconditioning is not a clinically relevant therapy in the setting of an acute MI, ischemic 
postconditioning and remote ischemic conditioning can potentially be. These methods activate similar 
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survival pathways as ischemic preconditioning to provide cardioprotection [41, 203, 204], but they have 
demonstrated mixed results in early clinical trials [15, 205, 206]. Larger clinical trials are needed to better 
understand their impact. One potential issue is that the clinical trials have had great heterogeneity in their 
conditioning regimens, and this is due to the undefined nature of ischemic conditioning. We hope to 
further use the platform to better define the important factors in conditioning regimens and turn these 
insights into a clinically relevant therapy.  
 
Simulating Ischemic Preconditioning 
Normally preconditioning involves multiple cycles of ischemia and reperfusion, and there is a great 
variance in ischemic conditioning regimens. We were concerned that the constant manipulation of the 
constructs with wash steps and handling outside of the incubator could be a potentially confounding 
factor in our comparisons; therefore, we limited preconditioning to one cycle of 30 minutes of ischemia 
followed by 15 minutes of reperfusion. One cycle of preconditioning has demonstrated cardioprotection 
in both in vitro and animal studies [44, 207, 208]. We utilized 30 minutes of ischemia in our 
preconditioning regimen to ensure that our stimulus reached a minimal threshold for cardioprotection 
[208], but we were concerned that the duration may be too long and lead to no change [209]. We did 
demonstrate decreases in cell death in our preconditioned constructs (Figure 12), but we do want to 
explore the importance of preconditioning duration and number of cycles in future studies.  
Our current simulation of preconditioning involves subjecting the constructs to the same ischemic 
conditions as our actual ischemic insult. We did this to limit the number of variables in our experimental 
protocol, but it may be incorrect for physiological simulation of ischemic preconditioning. Ischemic 
preconditioning involves subjecting the heart to nonlethal cycles of ischemia and reperfusion, but our 
ischemic solution aimed to simulate the ischemic state and injury with lactate addition, high extracellular 
potassium, and an acidic extracellular environment in addition to substrate deprivation and hypoxia. 
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Lactate accumulation, high extracellular potassium, and extracellular acidification are unlikely to occur in 
the short ischemic time of preconditioning, and it may be more appropriate to simulate preconditioning 
with only substrate deprivation and hypoxia. It will be necessary to compare construct responses between 
these two protocols and determine if there are any changes. We want to study ischemic preconditioning 
in our constructs to identify the signaling changes that lead to cardioprotection and the targets for future 
cardioprotective therapies. Any differences in construct response to these two preconditioning protocols 
will help us in the effort to identify relevant stimuli.  
 
Discussion 
Preconditioning involves subjecting the myocardium to short bouts of ischemia and reperfusion that cause 
no damage, but this was not verified in our platform. One of the controls we need to add in the future is 
to confirm that the 30 minutes of ischemia and 15 minutes of reperfusion we utilized to simulate 
preconditioning did not cause cell death. We need to analyze constructs immediately after the 
preconditioning cycle and compare them to our normoxic controls on cell death assays. There is a concern 
that the decrease in cell death that was assessed by intracellular enzyme release and mitochondrial 
membrane permeability assays may be due to washing away the dead cells on the preconditioning 
regimen. The extra wash steps and manipulation of the preconditioned constructs could be leading to a 
false decrease in cell death compared to reperfused constructs. By assessing cell death immediately after 
the preconditioning regimen, we can determine if there is an issue with these assays. In our studies, we 
utilized measurements of cell activity to determine cell viability and supplement our other cell death 
assays. Cell activity assays are not impacted by washing away dead cells. The increased cell activity that 
was saw in the preconditioned constructs compared to reperfused constructs supports our result that 
ischemic preconditioning reduced IRI.  
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 We further identified increased phosphorylation of Akt in our preconditioned constructs compared to 
reperfused constructs. This is consistent with animal and human studies which have identified activation 
of survival pathways as a mechanism behind cardioprotection by ischemic conditioning [41, 198, 210]. Akt 
activation is part of what has been termed the reperfusion injury survival kinase (RISK) pathway, and we 
should further assess the pathway and its importance in cardioprotection in our platform. To accomplish 
this, we first need to more fully characterize activation of the RISK pathway. We want to assess the 
activation of ERK1/2, which functions parallel to the PI3K-Akt activation, and the downstream GSK3β, 
which is the common target of PI3K-Akt and ERK1/2 activation. GSK3β is thought to be the end effector 
of the RISK pathway, where phosphorylation of GSK3β inhibits it and leads to inhibition of MPTP opening 
[211]. Characterization of the phosphorylation of these proteins will allow us to demonstrate activation 
of the RISK pathway in our preconditioned constructs.  
After characterization, we want to modify the RISK pathway to assess its importance. Currently, it is 
unclear if GSK3β inhibition is required for cardioprotection by ischemic preconditioning. Rodent studies 
using transgenic GSK3β that cannot be inhibited found mixed results [212, 213], and furthermore, the 
RISK pathway has been found to be not necessary for cardioprotection by ischemic postconditioning in 
pigs [214]. The importance may be species dependent. To further characterize the RISK pathway, we want 
to introduce inhibitors and activators of PI3K-Akt, ERK1/2, and GSK3β. There are many inhibitors of PI3K 
that target and inhibit downstream activation of Akt; however, the commonly used wortmannin and 
LY294002 inhibit all classes of PI3K. We want to use specific inhibitors of class I PI3K to target Akt 
activation. Furthermore, we can also directly inhibit or activate Akt itself to assess its effects. The use of 
ERK1/2 inhibitors in conjunction with inhibition of PI3K-Akt will allow us to fully inhibit the RISK pathway 
and also assess relative importance of these two parallel pathways. Furthermore, direct inhibition of 
GSK3β along with inhibitors of MPTP opening will allow us to assess the importance of GSK3β and the RISK 
pathway in cardioprotection by ischemic preconditioning in humans.  
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Independently of the RISK pathway, activation of the survivor activating factor enhancement (SAFE) 
pathway has been demonstrated to be a target of ischemic preconditioning. The SAFE pathway involves 
signaling through TNFα receptor 2, janus kinase (JAK), and signal transducer and activator of transcription 
(STAT) to ultimately target the mitochondria and prevent MPTP opening [215]. We need to characterize 
if activation of this pathway is prevalent in our preconditioned constructs. Furthermore, it has been found 
that while activation and phosphorylation of STAT3 drives the SAFE pathway in rodents and other animals 
[200], it is STAT5 activation that is relevant in humans [201]. These differences between species further 
emphasize the need for a human tissue platform to explore the mechanisms driving ischemic 
preconditioning. After characterization of STAT activation, we would like to further test the importance 
of the SAFE pathway through inhibition of the upstream JAK or direct inhibition of STAT activity in our 
preconditioned constructs. We want to use these studies to establish the importance of the RISK and SAFE 






Responses of Immature Cardiac Construct to Simulated Ischemia-Reperfusion  
We next sought to establish the importance of the bioreactor in providing a platform to mature the hiPS-
CMs by examining the responses of relatively immature cardiac constructs to simulated ischemia and 
reperfusion. Immature cardiac constructs were tested at three days after seeding (compared to the 
normal two weeks after seeding), when the constructs first started to demonstrate spontaneous 
contractions.  
The immature constructs were subjected to the same regimen of 6 hours simulated ischemia and 3 hours 
simulated reperfusion. The responses of the immature reperfused constructs were compared to 
immature preconditioned and normoxic (control) cardiac constructs. Cell membrane integrity and death 
were measured by analyzing lactate dehydrogenase (LDH) and adenylate kinase (AK) release (Figure 14A-
B). Reperfused constructs demonstrated no difference compared to normoxic controls on LDH release. 
They did have a significant increase on AK release, but overall, the differences were much smaller than 
those seen in more mature constructs. Preconditioned constructs had a significantly lower LDH and AK 
release compared to Rep. Cell viability and mitochondrial membrane permeability measurements 
demonstrated no difference between the three groups (Figure 14C-D). Overall, immature cardiac 
constructs did not demonstrate the comprehensive responses of increased cell death, decreased cell 
viability, and increased mitochondrial membrane permeability to ischemia-reperfusion that were 




Figure 14: Response of immature cardiac constructs to simulated ischemia-reperfusion. (A-B) 
Lactate dehydrogenase (LDH) and adenylate kinase (AK) release were used to assess cell 
membrane permeability and death. (C) Cell viability was determined by measuring cell activity 
using RealTime Glo assay. (D) Mitochondrial membrane permeability was determined by 
comparing emission of JC-1 dye at 528 nm and 590 nm, where the increased ratio correlates with 
higher permeability. Data represents aggregated results from 3 independent experiments and are 
depicted as individual data points with mean ± SD. Statistical analysis was done using ANOVA with 
post-hoc Tukey’s HSD, * indicates significant difference between groups, p < 0.05. 
 
The relative resistance of the fetal heart to hypoxia is recapitulated by the lack of response to IRI in the 
immature reperfused constructs [49]. These results help to establish the necessity of the bioreactors to 
promote maturation of the hiPS-CMs and increase their susceptibility to ischemic injury. Ischemic 
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preconditioning was studied in immature cardiac constructs because it has previously been demonstrated 
that preconditioning does not protect the neonatal heart [57]. The preconditioned constructs did 
demonstrate a decrease in LDH and AK release compared to reperfusion, but the overall lack of difference 
between reperfusion and normoxic constructs makes it difficult to draw insights about preconditioning in 
the immature constructs. The tolerance to ischemic injury seen in the immature constructs offers a 
platform to further explore the mechanisms that increase susceptibility to hypoxia in the mature heart. 
Furthermore, study into the mechanisms of cardiomyocyte maturation that lead to the development of 
cardioprotective measures during ischemic preconditioning may be insightful. It has been demonstrated 
that the diseased myocardium leads to a more fetal phenotype of cardiomyocytes [216, 217], which 
makes understanding the response of immature cardiomyocytes to IRI important.  
 
Discussion 
Relatively immature constructs were subjected to simulated ischemia-reperfusion after 3 days of culture, 
when they had just started to display spontaneous contractions. We saw that the reperfused relatively 
immature constructs did not demonstrate the same increase in cell injury compared to normoxic controls 
as displayed by our relatively more mature constructs. We hypothesized that this difference in response 
is due to the relative resistance to hypoxia that has been characterized in more immature cardiomyocytes 
[49]. We would like to further characterize these differences by direct comparisons of relatively immature 
and mature constructs and testing of constructs in between the two time points. Direct comparisons can 
be easily performed through characterization of gene expression in qPCR and protein levels in western 
blot. These studies can be done in an asynchronous manner to assess the changes and developments in 
cardiomyocyte maturity that may be leading to susceptibility to ischemic injury. We also would want to 
test a construct at a midpoint time point to establish its response to ischemia-reperfusion and characterize 
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its relative maturity compared to the 3 day and 2-week-old constructs. This would allow us to further 
assess the changes in construct properties that lead to increased ischemic injury.  
The lack of increased cell death in the relatively immature constructs may be because the cells are less 
metabolically active. They may have less energy demands and could thus better withstand ischemic stress. 
This is why we chose an early time point where the constructs had already started spontaneous 
contractions and were metabolically active. We need to directly compare metabolic activity of the 
relatively immature to more mature cardiac constructs through measurements of cell activity to 
determine if this is a cause. We could possibly determine if decreased cell activity is a cause of decreased 
cell death by comparing constructs subjected to electrical stimulation and blebbistatin under simulated 
ischemia-reperfusion. Electrical stimulation would force the cardiomyocytes to contract, while 
blebbistatin would inhibit contraction and reduce energy demands. However, we would first have to 
determine if electrical stimulation or blebbistatin causes an increase in cell death in normoxic constructs.  
Furthermore, it is known that fetal cardiomyocytes are more reliant on glycolysis for metabolism, while 
the mature adult heart primarily relies on fatty acid oxidation [115, 116]. Oxidative phosphorylation is 
more efficient at producing ATP than glycolysis; therefore, decreased metabolism may underly hypoxia 
resistance in immature constructs. It has also been demonstrated that cardiac tissue engineering 
platforms can help increase oxidative metabolism [75, 88]. We need to assess changes in cardiomyocyte 
metabolism. We can assess cellular metabolism by dissociating the cardiomyocytes from the constructs 
and measuring their energetics in the Seahorse platform [75]. Oxygen consumption rate and extracellular 
acidification rate can be measured to determine mitochondrial respiration and glycolysis in the constructs. 
We can also assess metabolism by using 14C-labeled energy substrates [88].  
Furthermore, we want to determine if the reliance on fatty acid oxidation for cellular metabolism in 
mature cardiomyocytes underlies susceptibility to ischemia. It has been shown that fatty acid oxidation is 
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far less efficient than glucose oxidation in the use of oxygen for ATP production [218]. To test this, we 
would culture the constructs normally, but for a few days prior to the experiment, we would culture the 
constructs in either media containing glucose-only or fatty acid-only as the energy substrate. This would 
limit any differences at baseline, but then condition the constructs to a fatty acid rich environment. It was 
demonstrated that cardiac constructs cultured under fatty acid-only containing media demonstrated no 
change in contractile behavior after one day [88]. However, these experiments were done under 40% O2 
culture conditions, and we will need to assess how long our constructs can tolerate fatty acid-only media. 
We would subject the groups to the same simulated ischemia-reperfusion conditions conducted in these 
studies. The thought is that culture under fatty acid-only conditions would make the cardiomyocytes more 
dependent on oxygen due to increased oxygen consumption. We would expect that constructs cultured 
under fatty acid-only conditions prior to IRI would demonstrate an increase in cell death due to prior 
culture and reliance on a more oxygen-consuming energy substrate. To control for glycolysis, we can test 
constructs under lactate-only conditions. Lactate oxidation should be as oxygen efficient as glucose 
oxidation without the ATP production from glycolysis.  
One issue in direct comparisons of the constructs as they develop over time is that it is difficult to directly 
compare the constructs at different time points. In our experiments, we only compared constructs seeded 
from the same batch of hiPS-CMs to minimize any initial differences. This made it difficult to directly 
compare immature with relatively more mature constructs. One way that we could alter our experimental 
setup to overcome these possible technical limitations is to remove the aspects of the bioreactor that 
assist in cardiomyocyte maturation. Mechanical conditioning by culture on the flexible pillars helps to 
promote maturation of the cardiac constructs. We can remove mechanical conditioning by cutting the 
flexible pillars so that they no longer provide passive tension after construct formation. In this manner, 
we can directly compare the same batch of constructs and further test the importance of mechanical 
conditioning for maturation in our bioreactor. Furthermore, when we reintroduce electrical stimulation 
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into our cardiac culture protocol, we can compare constructs that were cultured under chronic electrical 
stimulation to those that were not. Electromechanical stimulation can be utilized to promote maturation 
of hiPS-CMs, and removal of these conditioning regimens can allow us to more directly compare relatively 






Aim 3: Establish and Evaluate Therapeutic Strategies for Reducing IRI 
During Reperfusion 
 
Ischemic preconditioning of the cardiac constructs decreased IRI, but it is not a clinically relevant therapy 
because it must be applied prior to the ischemic insult. We sought to test therapeutic strategies that can 
be applied during reperfusion. These strategies entailed either modifying reperfusion conditions or 
addition of drugs during reperfusion to target the pathophysiology of IRI previously discussed.   
 
Reperfusion with Acidic Media to Prevent Rapid Normalization of Intracellular pH 
Our first therapeutic target was the rapid normalization of intracellular pH during reperfusion. As 
previously discussed, ischemia leads to a decrease in intracellular pH. Reperfusion rapidly restores normal 
intracellular pH, which leads to intracellular calcium overload and cell death. Previous studies have 
demonstrated a reduction of infarct size and IRI in animals using pharmacological inhibition of the sodium-
hydrogen exchanger (NHE) [219, 220]. However, clinical studies have failed to demonstrate improved 
outcomes using NHE inhibitors [22, 221]. In this study, we instead aimed to leverage the enhanced control 
of the in vitro platform and modify reperfusion conditions in a non-physiologic fashion to reduce IRI. We 
sought to prevent the rapid normalization of intracellular pH and subsequent reperfusion injury by 
reperfusion with acidic media to decrease the pH gradient. 
Normally, simulated reperfusion by culture media with pH of 7.4 leads to a large proton gradient between 
the extracellular and intracellular space (referred to as “Rep (pH 7.4)”), but reperfusion with a media pH 
of 6.4 serves to minimize this gradient and prevent intracellular calcium overload (referred to as “Rep (pH 
6.4)”) (Figure 15A). Phrodo staining confirmed a lower intracellular pH in tissue constructs after simulated 
ischemia (Figure 8G). Reperfusion with acidic media demonstrated a decrease in cell death, as assessed 
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by lactate dehydrogenase and adenylate kinase release compared to Rep (pH 7.4) (Figure 15B-C). 
However, the rep (pH 6.4) group did not demonstrate improvements in cell viability as measured by cell 
activity (Figure 15D). The rep (pH 6.4) group did have a significant decrease in mitochondrial membrane 
permeability compared to the rep (pH 7.4) group, thought it was still significantly higher than the normoxic 
constructs (Figure 15E). Western blot also determined that reperfusion with acidic media lead to a 
significant decrease in the cleavage and activation of caspase 3 compared to rep constructs (Figure 16). 
Overall, reperfusion with acidic media decreased IRI-related cell death, partially prevented mitochondrial 
membrane permeabilization, and resulted in decreased apoptosis. However, reperfusion with acidic 
media did not improve cell viability. This was most likely due to acidic media inhibiting normal cell activity. 
Reperfusion with acidic media has previously demonstrated a reduction in IRI in rat cardiomyocytes and 
isolated hearts [140, 222], and we have shown that it is cardioprotective in humans too. These results 
demonstrate that we can decrease IRI in the human tissue model by modifying the reperfusion conditions. 
The results also indicate that inhibition of intracellular pH normalization remains a viable therapeutic 




Figure 15: Reperfusion with acidic media (Rep pH 6.4) was compared to reperfusion using 
neutral pH media (Rep pH 7.4) to decrease reperfusion injury. (A) Schematic of the experimental 
protocol for the comparison groups. (B-C) Lactate dehydrogenase (LDH) and adenylate kinase (AK) 
release were used to assess cell membrane permeability and death. (D) Cell viability was 
determined by measuring cell activity using RealTime Glo assay. (E) Mitochondrial membrane 
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permeability was determined by comparing emission of JC-1 dye at 528 nm and 590 nm, where 
the increased ratio correlates with higher permeability. Data represent aggregated results from 4 
independent experiments and are depicted as individual data points with mean ± SD. Statistical 
analysis was done using ANOVA with post-hoc Tukey’s HSD, # indicates statistical significance 
compared to all other groups, * indicates significant difference between groups, p < 0.05. 
 
 
Figure 16: Western blot analysis of cardiac constructs reperfused with acidic media. Decrease in 
apoptosis was determined by cleaved to total caspase 3 ratio. Data is from 3 independent 
experiments, mean ± SD. * indicates significant difference between groups as determined by 





Reperfusion with acidic media demonstrated a decrease in intracellular enzyme release, but this result 
could potentially be erroneous. The intracellular enzyme release assays rely on measurements of enzyme 
activity by introducing substrates, but enzyme activity can be affected by pH. While the construct 
extracellular pH gradually normalized to a more neutral pH during the reperfusion time period, the 
extracellular pH still remained lower than that of reperfused constructs. We did not characterize how the 
enzyme activity changes over different pH, or the final pH at the end of the reperfusion period. These 
assays could be further improved by assessing if LDH or AK activity changes at the pH our experiments 
were performed at. We could have also normalized the extracellular pH by adding a base prior to 
measuring enzyme activity. We could also utilize ELISA as a direct measurement of intracellular protein 
release and cell membrane permeabilization. In our study, we utilized mitochondrial membrane 
permeability as a measurement of cell death that was not affected by extracellular pH differences. We 
saw that reperfusion with acidic media lead to a decrease in mitochondrial membrane permeability, which 
helps to validate that we saw a decrease in cell death by reperfusion with acidic media.  
We can further assess cardioprotection by inhibition of rapid intracellular pH normalization through 
further modification of reperfusion conditions. The intracellular acid extruders are the sodium hydrogen 
exchanger (NHE), sodium bicarbonate cotransporter (NBC), and monocarboxylate transporter/lactate-
proton cotransporter (MCT) [223]. The NHE is the primary acid extruder at low pH [224], but NBC is a 
significant contributor. The acidity of the media should inhibit NHE activity, but we can further modify our 
acidic reperfusion media to target the NBC by increasing bicarbonate concentration or by using 
bicarbonate-free HEPES-buffered media. Increasing bicarbonate concentration should increase acid 
extrusion and further exacerbate the rapid intracellular pH normalization and cell death. On the other 
hand, reperfusion with bicarbonate-free acidic media should further reduce cell death compared to 
normal acidic media. These results would further demonstrate the importance of inhibition of rapid 
98 
  
intracellular pH normalization for IRI reduction. The failure of NHE inhibitors to reduce IRI in clinical studies 
may be due to NBC activity [22, 221], and we would like to examine NHE inhibitors in conjunction with 






To further assess the utility of the engineered cardiac constructs as in vitro models of IRI, we explored the 
use of pharmacologic agents that could be added during reperfusion to decrease IRI. We previously 
identified important targets to treat IRI in our discussion about the pathophysiology of IRI.  
 
Targeting the MPTP 
Rationale 
During ischemia, the mitochondrial permeability transition pore (MPTP), a large and nonspecific pore in 
the mitochondrial membrane, is closed, resulting in low permeability of the inner mitochondrial 
membrane [225]. Reperfusion causes opening of the MPTP and depolarization of the mitochondria, and 
it is a critical step in reperfusion injury [119]. Opening of the MPTP leads to uncoupling of the electron 
transport chain and depletion of ATP. It also allows the entry of water and solutes into the mitochondria. 
This leads to rupture of the mitochondria, release of its contents into the cell, and cell death. Cyclophilin 
D (CypD) is a regulator of the MPTP, and it has been found that knockout of CypD in animals is 




We assessed the efficacy of cyclosporine A to reduce IRI in the engineered cardiac constructs (Figure 17A). 
It was shown that the addition of cyclosporine A (1 µM) during reperfusion (constructs referred to as 
“CsA”) was able to reduce cell death as shown by lactate dehydrogenase and adenylate kinase release 
and increased cell viability (Figure 17B-D). CsA-treated constructs also had a decrease in mitochondrial 
membrane permeability compared to reperfused constructs (Figure 17E). These results indicate that 
cyclosporine A can decrease IRI in the human tissue model. Cyclosporine A can prevent IRI by inhibiting 
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opening of the MPTP, and importantly, it was seen that cyclosporine A addition during reperfusion helped 
to decrease mitochondrial membrane permeability. 
 
Figure 17: Evaluating the efficacy of cyclosporine A (CsA, 1 µM) in reducing reperfusion injury 
by targeting the MPTP. (A) Schematic detailing experimental protocol for the comparison groups. 
(B-C) Lactate dehydrogenase (LDH) and adenylate kinase (AK) release were used to assess cell 
membrane permeability and death. (D) Cell viability was determined by measuring cell activity 
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using RealTime Glo assay. (E) Mitochondrial membrane permeability was determined by 
comparing emission of JC-1 dye at 528 nm and 590 nm, where increased ratio is correlated with 
higher permeability. Data represents aggregated results from 4 independent experiments and are 
depicted as individual data points with mean ± SD. Statistical analysis was done using ANOVA with 
post-hoc Tukey’s HSD, # indicates statistical significance compared to all other groups, * indicates 
significant difference between groups, p < 0.05. 
 
Comparison to preclinical and clinical studies 
Cyclosporine A has been demonstrated to be effective in both in vivo and in vitro models of IRI [78, 226], 
but there are also some preclinical studies that demonstrated no benefit [227, 228]. Early clinical trials 
indicated that its use during reperfusion could decrease infarct size and pathological ventricular 
remodeling [229, 230]. Cyclosporine A also helped reduce cardiac damage during coronary artery bypass 
graft (CABG) and aortic valve surgery [231, 232]. However, two recent large clinical trials, CIRCUS and 
CYCLE, showed that cyclosporine A administration upon reperfusion was ineffective in reducing IRI [1, 30]. 
Researchers have criticized the differences in formulations of cyclosporine A, greater use of 
cardioprotective platelet inhibitors, inappropriate use of clinical endpoints, and different selection of 
patients compared to the earlier clinical trial as the potential reasons for different results [4, 233]. 
Importantly, cyclosporine A was administered in patients up to 6-12 hours after the MI in the large clinical 
trials, compared to 4 hours in the early trial, which could be past the therapeutic window to salvage the 
ischemic myocardium. This suggests that more work still needs to be done in assessing cyclosporine A as 
a therapeutic. The early studies in this human in vitro model indicate that cyclosporine A may be effective 
in reducing IRI in cardiomyocytes, but it is possible that other factors in the clinical setting could be 




We saw that addition of CsA to reperfusion was able to demonstrate a decrease in in cell death and 
mitochondrial membrane permeability compared to reperfused constructs. CsA was dissolved in DMSO, 
and one of the controls we failed to add was a DMSO-only control. DMSO can be cytotoxic to cells, but 
the final concentration of 0.1% that we used in our study is generally regarded to be safe for cells. 
Furthermore, we were assessing cytoprotective effects of CsA, which is opposite of the cytotoxic effects 
of DMSO that are generally recognized. However, we do recognize that a vehicle-only control should be 
included in future studies in case of any extraneous effects. In addition, we also need to include CsA 
addition to normoxic constructs as a future control. This control will allow us to assess if CsA affects the 
constructs at baseline. While we do not anticipate these controls to affect our results, they should be 
included in future experiments to more fully verify the effect of CsA administration during reperfusion.  
In addition, we would like to better assess the interaction of CsA with the MPTP in future studies. CsA is 
also an immunosuppressive drug, and it functions through inhibition of calcineurin. We would like to 
separate out its immunosuppressive effects by assessing response of constructs to tacrolimus, a 
calcineurin inhibitor with no effect on the MPTP. The addition of tacrolimus on ischemia-reperfusion has 
demonstrated no effect in animal studies [234], and we would like to also confirm this in our human tissue 
model. Furthermore, the drug auranofin has been shown to induce opening of the MPTP [235], and its 
addition during reperfusion should further increase reperfusion injury. CsA addition should help prevent 
cell death by auranofin by blocking mitochondrial membrane permeabilization.  
CsA inhibits opening of the MPTP through regulation of cyclophilin D [236], and we would like to create a 
cyclophilin D knockout hiPS line. This would allow us to first independently verify the importance of 
cyclophilin D, where it has previously been demonstrated that cyclophilin D knockout in mice protected 
the heart against IRI [29]. In addition, CsA addition should have no effect on IRI in the cyclophilin D 
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knockout cell line. Furthermore, we will test the effects of NIM811, a CsA derivative that maintains 
inhibition of the MPTP without any of CsA immunosuppressive effects [237]. Demonstrating the effect of 
NIM811 in reducing IRI in our cardiac constructs and a neutral result in cyclophilin D cell lines will further 




Targeting Oxidative Stress 
 
Rationale 
Reperfusion leads to a rapid increase in the generation of reactive oxygen species (ROS) due to 
reactivation of the electron transport chain [238]. The large amount of ROS damages cellular membranes 
and proteins and induces opening of the MPTP to contribute to lethal reperfusion injury [155, 239]. The 
generation of ROS also helps recruit neutrophils to the infarct region, but it is unclear if neutrophils play 
a pathological role in the progression of IRI [240]. It is thought that using antioxidants to target oxidative 
stress can help reduce reperfusion injury.  
 
Experimental Results 
The antioxidant, N-acetyl-L-cysteine (NAC, 5 mM), was added during reperfusion to test if it could reduce 
IRI (constructs referred to as “NAC”) (Figure 18A). In the tissue engineered cardiac constructs, the 
administration of NAC on reperfusion significantly decreased ROS levels compared to normoxic and 
reperfused constructs, which confirmed its antioxidant properties (Figure 18B). However, NAC-treated 
constructs demonstrated no difference compared to reperfused constructs in measurements of cell death 
(Figure 18C-D). They also demonstrated no significant differences in cell viability or mitochondrial 
membrane permeabilization (Figure 18E-F). These results indicated that NAC can reduce ROS levels in the 




Figure 18: Evaluating the efficacy of N-acetylcysteine (NAC, 5 mM) as an antioxidant to prevent 
oxidative damage during reperfusion. (A) Schematic of the experimental protocol for the 
comparison groups. (B) Reactive oxygen species (ROS) levels in cardiac constructs as measured by 
ROS-Glo assay. Data represents aggregated results from 3 independent experiments. (C-D) 
Lactate dehydrogenase (LDH) and adenylate kinase (AK) release were used to assess cell 
106 
  
membrane permeability and death. (E) Cell viability was determined by measuring cell activity 
using RealTime Glo assay. (F) Mitochondrial membrane permeability was determined by 
comparing emission of JC-1 dye at 528 nm and 590 nm, where increased ratio is correlated with 
higher permeability. Data represents aggregated results from 4 independent experiments and are 
depicted as individual data points with mean ± SD. Statistical analysis was done using ANOVA with 
post-hoc Tukey’s HSD, # indicates statistical significance compared to all other groups, * indicates 
significant difference between groups, p < 0.05. 
  
Comparison to preclinical and clinical studies 
Previous preclinical studies in dogs demonstrated mixed results for NAC. One study indicated that 
administration of NAC during reperfusion could decrease infarct size [241]. On the other hand, another 
study demonstrated no difference in infarct size, but that NAC could reduce myocardial stunning [242]. A 
small clinical trial, ISLAND, indicated that NAC could increase ejection fraction and decrease infarct size 
alongside streptokinase treatment [243]. However, there has not been any testing of NAC in a large clinical 
trial to conclusively demonstrate its efficacy.  
NAC failed to reduce IRI in cardiac constructs despite the promise shown in the ISLAND clinical trial; 
however, the results from the human in vitro model are consistent with those of other antioxidants. The 
antioxidants superoxide dismutase and trimetazidine have not demonstrated clinical benefit in their 
respective clinical trials [244, 245]. Furthermore, it was seen that NAC can increase mortality in 
multisystem organ failure when administrated late in critically ill patients [246]. These results coupled 
with negative clinical trials for other antioxidants may have tempered the enthusiasm for NAC as a therapy 
for reperfusion injury and prevented its progression to a large clinical trial. Antioxidant therapy against IRI 
still demonstrates mixed results, indicating that it may not be suitable as a pharmacologic agent. More 
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recently, the specific targeting of mitochondrial ROS generation has become of interest [247]. Early results 
have indicated that these therapies can reduce IRI and need to be further explored [248]. 
Generation of reactive oxygen species and oxidative stress during reperfusion is a major mechanism in 
causing IRI. Here, we used a general antioxidant, N-acetyl-l-cysteine, to mitigate oxidative stress. We 
demonstrated that NAC does decrease overall ROS levels in the construct, but despite this reduction, NAC 
did not seem to inhibit cell death or improve cell viability. It also had no effect on mitochondria membrane 
potential and depolarization.  
 
Discussion 
The lack of benefit from the use of the antioxidant NAC was not unexpected due to mixed results seen in 
preclinical and clinical studies [242, 243]. Signaling through ROS is an important part of normal cell 
function [249], and we should have included NAC addition to normoxic constructs to establish any changes 
to baseline function. This would help us establish if NAC disrupts normal physiological function, which 
could abrogate any of its potential antioxidant benefits during reperfusion. 
NAC helps to reduce oxidative stress as a ROS scavenger by replenishing endogenous glutathione. Further 
developments in antioxidant therapy may instead want to focus specifically on mitochondrial ROS 
generation. The large generation of ROS seen in reperfusion is thought to be driven by reactivation of the 
electron transport chain [166]. Superoxide is produced due to electron leak and partial reduction of 
oxygen at complexes I and III as a part of normal physiology [250]. Superoxide then quickly 
disproportionates into hydrogen peroxide. Damage of these complexes due to ischemia leads to a greater 
generation of ROS during reperfusion [251]. The burst of ROS generation can lead to opening of the MPTP, 
which leads to further generation of ROS and injury in a positive feedback process termed ROS-induced 
ROS release [225, 252, 253]. It is possible that NAC is unable to reduce oxidative stress in the mitochondria, 
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and we will want to specifically examine the effect of NAC on mitochondrial ROS levels with the MitoSOX 
or MitoB dyes. Furthermore, we will want to focus on mitochondrial targeted antioxidant agents. There 
are mitochondrial ROS scavengers that have been developed, such as MitoVit-E and MitoQ10 [254, 255], 
and we should explore whether they are able to target and reduce injury at the site of oxidative stress. 
Furthermore, we can use rotenone and atovaquone to directly inhibit complex I and III respectively to 
prevent ROS generation during reperfusion. Targeting reperfusion oxidative stress at the source of ROS 




Cardiac Tissue Engineering Platform to Study IRI 
 
This is the first characterization of ischemia-reperfusion injury in a human tissue model. The model utilized 
hIPS-CMs seeded in hydrogel around flexible pillars that provided passive tension and allowed for 
auxotonic contractions for mechanical conditioning. hiPS-CMs are a robust source of human 
cardiomyocytes and can improve models by providing a patient-specific background. However, because 
immature cardiomyocytes are more resistant to ischemic injury, hiPS-CMs are limited in studies of IRI 
because of their relatively fetal phenotype. Cardiac tissue engineering has demonstrated enhanced 
maturation of hiPS-CMs. 
The cardiac constructs in these studies demonstrated aligned and striated cardiomyocytes along the 
periphery. However, the cardiomyocytes were not homogenously distributed throughout the construct, 
and did not demonstrate some of the structural hallmarks of maturity such as transverse tubule 
formation. This indicates that additional bioreactor design changes may be necessary to achieve a mature 
structure. The cardiac constructs did demonstrate functional maturation. The constructs had positive 
chronotropic and ionotropic response to β-adrenergic stimulation. Positive ionotropic responses to β-
adrenergic stimulation are not seen in monolayers because of their relative immaturity and is considered 
a sign of cardiomyocyte maturation [109]. The presence of aligned and cross-striated cardiomyocytes 
along the edge of the construct and a functionally mature response to β-adrenergic stimulation allowed 





Establishing Human Tissue Engineered Model of IRI 
 
We were able to establish the presence of ischemia-reperfusion injury by comparing constructs exposed 
to ischemia only and constructs exposed to ischemia followed by reperfusion. There was an increase in 
cell death and decrease in cell viability after ischemia, and these changes were further accelerated by 
reperfusion. Critically, we saw a significant increase in mitochondria membrane permeability after 
reperfusion, which correlates with opening of the MPTP and cell death in the pathophysiology of IRI. Many 
efforts to treat IRI have focused on the opening of the MPTP as a critical therapeutic target. Reperfusion 
also led to the acceleration of apoptosis with increased caspase 3 cleavage and activation compared to 
the minimal levels in the normoxic and ischemic constructs. These results established differences in the 
processes leading to injury in ischemia and reperfusion, and we also established assays that can detect 
these changes.  
We also examined the response of relatively immature constructs to simulated ischemia-reperfusion. 
These constructs had just started to display spontaneous contractions 3 days after formation, and they 
had not had the time to mature in the bioreactor. We saw that these constructs were resistant to ischemic 
injury. The immature constructs did not demonstrate significant differences in our assays compared to 
normoxic constructs and helps to establish the importance of mechanical conditioning and maturation in 
developing a model of IRI.  
 
Ischemic Preconditioning Reduced IRI in the Human Tissue Engineered 
Model 
 
Ischemic preconditioning has demonstrated robust and strong cardioprotection in various animal species 
[190], but study in humans has been difficult. Because ischemic preconditioning must occur before the 
ischemic insult, it cannot be tested in patients with an acute MI. Studies in patients undergoing CABG 
surgeries and other limited in vitro models have indicated cardioprotection by ischemic preconditioning 
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[191, 192]. In this study, we demonstrated that ischemic preconditioning helped to decrease IRI in the 
human tissue model. The preconditioned constructs had a decrease in cell injury, increase in cell viability, 
and decrease in MPTP opening.  
Similar to what has been shown in animals, the preconditioned constructs had increased activation of pro-
survival kinases. This indicates that ischemic preconditioning functions similarly in humans through the 
activation of cell survival pathways to protect the cardiomyocytes during reperfusion. Further 
identification of the specific activated proteins will be important because they differ between humans 
and animals. The more clinically relevant ischemic postconditioning and remote ischemic conditioning 
function through similar activation of pro-survival pathways [41, 203], and further use of this human tissue 
model for study of ischemic conditioning can help bring greater insights into preventing IRI.  
 
IRI can be reduced by modification of reperfusion conditions 
 
Ischemic preconditioning of the cardiac constructs helped to decrease IRI, but because it must occur 
before the ischemic insult, it is not a clinically relevant treatment. Instead, we sought to prevent IRI by 
modifying the reperfusion conditions. The rapid normalization of intracellular pH has been targeted in 
studies through the pharmacologic inhibition of the NHE to varying degrees of success [22, 219, 220]. In 
our study, we instead leveraged the increased control offered in an in vitro model and sought to prevent 
pH normalization by reperfusion with acidic media to decrease the pH gradient. We saw a decrease in cell 
death, MPTP opening, and apoptosis. While there was no difference in cell viability, this was most likely 
due to decreased cell activity in the acidic media. Reperfusion with acidic media demonstrated that we 
could decrease IRI by modifying the cellular environment during reperfusion. 
One of the ideal uses of the proposed model of IRI would be for pharmacological screening of therapeutics 
that can be added during reperfusion to decrease IRI. Many drugs have demonstrated a decrease in infarct 
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size in animals, but none have shown benefit in a large clinical trial. We sought to decrease IRI by using 
cyclosporine A (CsA) to prevent MPTP opening and N-acetyl-l-cysteine (NAC) to reduce oxidative stress. 
CsA addition during reperfusion demonstrated a decrease in IRI, and critically, it decreased the 
mitochondria membrane permeability. This indicated that CsA was able reduce reperfusion injury by 
preventing opening of the MPTP. CsA usage in the CYCLE and CIRCUS clinical trials did not demonstrate 
better clinical outcomes [30, 256], but the trials have also been criticized for utilizing a different 
formulation of CsA compared to the earlier clinical trial and using cardioprotective platelet inhibitors in 
the patients [233]. The encouraging results of CsA in the human tissue model indicate that clinical issues 
may be confounding the cardioprotective effect of the drug. On the other hand, the antioxidant NAC failed 
to reduce IRI in the cardiac constructs despite the importance of oxidative stress in causing reperfusion 
injury [155, 239]. Antioxidants have shown mixed results in preclinical studies and small clinical trials [243–
245]. More recent efforts have focused on specifically targeting mitochondrial ROS generation. We aim 




Overall, it is difficult to determine the clinical predictivity of the cardiac constructs for pharmacological 
screening. CsA helped to decrease IRI in the cardiac construct and in other preclinical studies, but it has 
not been effective in patients. This difficulty is further compounded by the fact that no therapeutic has 
robustly demonstrated improved clinical outcomes in patients. Ischemic preconditioning has 
demonstrated the most robust cardioprotection against IRI [190], but even its effect in an acute MI in 
humans has not been fully verified.  
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In this study, we demonstrated comparable results to animal models with cardioprotection by ischemic 
preconditioning, reperfusion with acidic media, and CsA administration. However, the human tissue 
engineered model has significant advantages over animal models for clinical translation. The in vitro 
model offers enhanced control of the various variables in IRI, study on a biomimetic platform of human 
physiology, and furthermore, hiPS-CMs offer the opportunity to study the response in patient-specific 
backgrounds. The human tissue engineered model of IRI presented in this study offers much potential in 
gaining insights into the pathophysiology of IRI, its treatments, and how we can translate therapies into 
the clinical setting.  
 
Issues with Current Preclinical Ischemia-Reperfusion Injury Models 
In vitro models are useful tools to capture the direct effect of treatments or drugs on cardiomyocytes, 
while isolating out the confounding factors that are encountered in animal models. In vivo animal models 
are important in their physiological simulation of ischemia-reperfusion and their ability to capture the 
interactions between various cell types. However, these preclinical models still fail to fully simulate the 
clinical setting. Future models will need to address these shortcomings, and a tissue engineered cardiac 
construct may be most suitable to account for them in preclinical studies of IRI (Figure 19). 
 
Accounting for Comorbidities 
A common criticism levied on preclinical IRI studies is that therapies are tested on a homogenous, young, 
and healthy set of small animals. In contrast, myocardial infarction primarily affects a diverse and older 
population with many comorbidities, such as diabetes and cardiac hypertrophy. These factors alter the 
cardiomyocyte response to IRI in different ways, usually be increasing their susceptibility to reperfusion 
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injury and decreasing the effectiveness of treatments (e.g. ischemic preconditioning) against it [207, 257, 
258].  
In recent years, the researchers have begun demonstrating that hiPS-CMs can recapitulate the key 
features of chronic diseases. Drawnel et al. established a diabetic hiPS-CMs screening platform using cells 
exposed to a prodiabetic environment and hiPS cell lines derived from diabetic patients [141]. The diabetic 
patient-specific hIPS-CMs were not exposed to any diabetes-specific environmental signals, and yet, they 
demonstrated a diabetic phenotype and the corresponding responses to drugs. These findings indicate 
that the hIPS-CMs recapitulating the disease phenotype should be a part of patient-specific diabetic 
models. A diabetic phenotype was also demonstrated in an engineered heart tissue model, utilizing 
neonatal rat cardiomyocytes [259]. In addition, increased diabetic susceptibility to IRI has been 
demonstrated in an animal model [260], but not in vitro using human cells or tissues. 
Tissue engineering could also be instrumental for modeling comorbidities in vitro. In some models, 
engineered heart tissue was suspended between two attachment sites to allow for mechanical stress and 
auxotonic contractions [261]. Hirt et al. was able to expand upon this concept by inserting metal braces 
to increase the afterload sensed by the cardiac tissue. Consequently, the cardiomyocytes developed a 
pathologic cardiac hypertrophic phenotype. The results were validated against a hypertrophy-promoting 
pharmacologic conditioning protocol [262]. In summary, there is increasing evidence that tissue 
engineering enables various approaches to model comorbidities of interest, and could thus provide a 
more biomimetic model of IRI.   
 
Concomitant Drugs 
It has been found that many of the medications taken to treat the comorbid conditions found in patients 
can alter the effects of IRI and could be cardioprotective themselves. For example, statins are 
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cardioprotective, but also interfere with the cardioprotective effects of ischemic preconditioning [263]. 
Some of the anesthetics used during PCI to reperfuse the artery are also cardioprotective, while others 
are not [264, 265]. Further complicating the matter, it has been found that comorbid conditions, such as 
diabetes, can interfere with the cardioprotective effect of anesthetics and statins [266, 267]. These 
interactions are not being systematically tested and identified in preclinical animal models, and may play 
a role in the mixed results from clinical trials of promising drugs. In fact, the concomitant drug may be 
providing cardioprotection through the same pathway as the therapeutic of interest, or it may be actively 
hindering the therapy.   
The cardioprotective features of anesthetics have been demonstrated on isolated human atrial trabeculae 
ex vivo [268]. In vitro models would be ideal for performing these studies in a high-throughput manner. 
In particular, tissue engineered cardiac constructs derived from patient-specific hIPS-CMs will be of value 
in identifying the drug-drug interactions. As the patient population grows older and requires more drugs 
for treating multiple comorbidities, such screenings will become even more important. Reductionist 
models could be very helpful for understanding how different drugs and conditions interact, in order to 
avoid false negative results.  
Modeling Microvascular Obstruction 
In addition to the direct effects of reperfusion on the cardiomyocytes, a long-lasting source of damage is 
microvascular obstruction [18, 269, 270]. In the heart, microvascular obstruction is the failure of coronary 
artery reperfusion to fully reperfuse the underlying myocardial microvasculature. This is an independent 
risk factor that correlates with worsened clinical outcomes [271]. Reperfusion causes the influx of 
leukocytes and platelets, endothelial damage, and vasoconstriction, which all contribute to microvascular 
obstruction [272–274]. These phenomena could be studied in vitro in a heart muscle engineered to 
contain microvasculature. There have been many advances in engineering vascularized cardiac tissue for 
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implantation [82, 84, 275], and the existing platforms could potentially be further developed to examine 
microvascular obstruction in a tissue model of IRI. With a functional microvasculature and surrounding 
pericytes, it would be possible to study in vitro the endothelial damage and vasoconstriction associated 
with microvascular obstruction. Tissue engineered constructs with a functional microvasculature can help 
better recapitulate the clinical setting of IRI on a highly manipulatable platform.  
 
 
Figure 19: Improving preclinical studies of ischemia-reperfusion injury. Current studies primarily 
rely on animal models, but also include the use of isolated animal cardiomyocytes and perfused 
hearts. Current tools at our disposal include hiPS-CMs and tissue engineering techniques to 
mature them, and these tools were the focus of this thesis. Patient-specific hIPS cells have also 
been developed to more accurately model a particular patient phenotype. Future studies will 
need to incorporate comorbidities and medications that patients have to better assess clinical 
efficacy. Microvascular obstruction is also an important source of reperfusion injury that also 





Improvements to the model 
Part of the next steps in this research will involve some alterations to the platform design to improve 
cardiomyocyte development and platform usability for future studies. A current issue with the design is 
that the construct thickness made it difficult to utilize assays that relied on optical visualization of the 
cardiomyocytes within and made for an inhomogeneous distribution of cardiomyocytes throughout due 
to diffusion limitations. We want to focus on forming a thinner construct by decreasing the height of the 
construct formation well and diameter of the flexible pillars. This would also allow us to use fewer 
cardiomyocytes per construct. A prototype version of the thinner construct platform mold has already 
been constructed, but it was not used due to time constraints. It involved very few changes to the 
manufacturing process for the mold besides utilizing a very small diameter end mill for the flexible pillars. 
We think that these changes will improve the use of the platform as a model for IRI.  
The oxygen and nutrient diffusion limit can also be overcome by culturing the constructs on a rocker. This 
method is superior to perfusion systems for simultaneous analysis of multiple platforms because it does 
not require setting up pumps and tubing. Furthermore, this method eliminates potential sources of 
contamination due to tubing connections. There is a concern that the shear stress from media movement 
may negatively impact cardiomyocyte development. However, Jackman et al. demonstrated that culture 
on a rocker, termed “dynamic culture”, improved the distribution and maturation of cardiomyocytes in 
the engineered cardiac construct through improved nutrient delivery compared to static culture [107]. 
Our platform can accommodate culture on a rocker with its two large spaces for media on each side of 
the construct formation well, and we briefly explored its use in initial experiments. However, we 
discontinued its use to troubleshoot some other aspects of construct formation. Dynamic culture can be 
reintroduced back to the construct culture process if the thinner construct platform does not achieve a 
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homogenous cardiomyocyte distribution. Furthermore, we can utilize the change from dynamic culture 
under normoxia to static culture under hypoxia to further simulate loss of blood flow and nutrient 
availability during ischemia.  
Electrical stimulation of engineered cardiac constructs has also demonstrated that it can help mature hiPS-
CMs [73, 75], and it should be utilized in future studies. The platform incorporates carbon rods that can 
be utilized for electrical stimulation of the constructs. However, we had to remove electrical stimulation 
from our platform after initial studies indicated that it caused cell death. Multiple cardiac tissue 
engineering platforms have successfully utilized electrical stimulation in their culture protocols [73, 75], 
and it will require some troubleshooting to understand what design changes led to issues in our platform. 
Reincorporation of electrical stimulation will also allow for better simulation of ischemic conditions by 
forcing the cardiomyocytes to contract during ischemia. This will prevent cardiomyocytes from going into 
hibernation to reduce energy requirements, and this will better simulate the in vivo environment where 
the heart still needs to meet contractile demands.  
 
Preconditioning Threshold for Cardioprotection 
There is a great variance in preconditioning regimens in the field, and no standard has been developed as 
of yet. There have been a few studies that have compared ischemic conditioning regimens in animals by 
varying the number of cycles and duration of ischemia [208, 209, 276, 277]. They suggest that conditioning 
regimens have to cross a threshold of duration or number of cycles to provide a stimulus for 
cardioprotection, but additional duration or cycles after that do not provide additional cardioprotection. 
Furthermore, extending the ischemic duration too much may lead to a loss of protection.  
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We want to compare preconditioning regimens in our platform to determine the signaling transduction 
changes that are required to meet the minimum threshold for cardioprotection. To accomplish, we will 
examine the number of ischemic preconditioning cycles required to achieve cardioprotection. It will be 
technically simpler to compare number of cycles compared to ischemia duration due to our method of 
inducing hypoxia by flushing anoxic gas in a hypoxic chamber. In our experiments, we utilized one cycle of 
30 minutes of ischemia and 15 minutes of reperfusion for preconditioning. This indicates that we will need 
to significantly reduce the ischemia duration for each cycle in order to obtain a conditioning regimen that 
does not demonstrate cardioprotection. We will measure cell death to determine when the threshold for 
ischemic preconditioning is met.  
We want to assess changes in Akt activation on Western blot to determine if the threshold is met due to 
activation of cell survival proteins. That is, we do not expect a gradual increase in Akt activation with 
increasing preconditioning stimulus, but rather, a significant increase when the threshold is met. 
Furthermore, we want to assess changes in the other proteins of the RISK pathway, such as ERK1/2 and 
GSK3β, to confirm our results. By characterizing the differences when the threshold is met, we can begin 
to assess when the ischemic preconditioning stimulus should be cardioprotective. Similarly, if we are able 
to characterize these changes in protein activation, we will want to utilize serial dilutions of PI3K-Akt 
pharmacologic activators to demonstrate that we can recapitulate the presence of a threshold for 
preconditioning. We will then want to assess how changes to the construct baseline, such as maturity, 
chronic medications, comorbidities, change the threshold for activation to better characterize 




More clinically relevant model 
Our goal is to create a human tissue platform that is predictive of the clinical setting. As part of this goal, 
we need to identify the influence of the patient background on IRI in the cardiac constructs. Patient 
comorbidities and comedications have been found to have an effect on myocardial susceptibility to IRI 
and therapeutic cardioprotection [257]. The impact of the patient background is not routinely assessed in 
preclinical studies, but it is believed to heavily contribute to neutral results of cardioprotective 
therapeutics in clinical studies [3, 17, 233]. We aim to start by testing the influence of medications and 
disease backgrounds on cardioprotection by ischemic preconditioning. Ischemic preconditioning 
demonstrates the strongest and most robust cardioprotection [190], and identification of the setting and 
changes that cause it to fail will be important to clinical translation of therapies.   
 
Chronic Statin Use 
Statins are commonly taken by patients with cardiovascular disease for hyperlipidemia, and are commonly 
cited as a confounding factor in clinical studies [3, 257, 278]. Statin therapy is thought to be inherently 
cardioprotective [279], and a retrospective analysis indicated that patients on chronic statin treatment 
have reduced injury after an acute MI [280]. Thus, there is a concern that cardioprotective therapeutics 
cannot provide any additional reduction in IRI. However, there is also a concern that statin therapy 
interferes with ischemic conditioning protocols and contributes to neutral results [205, 281]. We wish to 
clarify the interaction between chronic statin use and ischemic preconditioning to better understand the 
clinical setting.  
A study using chronic lovastatin in rat hearts confirmed a reduction in infarct size [263]. Moreover, they 
found that acute and chronic lovastatin treatment prevented cardioprotection by ischemic 
preconditioning and postconditioning respectively. Both acute and chronic lovastatin treatment 
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decreased baseline Akt phosphorylation but maintained ERK1/2 activity. Another study that examined 
acute and chronic atorvastatin treatment in ischemic postconditioning found that only ischemic 
postconditioning with chronic atorvastatin use did not demonstrate a reduced infarct size [282]. Chronic 
atorvastatin abolished ischemic-postconditioning induced Akt activation. These studies indicate that 
chronic statin use negatively inhibits the ability of cardiomyocytes to adapt to ischemic conditioning 
protocols, and further suggests that their combined use increases injury over chronic statin use alone. 
Chronic lovastatin use is associated with an increase in PTEN expression and levels, where PTEN is a 
negative regulator of Akt activity [283]. This suggests that chronic statin use directly inhibits Akt-
dependent ischemic conditioning cardioprotection, but it separately maintains cardioprotection through 
other mechanisms.  
Our experiments will focus on chronic statin treatment because it is the most representative of the clinical 
setting. Our first step is to characterize cell death after simulated ischemia-reperfusion in the setting of 
chronic atorvastatin use, ischemic preconditioning, and their combination. Atorvastatin is a first line statin 
[284]. We need to first establish under which conditions is there a reduction in IRI. We expect that chronic 
atorvastatin and ischemic preconditioning will both demonstrate reduced cell death compared to non-
treated reperfused constructs, but their combination will not. We will then assess Akt, ERK1/2, and GSK3β 
phosphorylation and PTEN levels between the groups and in baseline non-ischemic chronic atorvastatin 
use. This will allow us to assess the parallel activators of the RISK pathway (Akt, ERK1/2), their downstream 
target (GSK3β), and the PI3K-Akt inhibitor (PTEN). Critically, we need to correlate phosphorylation of 
GSK3β and its inhibition with reduction of IRI. Any group that demonstrates a reduction in cell death 
without increased GSK3β phosphorylation suggests cardioprotection through a RISK-independent 
pathway. In that case, we would need to explore other reperfusion survival pathways, such as the SAFE 
pathway and STAT activation.  
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Our next step is to assess if we can reestablish cardioprotection by ischemic preconditioning in the setting 
of chronic statin treatment. We would expect low GSK3β phosphorylation in the combined treatment 
group due to inhibition of PI3K-Akt through PTEN activation in chronic statin treatment. However, chronic 
statin treatment should not have an effect on ERK1/2 signaling, and this discrepancy needs to be assessed 
by examining GSK3β and ERK1/2 phosphorylation in the chronic atorvastatin treatment group. If GSK3β 
phosphorylation is low, we would first aim to reestablish cardioprotection through pharmacological 
inhibition of GSK3β and then target activation of upstream PI3K-Akt. If GSK3β phosphorylation is high 
despite no reduction in cell death, we would then aim to inhibit PTEN or directly activate Akt to identify if 
reactivation of the PI3K-Akt pathway can restore cardioprotection independently of GSK3β inhibition. 
Identification that the combination of ischemic preconditioning and chronic statin treatment inhibits 
cardioprotection by each independent therapy will be important in establishing the utility of the platform. 
Chronic statin treatment is utilized by many patients and could help explain neutral results in clinical trials. 
Furthermore, by assessing how we can reestablish cardioprotection, we can identify what additional 
therapeutics and targets we must incorporate to reduce IRI in patients.  
 
Diabetes 
We would like to further demonstrate the utility of the platform by studying IRI utilizing hiPS-CMs that 
recapitulate the comorbidities that patients have. One study found that they were able to guide hiPS-CMs 
into a diabetic phenotype by culturing then under pro-diabetic conditions or by deriving them from 
patients with type 2 diabetes [141]. We want to expand upon these initial studies by assessing the 
response of diabetic hIPS-CMs to ischemia-reperfusion and preconditioning. Studies on diabetic animal 
models and atrial appendage slices from patients with diabetes have demonstrated that the protective 
effects of ischemic preconditioning are not present in diabetes [285–287]. Another study on isolated atrial 
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trabecula from diabetic patients demonstrated that the normal ischemic preconditioning protocol did not 
provide cardioprotection, but a longer preconditioning protocol could [207]. They also found that the 
samples from diabetic patients had decreased Akt phosphorylation, which could explain the need for a 
greater preconditioning stimulus. One confounding aspect of human studies is that patients are being 
managed on therapeutics. The commonly prescribed drug, metformin, is an activator of AMPK, which 
initiates autophagy, and acute treatment with metformin has demonstrated a decrease in IRI [288]. 
However, it is unclear how chronic metformin treatment influences the cardiomyocytes. We want to 
separate the medications and first examine only the influence of diabetes on IRI to better understand its 
role.  
We first want to subject diabetic constructs to ischemia-reperfusion and compare cell death to normal 
reperfused constructs. Diabetic patients have demonstrated increased infarct size after an acute MI [289], 
and we expect to see increased cell death in the diabetic constructs. Furthermore, we want to compare 
ischemic preconditioning cardioprotection in diabetic and normal constructs. We expect a decrease in 
cardioprotection in the diabetic constructs due to impairment of PI3K-Akt signaling [290]. We want to 
identify if we can overcome this decrease through addition of pharmacologic agents or a stronger ischemic 
preconditioning stimulus. We want to test if a longer ischemic duration or additional cycles in 
preconditioning can lead to increased Akt activation to demonstrate increased cardioprotection in 
diabetic cardiac constructs. Furthermore, activators of PI3K or Akt should provide a strong stimulus to 
overcome baseline decrease to allow for cardioprotection by ischemic preconditioning. We also want to 





We also want to further investigate cyclosporine A in a more clinically-representative setting. The phase 
III clinical trial for cyclosporine A demonstrated no benefit [1]. Some of the criticisms of the trial and 
reasoning for lack of response were centered around the different formulation of cyclosporine A and the 
higher use of P2Y12 platelet inhibitors [233]. Intralipid, the newer formulation of cyclosporine A used, has 
demonstrated increased cardioprotection over cyclosporine A [291]. Intralipid use further demonstrated 
phosphorylation of Akt and GSK3β that was not seen with cyclosporine A use. The P2Y12 platelet inhibitor, 
clopidogrel, also demonstrated a reduction in infarct size that was blocked by wortmannin, which 
suggested activation of PI3K-Akt for cardioprotection [292]. Thus, these results suggest that PI3K-Akt 
activation with GSK3β inhibition demonstrates a stronger cardioprotective effect compared to direct 
inhibition of the MPTP.  
We want to compare the cardioprotective effects of cyclosporine A, intralipid, and clopidogrel to identify 
if cyclosporine A is able to demonstrate any additional reduction of IRI. Furthermore, we want to assess if 
intralipid and clopidogrel interfere with each other and cyclosporine A to cause neutral results. Because 
intralipid and clopidogrel have both indicated cardioprotection by PI3K-Akt signaling, we also want to use 
inhibitors of the pathway and test if cyclosporine A can still demonstrate cardioprotection in this setting. 
This will further let us assess if cyclosporine A can still decrease cell death in the a patient background of 
impaired PI3K-Akt signaling [290].  
 
Many clinical studies of cardioprotective therapeutics have demonstrated no benefit. It is thought that 
this failure is due to the patient background, where patient comorbidities and comedications can interfere 
with or mask any potential cardioprotective benefit. We want to test our cardioprotective therapeutics 
on a modified background to indicate that we can recapitulate these potential confounding factors. 
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Furthermore, we want to identify the changes at baseline in these constructs to understand what we need 
to target to overcome impaired activation of pro-survival pathways. Testing these therapies in a setting 
that is more representative of the patient background will allow us to better predict the clinical response.  
 
Preconditioning Proteomics 
In this thesis, we identified that preconditioned constructs demonstrated increased activation and 
phosphorylation of Akt that could be contributing to the decrease in cell death. Animal studies have also 
identified activation of Akt through preconditioning, but preconditioning involves changes across multiple 
signaling pathways [210]. The full identity of these pathways still needs to be sorted out, while the scope 
is still expanding. Furthermore, it has been recognized that there may be species differences in the 
proteins that are relevant. For example, STAT5 activation, but not STAT3, was found to be cardioprotective 
in humans, while the opposite was found in rodents [200, 201]. Therefore, we want to utilize proteomics 
and phosphoproteomics in future studies to identify the proteins that drive cardioprotection by ischemic 
preconditioning in an unbiased and wide-ranging manner. Many of the signaling changes in ischemic 
conditioning are driven by phosphorylation due to the time scale of these changes [293], which makes 
phosphoproteomics important in the identification of the activated and relevant proteins.  
There was a proteomics study that compared LV biopsies taken from patients undergoing CABG surgeries 
with and without remote ischemic preconditioning [294]. However, they did not find a statistically 
significant difference between the two groups. They attributed the lack of difference to the high baseline 
variation seen in the patients. The patients had many differences in their comorbidities and 
comedications, and furthermore, these comorbidities and comedications have been found to affect the 
myocardial response to ischemic conditioning [257]. Our platform is advantageous in providing a 
homogenous baseline sample and will allow us to better detect differences.  
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We want to continue studying ischemic preconditioning because this cardioprotective strategy has shown 
the strongest and most robust reduction in IRI. The initial groups we want to examine are normoxic 
controls, preconditioned constructs prior to the ischemic insult, reperfused constructs, and reperfused 
constructs with prior ischemic preconditioning. These groups will allow us to assess changes in the initial 
and end state due to preconditioning that are leading to and causing the differences in outcome. We 
would like to also further test constructs immediately after the ischemic insult to establish a time course 
of changes. 
Comparing constructs subjected to ischemia-reperfusion with and without ischemic preconditioning will 
allow us to identify the proteins that are relevant to cardioprotection. In particular, we would like to 
identify which proteins are phosphorylated and activated as part of changes in signal transduction 
pathways in order to target therapeutic development. Furthermore, we want to compare the initial and 
end states to assess how protein and phosphorylation levels change over time.   
Finally, differences between the normoxic controls and preconditioned constructs before the ischemic 
insult may give us an indication into how patient comorbidities and comedications change the response 
to IRI and preconditioning. Proteomics allows us to identify the changes in the initial state caused by 
preconditioning that are needed to protect the cardiomyocytes during ischemia and reperfusion. This 
gives us an indication of how comorbidities or medications fail to allow the heart to adapt to these 
changes, and thus, prevent cardioprotection by ischemic conditioning.  
There have been some proteomic studies done in animal models, but we want to perform these studies 
in our human tissue model to establish if there are any species differences. A review of proteomic studies 
done in animals for ischemic preconditioning and pharmacologic therapy to simulate ischemic 
preconditioning found that changes in signal transduction only demonstrated the fourth most number of 
changes [295]. Of course, we expect that signal transduction changes should have an outsized impact 
127 
  
compared to the relative percentage of changes. However, these results indicate that we need to expand 
our scope of analysis. The top 3 categories of changes were energy production and conversion; post-
translational modification, protein turnover, and chaperones; and cytoskeleton. Our discussion has so far 
focused on mitochondria and changes in PI3K-Akt signaling that affect the mitochondria because 
mitochondria are at the center of energy production in cardiomyocytes. But, we need to also assess the 
role of autophagy and ER stress in IRI and cardioprotection by ischemic preconditioning. 
 
Autophagy 
Autophagy is an important aspect of IRI, and it should be characterized in future experiments on the 
human tissue platform. Currently, the role of autophagy in IRI remains to be fully defined. Autophagy is 
activated during ischemia due to nutrient deprivation, and at low levels, autophagy promotes cell survival 
by degrading damaged cellular components to generate amino acids and ATP [183, 184]. However, 
overactivation of autophagy leads to excessive degradation and cell death [187]. Thus, autophagy can be 
cardioprotective or contribute to IRI depending on the circumstances, and these conditions need to be 
identified. Furthermore, reperfusion leads to a change in autophagy. It has been demonstrated that 
reperfusion leads to increased formation of autophagosomes through a mechanism distinct from that of 
ischemia [183], but this increase may be due to decreased clearance autophagosomes in the lysosomes 
[186]. Both inhibition [296, 297] and stimulation [32, 129, 185] of autophagy has been found to be 
cardioprotective in ischemia-reperfusion. Ischemic preconditioning has also been found to increase 
autophagy for cardioprotection [298, 299]. Furthermore, different cell sources have different activation 
of autophagy, which was seen in increased autophagosome formation in neonatal rat cardiomyocytes 
over H9c2 cells [60]. Study on the human tissue model will be important to better assess and clarify the 
importance of autophagy in human cardiomyocytes. 
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The first assessment needs to characterize autophagy during simulated ischemia. Ischemic conditions 
involve depletion of nutrients. The resulting decrease in ATP and increase in AMP activates AMP-activated 
protein kinase (AMPK). AMPK activates autophagy directly by recruiting proteins to form the 
autophagosome and indirectly by inhibiting mammalian target of rapamycin (mTOR) inhibition of 
autophagy [183]. Beclin1 is another protein that is involved in the formation of the autophagosome, and 
increased levels correspond to an increase in initiation of autophagosome formation. Formation of the 
autophagosome is associated with an increase in LC3-II levels. We want to identify when autophagy 
switches from being cardioprotective to causing cell death by comparing cell death in constructs exposed 
to short and long ischemic times, with and without moderators of autophagy. We believe that stimulation 
of autophagy will decrease cell death in short ischemic times, but it will increase cell death in long ischemic 
times due to autophagy-related cell death. 
There are many targets that we can modify to inhibit or activate autophagy to characterize it in regards 
to ischemic time. Class I phosphatidylinositol 3-kinase (PI3K) inhibits autophagy through activation of Akt 
and mTOR, while class III PI3K activates autophagy directly by helping to form the autophagosome [300]. 
Wortmannin is generally considered to be an inhibitor of autophagy, but it affects all PI3K classes. Instead, 
we would like to use 3-methyladenine (3-MA) as a specific inhibitor of class III PI3K. We can also use 
inhibitors of AMPK to control initiation of autophagy during ischemia. Beclin 1 knockout can also be 
utilized to inhibit initiation of autophagy. To stimulate autophagy, we can utilize rapamycin to inhibit 
mTOR inhibition of autophagosome formation or utilize AMPK activators. There are many indirect and 
direct activators of AMPK available [301]. We aim to inhibit or stimulate autophagy and characterize 
changes in the downstream protein levels and cell death. An ischemic time that induces mild activation of 
autophagy with cardioprotection should see an increase in cell death with inhibition of autophagy. 
Conversely, an ischemic time that results in excessive autophagy should see either a decrease or no 
change in cell death with inhibition of autophagy. No change might be seen because the large amounts of 
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necrotic cell death may overwhelm any signal from autophagy. Many studies have identified stimulation 
of autophagy to be a cardioprotective strategy [32, 129, 185], and we must establish if this is dependent 
on the ischemic time.   
The next step is to characterize autophagy during reperfusion. We aim to clarify whether the increase in 
autophagosomes seen during reperfusion is due to increased initiation of autophagy or decreased 
clearance of autophagosomes [183, 186]. As previously discussed, autophagic flux can be measured by 
either comparing LC3 levels with and without inhibition of lysosomal clearance or transfecting the cells 
with RFP-GFP-LC3 lentiviral vectors and measuring red fluorescence to assess quenching of the GFP signal 
in the acidic lysosome. We want to assess if inhibition of autophagic flux using bafilomycin to inhibit 
autophagosome fusion with the lysosome or chloroquine to inhibit lysosomal degradation leads to an 
increase in reperfusion injury [186, 302]. We also want to identify if reperfusion autophagy is different 
depending on the nature of autophagy during ischemia. It has been found in studies that autophagy 
stimulation was only cardioprotective in the border zone of the infarct [32]. The ischemic insult to the 
border zone is presumably lower due to collateral circulation, and it would have lower levels of autophagy 
that would be cardioprotective compared to the center of the infarct.  
We believe that the beneficial effects of autophagy stimulation are reliant on increasing autophagic flux, 
and we want to test this by inhibiting autophagic flux on reperfusion to determine if this leads to a 
reduction in the beneficial effects of autophagy stimulation. We expect that the use of AMPK activators 
or rapamycin for increased activation of autophagy with bafilomycin or chloroquine inhibition of lysosome 
fusion or degradation will lead to an increase in cell death. We think that stimulation of autophagy for 
cardioprotection is dependent on increasing autophagic flux to overcome the impaired autophagic flux 
that is seen during reperfusion, and stimulation of autophagy initiation is not cardioprotective in itself.  
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Furthermore, we also want to clarify the role of ischemic preconditioning in promoting autophagy. 
Ischemic preconditioning leads to increased formation of autophagosomes, and it has been shown that 
3-MA and bafilomycin inhibition of autophagy both prevented neuroprotection by ischemic 
preconditioning [299, 303]. We believe that cardioprotection by ischemic preconditioning is also 
dependent on increasing autophagic flux. To test this, we first want to characterize the formation of 
autophagosomes and identify increased clearance of them due to ischemic preconditioning.  
We want to identify if preconditioning leads to increased activation of AMPK and clarify preconditioning-
associated activation of PI3K-Akt. Activation of Akt leads to activation of mTOR, where mTOR is an 
inhibitor of autophagy. However, AMPK acts to inhibit mTOR inhibition. It is clear that ischemic 
preconditioning acts to increase autophagy activation [299, 303]; therefore, we want to determine if 
addition of rapamycin to block any increase in mTOR activation through PI3K-Akt can lead to further 
cardioprotection in ischemic preconditioning.   
We then want to identify if treatment with bafilomycin or chloroquine to inhibit autophagosome 
clearance will abolish the protective effects of ischemic preconditioning. Furthermore, we want to identify 
if inhibition of autophagic flux causes a change in RISK pathway signaling by assessing Akt, ERK1/2, and 
GSK3β. The RISK pathway is thought to provide cardioprotection by targeting the mitochondria and 
inhibiting the MPTP. If the signaling of this pathway remains while cardioprotection is abolished, that 
could indicate that cardioprotection is not only reliant on inhibition of the MPTP, but also clearance of 





Further characterization of ischemia-reperfusion needs to assess mitophagy. Mitophagy is clearance of 
damaged mitochondria to help maintain cellular homeostasis. Mitophagy is also critical for reducing IRI 
because it has been recognized that injured mitochondria cause further damage to neighboring healthy 
mitochondria in a viscous cycle [304]. Thus, removal of these damaged mitochondria before they can 
inflict widespread damage is important to limiting cell injury. Mitophagy is primarily mediated by the 
interactions of the proteins PINK1 and Parkin. PINK1 is normally maintained at low levels through 
transport and cleavage in the mitochondria [305, 306]. However, loss of mitochondrial membrane 
potential and increase in permeability prevents the cleavage of PINK1, and this results in accumulation of 
PINK1 on the mitochondrial surface [307]. PINK1 accumulation recruits and activates Parkin, which is 
normally in the cytosol, to the damaged mitochondria to direct mitochondria clearance [308, 309]. Thus, 
mitophagy can be assessed through western blot by increased PINK1 levels overall and in the 
mitochondrial fraction, and by translocation of Parkin from the cytosol to mitochondrial fraction. 
Furthermore, p62 has been recognized to bind to the mitochondria and assist in recruitment to the 
autophagosome [298].  
We can also assess mitophagy by examining mitochondrial mass. However, we are cautious of the 
suggested methods of mitochondrial mass quantification using cardiolipin content, citrate synthase 
activity, and complex I activity because they are inherently affected by IRI and ischemic preconditioning 
[310]. It has also been demonstrated that fluorescent dyes that target the mitochondria, such as 
Mitotracker, are also inherently influenced by the mitochondrial membrane potential and are not 
appropriate for mitophagy analysis in the setting of IRI [117]. It may be more appropriate to monitor 
mitochondrial proteins, such as TOMM20 or TIMM23, and compare ratios to cytosolic housekeeping 
proteins to determine mitochondrial mass [118].  
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We want to assess whether cardioprotection by autophagy stimulation is dependent on mitophagy, and 
if impairments in mitophagy lead to an increase in IRI. Mitochondria are recognized as critical effectors of 
cell injury overall and especially in IRI [225], and we want to better understand the importance of 
mitochondria as targets for cardioprotective strategies. To accomplish this, we need to selectively target 
and inhibit mitophagy while maintaining autophagy intact. Mitophagy can be targeted through either 
genetic editing (e.g. CRISPR) or introduction of siRNA against Parkin. In this manner, we can monitor an 
increase in PINK1 levels to confirm that mitophagy is activated, but a decrease in p62 translocation to 
mitochondria to confirm that the mitochondria are not being directed to the autophagosomes. 
Furthermore, we want to confirm that autophagic flux is maintained through previously described 
methods. We next want to stimulate autophagy with drugs when it is cardioprotective (i.e. short ischemic 
times). We expect that autophagy stimulation with mitophagy inhibition will still reduce cell death during 
the ischemic period due to the autophagy degrading cellular contents for nutrients. However, we expect 
that autophagy stimulation with mitophagy inhibition will result in no change to increased cell death 
compared to no stimulation during the reperfusion period due to impaired clearance of damaged 
mitochondria. Opening of the MPTP and depolarization of the mitochondrial membrane is a critical step 
in reperfusion injury, and damaged mitochondria negatively impact neighboring healthy mitochondria 
[253]. We suspect that cardioprotection by autophagy stimulation is dependent on clearance and isolation 
of damaged mitochondria from the otherwise viable cardiomyocyte.   
We also want to assess if cardioprotection by ischemic preconditioning is reliant on increases in 
mitophagy. Ischemic preconditioning mediates cardioprotection partially through autophagy and 
mitophagy. Knockout of Parkin has also been demonstrated to negate the cardioprotective effects of 
ischemic preconditioning [298]. We wish to demonstrate this in our human tissue model. It is suggested 
that ischemic preconditioning promotion of mitophagy helps to eliminate the mitochondria with the 
lowest threshold for opening of the MPTP and depolarization. It has also been previously established that 
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preconditioning reduces opening of the MPTP [202]. Thus, the decrease in preconditioned mitochondrial 
membrane permeability that we demonstrated in preconditioned constructs can be due to both 
elimination of mitochondria with low thresholds and increased resilience of healthy mitochondria. We 
want to distinguish these two mechanisms by assessing GSK3β phosphorylation and mitochondrial 
membrane potential in the setting of mitophagy inhibition. If GSK3β phosphorylation is maintained but 
mitochondrial membrane potential and cell death continue to increase due to mitophagy inhibition, this 
indicates that preconditioning is reliant on increased mitophagy. MPTP inhibition could just be a bridge to 
eliminating the damaged mitochondria. It has also been demonstrated that Akt signaling leads to 
mitophagy [311], and we want to identify if inhibition of PI3K-Akt signaling by ischemic preconditioning 
abolishes its increase in mitophagy.  
We expect that ischemic preconditioning not only leads to increased mitophagy after the preconditioning 
regimen, but also it increases autophagic flux to clear the damaged mitochondria during reperfusion. 
Furthermore, mitochondrial dysregulation has been identified in chronic cardiovascular diseases such as 
heart failure and diabetes [312, 313]. Disruptions in mitophagy may explain why patient comorbidities 
lead to increased susceptibility to IRI and decreased cardioprotection by ischemic preconditioning [257]. 
We think that mitophagy and isolation and clearance of damaged mitochondria is critical to 
cardioprotective strategies.  
 
ER stress 
Ischemia disrupts endoplasmic reticulum (ER) function and results in ER stress, which is the accumulation 
of misfolded and unfolded proteins in the ER. To alleviate ER stress, the unfolded protein response (UPR) 
is initiated to decrease protein translation to prevent further accumulation of unfolded proteins, 
upregulate chaperones to assist in protein folding, and increase ER-associated protein degradation (ERAD) 
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components to help clear the proteins [314]. Activation of the UPR can help restore cell homeostasis, but 
overactivation or prolonged activation of the UPR leads to apoptosis [315]. ER stress and the UPR have 
been recognized as having important roles in cardiovascular disease and ischemic injury [316].   
We want to first characterize ER stress and the UPR in the cardiac constructs. Direct measurements of ER 
stress and the misfolded and unfolded proteins are difficult. Instead, we will assess ER stress and the UPR 
through the UPR master regulators: inositol-requiring enzyme 1 (IRE1); protein kinase RNA-like ER kinase 
(PERK); and activating transcription factor 6 (ATF6). Normally, BiP (immunoglobulin binding protein) is a 
chaperone protein that binds to the master regulators to keep them inactivate. ER stress causes BiP to 
dissociate from the regulator proteins, and activation of the UPR can be measured through 
phosphorylation of IRE1 and PERK and cleavage of ATF6 in western blots. We will also measure 
downstream signals of UPR activation and ER stress. We will measure CHOP (CCAAT/enhancer-binding 
protein homologous protein, downstream of PERK) and caspase 12 levels. These two proteins are 
important to the activation of ER stress related apoptosis [317–319]. Furthermore, we can also monitor 
PERK-mediated phosphorylation of eIF2α that leads to the decrease in protein translation seen in the UPR 
[320]. We can also use the drug MG132 to block ERAD to inhibit the UPR [321].  
We want to understand the role of ER stress and the UPR in IRI and as a target for therapeutic strategies. 
Stimulation and inhibition of ER stress through drugs has demonstrated a respective increase and 
decrease in infarct size [31]. We want to first establish that direct stimulation and inhibition of ER stress 
can respectively increase and decrease cell death after IRI in our constructs. In the study on rat hearts, 
dithiothreitol (DTT) was utilized to quickly stimulate ER stress by inhibiting disulfide-bond formation [31]. 
The chemical chaperone, sodium 4-phenylbutyrate (PBA), was used to directly inhibit ER stress [322]. We 
wish to test the effects of these compounds in our model and assess changes in the UPR.  
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Studies suggest that ischemic preconditioning is dependent on activation of the UPR rather than any direct 
reduction in ER stress. It has been seen that ischemic preconditioning protocol itself without ischemic 
injury leads to activation of the UPR, which suggests that the preconditioning regimen causes mild ER 
stress [323]. It has also been identified that inhibition of the UPR prevents cardioprotection by ischemic 
preconditioning [323, 324]. Furthermore, another study demonstrated that postconditioning 
demonstrated an increase in UPR activation, but remote ischemic conditioning did not [325]. They found 
that addition of the chemical chaperone (PBA), which directly reduces ER stress, abolished 
cardioprotection by ischemic postconditioning only and prevented UPR activation. This suggests that by 
preventing ER stress directly with PBA, the cells could not activate the UPR and decrease injury through 
the UPR. However, this result conflicts with the previous study that demonstrated that PBA reduced 
infarct size [31]. We need to reconcile these results in our platform to by testing both direct inhibition of 
ER stress with PBA and ischemic preconditioning. We also want to identify if we can inhibit 
cardioprotection by ischemic preconditioning through UPR inhibitors in IRE1 or PERK inhibition [314]. This 
would allow any changes in ER stress to still occur but block the construct response to ER stress.  
Furthermore, we wish to assess if activation of the UPR can be cardioprotective in itself, regardless of ER 
stress. The UPR is controlled by three master regulators, IRE1, PERK, and ATF6, where IRE1 and PERK are 
activated by phosphorylation and ATF6 by cleavage. Unfortunately, it is unclear if there are any direct 
pharmacologic activators of these proteins available. There is a PERK activator that has been tested [326], 
and we can also validate its activity in our platform by examining downstream eIF2α phosphorylation and 
CHOP levels. Any potential IRE1 activators can be validated by demonstrating splicing of the intron in its 
downstream target, XBP1 mRNA [327]. We may need to introduce transgenic constitutively activated 
IRE1, PERK, or ATF6 instead. We can also utilize salubrinal as an inhibitor of eIF2α dephosphorylation to 
potentiate eIF2α activity and UPR signaling [328]. We want to assess if activation of the UPR in the setting 
of ER stress reduction by PBA demonstrates cardioprotection. This would allow us to determine if the UPR 
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has other beneficial effects outside of ER stress reduction. Furthermore, we wish to determine if CHOP 





In this thesis, we established a human tissue engineered model of ischemia-reperfusion injury. A cardiac 
construct was formed by seeding a hiPS-CM and hydrogel mixture around flexible pillars that provided 
mechanical conditioning for cell maturation. The cardiac construct demonstrated aligned and striated 
cardiomyocytes along the edge of the construct, and functional maturity with both a chronotropic and 
ionotropic response to β-adrenergic stimulation. The constructs subjected to simulated ischemia and 
reperfusion demonstrated an increase in cell death after reperfusion compared to ischemia only.  
We also demonstrated a decrease in IRI through ischemic preconditioning of the cardiac constructs prior 
to simulated ischemia-reperfusion. Ischemic preconditioning is difficult to study in patients, and this 
model has the potential to further our understanding of the cardioprotective mechanisms in ischemic 
conditioning regimens. We further demonstrated a decrease in IRI by modifying the reperfusion 
conditions. Reperfusion with acidic media helped decrease cellular injury by attenuating rapid 
normalization of intracellular pH. We also targeted opening of the MPTP and oxidative stress with 
cyclosporine A and N-acetyl-L-cysteine respectively, but only cyclosporine A demonstrated a decrease in 
IRI.  
This model of IRI demonstrated comparable results to animal studies, but it has greater potential by 
providing a platform to study human responses to ischemia and reperfusion. Animals and humans have 
critical differences in their physiology that make animal models less suitable for preclinical use. 
Furthermore, we anticipate that the growing use of patient-specific hIPSCs will allow for a better model 
that recapitulates patient comorbidities and more accurately simulates the clinical setting.  
Our future studies will focus on better defining the factors that lead to differences in cell death that we 
saw in our experiments. We need to identify the molecular changes that underly different cell behavior in 
ischemia, reperfusion, and ischemic conditioning. This will allow us to understand how we need to modify 
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construct response to reduce IRI and help in developing clinical predictive utility of the platform by 
understanding how baseline changes may lead to a lack of response. The human tissue engineered model 
developed in this thesis has demonstrated key aspects of IRI and will help in developing therapies to 




Research Design and Methods 
Bioreactor Fabrication 
A custom mold for the bioreactor was designed in SOLIDWORKS and manufactured using a computer 
numerical control (CNC) milling machine (Haas OM 2) to mill a sheet of Delrin Acetal Resin. Sylgard 184 
Polydimethylsiloxane (PDMS) was mixed in a 10:1 ratio with Sylgard 184 curing agent, and poured into 
the custom mold. Carbon electrode rods (CST T319Lm, 1.5 mm diameter) were also inserted into the 
molds. The molds were placed under vacuum to remove bubbles, and left to cure in the oven at 60°C 
overnight. The subsequently formed reactors were washed and plasma bonded to a glass slide (75 x 50 
mm). The bioreactors were sterilized by autoclaving prior to construct seeding and culture. The pillars of 
the bioreactor are 4.5 mm apart, and the tissue well is 6 x 8 mm. Each bioreactor supported the formation 
of four constructs. 
 
Cell Culture 
The human induced pluripotent stem (hIPS) cell line WTC11 was obtained from Dr. Bruce R. Conklin 
(Gladstone Institute of Cardiovascular Disease, UCSF). The hIPS cells were cultured in mTeSR 1 (Stemcell 
Technologies) supplemented with 100 U/mL penicillin and 100 µg/mL streptomycin at 37°C in a humidified 
incubator with room air and 5% CO2. The hIPS cells were continuously passaged at 60-70% confluency into 
6 well plates. 2 µM of Thiazovivin (Tocris 3845) was added to the mTeSR media immediately after 
passaging, but was then switched out for normal mTeSR media on subsequent days. The plates were 
coated with 1 mL of Growth Factor Reduced Matrigel (Corning 356231) diluted 1:80 in DMEM/F12 media 





hIPS cultures were differentiated at 90-95% confluency. Differentiation was started by washing the wells 
with PBS, and adding CDM3 (RPMI 1640 (ThermoFisher 11875093) supplemented with 213 µg/mL ascorbic 
acid (Wako Chemicals 321- 44823), 500 µg/mL albumin (ScienCell OsrHSA), and 100 U/mL penicillin and 
100 µg/mL streptomycin) supplemented with 3 µM CHIR 99021 (Tocris 4423).  After two days, the media 
was changed to CDM3 supplemented with 2 µM Wnt-C59 (Tocris 5148). Media was continuously changed 
with normal CDM3 every two days afterwards. 
 
Cardiac Construct Formation 
Cardiomyocytes differentiated from hIPS cells (hiPS-CMs) began spontaneously beating after 8-10 days in 
culture. They were harvested between 12-17 days after the start of differentiation to be formed into tissue 
engineered constructs. hIPS-CM monolayers were dissociated using 0.2% collagenase II (Worthington 
LS004177) in HBSS. Prior to construct seeding, the construct formation wells were coated with 4% Pluronic 
F127 (Sigma P2443) for 30 minutes, washed, and then allowed to air dry for 30 minutes. This pretreatment 
helped to prevent hydrogel attachment to the sides and bottom of the well during condensation of the 
construct structure. Approximately 3 x 106 hiPS-CMs were mixed into a collagen-fibrinogen hydrogel (final 
concentration of 1.5 mg/mL rat tail collagen type I (Corning CB354249), 4 mg/mL bovine fibrinogen (Sigma 




The constructs were cultured in RPMI 1640 (Thermofisher 11875) supplemented with 2% B27 supplement 
(Thermofisher 17504044), 213 µg/mL ascorbic acid, 100 U/mL penicillin and 100 µg/mL streptomycin. 
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Aprotinin (33 µg/mL, Sigma A3428) was added to the media for the first 7 days of culture, and the media 
was changed every two days. Ischemia-reperfusion experiments were started two weeks after tissue 
formation.  
Isoproterenol Dose Response 
To assess the response of constructs to β-adrenergic stimulation, serial dilutions of isoproterenol (Sigma 
I6504) were made in normal culture media.  The constructs were allowed to incubate at 37°C for 15 
minutes before being moved to the microscope to take twenty second videos. The videos were then 
analyzed in MATLAB using custom code to analyze pixel displacement to determine beat frequency and 
threshold masked to determine fractional area change (FAC). Dose-response curves were then analyzed 
in GraphPad Prism 6 software using built-in nonlinear regression tools to determine EC50 for beat 
frequency and significance compared to a horizontal line for FAC.  
 
Ischemia 
The constructs were washed in PBS and then 120 µL of ischemic solution (in mM, NaCl 119, KCl 12, 
NaH2PO4 1.2, MgSO4 1.3, MgCl2 0.5, CaCl2 0.9, Sodium Lactate 20, HEPES 5, pH 6.4) was added to each 
tissue well. The reactors were then placed into a hypoxic chamber, and anoxic gas (95% N2, 5% CO2) was 
flushed in. The chambers were placed into the incubator at 37°C for 6 hours. Constructs subjected to 
ischemia-only (referred to as “Isch”) were analyzed immediately after 6 hours of simulated ischemia.   
 
Reperfusion 
Reperfusion was achieved by returning the constructs (referred to as “Rep” or “Rep (pH 7.4)”) to room air 
and adding RPMI 1640 supplemented with 1.4 mM calcium chloride (for a final calcium concentration of 
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1.8 mM) and 2% B27 supplement, minus antioxidants (Thermofisher 10889038) to achieve a physiological 
calcium concentration. Normoxic constructs were also cultured in this media for the duration of the 
experiment. Constructs were placed in the incubator at 37°C for 3 hours before endpoint analysis was 
performed.  
 
Treatments to Reduce IRI 
Ischemic preconditioning (referred to as “PreC”) was simulated by subjecting the constructs to simulated 
ischemia for 30 minutes, followed by simulated reperfusion for 15 minutes. The constructs then 
proceeded as normal through simulated ischemia for 6 hours followed by reperfusion for 3 hours. 
The other treatment groups were all subjected to simulated ischemia the same as before, but simulated 
reperfusion was modified in an attempt to decrease IRI. Reperfusion with acidic media (referred to as 
“Rep pH (6.4)”) was tested by titrating the simulated reperfusion media down to a pH of 6.4. For testing 
the effects of drugs, cyclosporine A (CsA, 1 µM, Sigma C1832, group referred to as “CsA”) and N-
acetylcysteine (NAC, 5 mM, Sigma A9165, group referred to as “NAC”) were added to the reperfusion to 





Figure 20: Graphical summary of various comparison and treatment groups to assess the validity of the 
engineered cardiac construct as a model of IRI.  
 
Assays  
Cell death was assessed using LDH release (Thermofisher 88954) and adenylate kinase release (Toxilight, 
Lonza LT07) into the media. Cell viability was determined using RealTime-Glo (Promega G9712). Construct 
reactive oxygen species levels were measured using ROS-Glo (Promega G8820). Construct intracellular pH 
was measured using pHrodo Green dye (ThermoFisher P35373). Mitochondria membrane permeability 
was assessed using JC-1 dye and measuring excitation at 485 nm, and comparing emission at 528 and 590 
nm. All kits were executed according to manufacturer’s instructions.  
 
Imaging 
For histology, constructs were fixed in 4% paraformaldehyde in PBS, transferred to 30% sucrose in PBS, 
and then frozen in OCT embedding compound. 10 µm sections were stained for using cardiac troponin T 
antibody (1:100, Thermofisher MS-295-P1), and nuclei were counterstained using DAPI. Secondary 
antibody used was Goat anti-mouse Alexa Fluor 488 conjugate (Thermofisher A-11001). Coverslips were 
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mounted using VECSTASHIELD antifade mounting medium (Vector H1200), and images were taken under 
epifluorescence and confocal microscope.  
 
Western Blot 
Constructs were flash-frozen in liquid nitrogen and then transferred to a -80°C freezer until they were 
ready for protein isolation. Three-four constructs were pooled together, and were homogenized using 
TissueRuptor II (Qiagen) in Tissue Protein Extraction Reagent (Thermofisher 78510) supplemented with 
1X Protease/Phosphatase Inhibitor Cocktail (Cell Signaling Technology 5872S). The homogenized 
constructs were then placed on a vortex mixer at 4°C for 2 hours. Protein concentrations were then 
determined using a Pierce BCA protein assay kit (Thermofisher 23225).  
For the western blot, 30 µg of total protein were added to each lane. Blots were transferred onto 
nitrocellulose membranes (0.2 µm) (Bio-Rad 1620112) and blocked using 5% non-fat milk in TBS-T. 
Membranes were probed using antibodies and developed under chemiluminescence. Antibodies used 
were: cleaved caspase-3 (Cell Signaling Technology 9664), total caspase-3 (Cell Signaling Technology 
9668), phospho-Akt (Ser473) (Cell Signaling Technology 4060), Akt (pan) (Cell Signaling Technology 2920), 
and β-tubulin (Cell Signaling Technology 86298). Quantification was done in Licor Image Studio software.  
Statistics 
Statistical tests were performed using GraphPad Prism 6 software. ANOVA was performed with post-hoc 
Tukey’s HSD to determine significant differences between groups. P < 0.05 was used to assess for 
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